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Chapter 1 
Introduction 
1.1 Hyaluronic acid 
 
1.1.1 Structure and physicochemical properties 
Hyaluronic acid (hyaluronan, HA), a main component of the extracellular matrix, 
was first found in the vitreous humor of bovine eyes by Meyer and Palmer in the 
year 19342. This versatile and fascinating macromolecule belongs to the family 
of glycosaminoglycanes (GAG), which are linear polysaccharides of high mo-
lecular weight composed of aminosugars (N-acetylglucosamine or N-acetylga-
lactosamine) and uronic acids (glucuronic acid or iduronic acid), along with 
chondroitin-, keratan- and dermatane sulfate, heparin and heparan sulfate. 
 
Fig. 1.1: Chemical structure of hyaluronic acid. H (blue colored): axial hydrogens that contribute 
to the hydrophobic face 
 
The chemical structure of hyaluronan is the simplest of all GAGs consisting of 
straight-lined repeating disaccharide units of [→4)-β-D-glucuronic acid(1→3)-β-
D-N-acetylglucosamine(1→]n, where n can be up to 25000 dependent on the 
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 2 
tissue source (Fig. 1.1). When considering the energetically state the HA struc-
ture is very stable since the bulky groups (the hydroxyl groups, the carboxylate 
moiety, the N-acetyl residue and the adjacent sugars) are situated in sterically 
favorable equatorial positions while all of the small hydrogen atoms occupy the 
axial positions. In contrast to the other glycosaminoglycanes, hyaluronan is not 
covalently bound to a protein core and is not sulfated. Lately, the term hyalu-
ronan, suggested by Balasz et al.3, has substituted the terms hyaluronic acid 
and hyaluronate reflecting the fact that it exists in vivo as a polyanion due to the 
mostly charged carboxyl groups of the glucuronic acid residues (pKa = 3-4, de-
pending on ionic conditions4). 
For decades, it was assumed that hyaluronan chains were expanded random 
coils in physiological solutions. However, nuclear magnetic resonance studies 
performed by Scott et al.5 suggested an ordered structure of hyaluronan in solu-
tion. This conformation is characterized by a gently undulating, tape-like, two-
fold helix which is formed as a result of 180 °C rotations between alternating 
disaccharide units and is stabilized via internal hydrogen bonds and interactions 
with the solvent6,7. The striking feature of this secondary structure of hyaluronan 
is an extensive hydrophobic patch (represented by the axial hydrogen atoms) of 
about 8 CH-groups of 3 carbohydrate units. Thus, hyaluronan is amphiphilic 
because it includes properties of highly hydrophilic material simultaneously with 
hydrophobic patches, which is characteristic of lipids. 
In addition, the application of rotary shadowing-electron microscopy revealed 
that HA self-aggregates into strands of a honeycomb meshwork in an aqueous 
solution whereby the thickness of the strands increased with HA concentration8. 
According to 13C-NMR studies9, this aggregation is stabilized both by hydropho-
bic interactions between the hydrophobic patches and by hydrogen bonds be-
tween acetamido and carboxylate groups of neighboring HA chains arranged 
antiparallel to each other. Since such hydrophobic and hydrophilic “bonds” can 
be formed on both sides of the hyaluronan polymer higher order aggregates can 
assemble causing strands of increased thickness in a HA meshwork. Recently, 
NMR spectroscopy investigations10 demonstrated that the tertiary structures 
(aggregation of antiparallel HA chains) are specifically and reversibly disaggre-
gated by mild physicochemical methods (raising temperature or pH). Further on, 
it was highlighted that the supramolecular organization of HA is on the edge of 
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stability indicating that reversible formation and breakdown of tertiary structures 
have a major influence on controlling biological properties. 
These properties lead to highly viscous solutions, i.e. by binding water, the vol-
ume of HA increases by about 1000-fold compared to the non-hydrated state11. 
In the hydrated state, the diffusion of e.g. proteins and electrolytes is considera-
bly facilitated. Generally, all molecules can pass through this network but with 
different velocity depending on their hydrodynamic volumes. Therefore, the 
hyaluronan network acts as a diffusion barrier in vivo and regulates the trans-
port of other substances through the intercellular space12. 
The organized structure of HA is supposed to possess a substantial influence 
on the binding of HA to receptors and to the active site of hyaluronidases. 
 
1.1.2 Occurrence and physiological importance 
All vertebrates as well as some Streptococci strains produce hyaluronan. As a 
major component of the extracellular matrix, HA is found in the vitreous body of 
human eye (0.1-0.4 mg/g wet weight), in synovial joint fluid (3-4 mg/ml), in um-
bilical cord (~4 mg/ml), in rooster comb (up tp 7.5 mg/ml), in the matrix pro-
duced by the cumulus cells around the oocyte prior to ovulation (~0.5 mg/ml) or 
in the pathological matrix that occludes the artery in coronary restenosis. The 
largest amount of hyaluronan (7-8 g per average adult human, about 50% of the 
total in the body) resides in the skin tissue where it is present in both the dermis 
(~0.5 mg/g wet tissue) and the epidermis (~0.1 mg/g wet tissue). Furthermore, 
hyaluronic acid serves as a structural element in the matrix, e.g. in hyaline car-
tilages (1 mg/g wet weight) where it retains aggrecan molecules in the matrix 
through specific protein-hyaluronan interactions4. 
Lower concentrations of HA are found in the matrix of other connective tissues 
such as those surrounding smooth muscle cells in the aorta. 
Hyaluronan as an essential structural element in the matrix plays an important 
role for tissue architecture by immobilizing specific proteins (aggrecan, versican, 
neurocan, brevican, CD44 etc.) in desired locations within the body. Moreover, 
hyaluronan is implicated in many biological processes including fertilization, 
embryonic development, cell migration and differentiation, wound healing, in-
flammation, growth and metastasis of tumor cells and whenever rapid tissue 
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turnover and repair are occuring11-13. The function of HA may be partly regu-
lated dependent on its chain length, e.g. angiogenesis is presumably induced 
by small HA oligosaccharides, whereas high molecular weight HA exerts in-
hibitory effects14. 
HA interacts with a variety of receptors and hyaluronan binding proteins (hyal-
adherins) on the surface of cells12,15. The great number of hyaladherins known 
so far can be grouped into (i) the structural hyaluronan-binding proteins of the 
extracellular matrix, such as link protein and the aggregating proteoglycanes, (ii) 
cell surface hyaluronan receptors and (iii) intracellular hyaluronan binding pro-
teins. The most studied hyaluronan receptor to date is CD44 (lymphocyte hom-
ing receptor), which is responsible for a wide variety of cellular functions, e.g. 
receptor mediated internalization/degradation of hyaluronan, cell migration and 
cell proliferation. Several other cell membrane-localized receptors have been 
identified including the RHAMM (receptor for hyaluronan which mediates motil-
ity), ICAM-1 (intercellular adhesion molecule-1), the LEC receptor (Liver Endo-
thelial Cell clearance receptor)12,16 and LYVE-1 (Lymphatic endothelial hyalu-
ronan receptor)17. While most interactions between hyaluronan and hyaladher-
ins are non-covalent the SHAP(Serum-derived Hyaluronan-Associated Protein)-
complex represents the only case with covalent hyaluronan-protein crosslinking. 
The formation of this SHAP-hyaluronan complex plays an important role in the 
construction and maintenance of certain hyaluronan-rich extracellular matri-
ces18. 
 
1.2 Hyaluronidases 
 
1.2.1 History and occurrence 
Hyaluronidase is a general term initially introduced by Karl Meyer in 1940 to 
describe enzymes that are able to break down primarily hyaluronan. Hyaluroni-
dase activity was first identified in an extract of mammalian testes and other 
tissues as a ‘spreading factor’ that facilitated diffusion of antiviral vaccines, dyes 
and toxins injected subcutaneously19. A second line of independent investiga-
tion led to the first isolation of hyaluronan by Meyer and Palmer2. After the iden-
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tification of a HA degrading enzyme in bacteria20, it could soon be shown that 
the mammalian spreading factor was also an enzyme degrading hyaluronan21. 
In the following years similar hyaluronidase-like enzymes were identified from a 
large number of tissues and organisms, e.g. skin, liver, kidney, spleen, testes, 
uterus, placenta, from the venoms of snakes, lizards, fish, bees, wasps, scorpi-
ons, spiders, from body liquids (tear liquid, blood, sperm) as well as from some 
bacteria, fungi and invertebrate animals (leech, crustacean). The hyaluroni-
dases from different sources vary in their molecular weight, substrate specificity, 
pH optima and catalytic mechanism1,13,22,23. Although widely distributed in na-
ture, hyaluronidases are not well characterized and are a group of neglected 
enzymes owing to their difficult purification and lack of scientific interest over a 
large period of time. However, in recent years there is growing interest in the 
possible role of hyaluronan and hyaluronidase in numerous biological proc-
esses. 
 
1.2.2 Classification of hyaluronidases 
K. Meyer established the first classification scheme for hyaluronidases in 1971. 
Based on detailed biochemical analysis of the enzymes and their reaction prod-
ucts, the hyaluronidases are subdivided into three main families (Fig. 1.2)1. 
The first groups of hyaluronidases are the hyaluronate 4-glycanohydrolases (EC 
3.2.1.35) degrading hyaluronan by cleavage of the β-1,4-glycosidic bond to the 
tetrasaccharide as the main product. Apart from the preferred substrate HA, 
these enzymes depolymerize also chondroitin, chondroitin-4- and chondroitin-6-
sulfate and, to a small extent, dermatan sulfate. As a special characteristic, this 
class of enzymes reveals both hydrolytic and transglycosidase activity24,25. The 
best-known enzymes are the testicular, the lysosomal and the bee venom hya-
luronidase. 
The second type is represented by hyaluronidases occurring in the salivary 
glands of leeches and hookworms. These hyaluronate 3-glycanohydrolases (EC 
3.2.1.36) hydrolyze the β-1,3-glycosidic bond of HA yielding sugar fragments 
bearing glucuronic acid at the reducing end. The main product of this reaction is 
a tetrasaccharide, too. 
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The last group, the microbial hyaluronidases or hyaluronate lyases (EC 4.2.2.1 
or EC 4.2.99.1), act via a β-elimination reaction resulting in the unsaturated di-
saccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-ene-pyranosyluronic acid)-
D-glucose as main product22,26. The hyaluronate lyases, isolated from various 
microorganisms as e.g. strains of Clostridium, Micrococcus, Streptococcus or 
Streptomyces, differ in substrate specificity27,28. 
Based on molecular genetic analysis the hyaluronidases can be divided alter-
natively in two main families – the hyaluronidases from eukaryotes and from 
prokaryotes – according to amino acid sequence homology13,29. 
 
1.2.3 Hyaluronidases from eukaryotes 
 
1.2.3.1 Mammalian hyaluronidases 
As a consequence of the knowledge gained by the “human genome project” in 
the last years, six hyaluronidase-like sequences in the human genome were 
identified with about 40% amino acid sequence identity. Three genes (HYAL1, 
HYAL2 and HYAL3) coding for Hyal-1, Hyal-2 and Hyal-3 are located tightly 
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Fig. 1.2: Classification scheme of hyaluronidases according to Meyer1 
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clustered on human chromosome 3p21.3. HYAL4, HYALP1 (a pseudogene) 
and PH20 (SPAM 1), coding for Hyal-4 and PH-20, are found on chromosome 
7q31.3. Among these enzymes, Hyal-2, Hyal-4 and PH-20 are anchored to the 
plasma membrane by a glycosylphosphatidylinositol (GPI) linker29,30. 
The activity of the PH-20 protein (also known as SPAM 1 (sperm adhesion 
molecule 1)) was first found by Gmachl et al.31 due to the significant similarity to 
bee venom hyaluronidase which was the first cloned eukaryotic hyaluroni-
dase32. The human testicular hyaluronidase is required for sperm penetration 
through the cumulus cell layer that surrounds the oocyte and for fertilization33. It 
is a multifunctional protein with a separate domain that binds to the zona pellu-
cida34. The PH-20 occurs in two forms, a GPI-anchored one attached on the 
surface of mammalian sperm and a soluble one35,36. 
Hyal-1 and Hyal-2 constitute the major hyaluronidases of somatic tissue. Thus, 
they are present in most tissues and body fluids. However, Hyal-2 is not exis-
tent in the adult brain37. Both proteins are localized in lysosomes and addition-
ally, Hyal-2 can be anchored to the plasma membrane by a GPI-linker. Hyal-1 
produces small oligosaccharides with the tetrasaccharide as major product 
whereas Hyal-2 degrades high molecular weight HA to intermediate size frag-
ments of about 20 kDa (approximately 50 disaccharide units)30,38. Therefore, 
they are believed to act in succession on depolymerizing HA: at the cell surface 
GPI-anchored Hyal-2 generates HA fragments of approx. 20 kDa, which are 
absorbed by the cell and digested to tetrasaccharides by the lysosomal 
Hyal-129,39. Hyal-1 is also found in human urine40 and mammalian plasma41. 
Mucopolysaccharidosis IX, a newly described lysosomal disorder, stems from 
mutations in the gene HYAL1 42,43. Moreover, Hyal-1 and Hyal-2 seem to be 
involved in tumor formation. Hyal-1 is a candidate tumor suppressor gene that is 
inactivated in many tobacco-related lung tumors44,45 and was found to promote 
tumor cell cycling46. Hyal-2 might share an oncogenic and a tumor suppressor 
gene function. On the one hand, an overexpression of Hyal-2 is reported accel-
erating tumor formation of murine astrocytoma cells47 and on the other hand, 
Hyal-2 seems to speed up apoptosis48. Additionally, a distinct influence of the 
size of HA degradation products on proliferation and, to a lesser extent, on mi-
gration has been discussed14, often referred to as angiogenic switch. In the be-
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ginning of tumor growth, high molecular weight HA is necessary to provide the 
flow of nutrients at the primary site and subsequently, intermediate HA frag-
ments generated by Hyal-2 induce angiogenesis49,50. 
Although Hyal-3 is widely expressed, e.g. in testes and bone marrow, no activity 
was measured using the available hyaluronidase assays30. Interestingly, Hyal-4 
seems to be a chondroitinase which would be the first one found in vertebrate 
tissue. In contrast to Hyal-1 and PH-20 which are cleaving both HA and chon-
droitin sulfate, albeit at a slower rate, Hyal-4 has an absolute substrate specific-
ity for chondroitin and chondroitin sulfate30. With the exception of PH-20, which 
is displaying activity at neutral pH, all known mammalian hyaluronidases are 
active at acidic pH. 
 
1.2.3.2 Bovine testicular hyaluronidase (BTH) 
As well-known representative of the mammalian hyaluronidases, the bovine 
testicular hyaluronidase (BTH) was adopted as a spreading factor in several 
medical fields for a long time, e.g. orthopaedia, surgery, opthalmology, derma-
tology or internal medicine51,52. BTH acts as endo-glycanohydrolase (EC 
3.2.1.35) by cleaving the β-1,4-glycosidic bond of hyaluronan. The structurally 
related GAGs chondroitin, chondroitin-4- and -6-sulfate are accepted as sub-
strate, too. 
As confirmed by ion-spray mass spectrometry the enzymatic hydrolysis of HA 
by BTH generates tetrasaccharide and saturated disaccharide fragments24. A 
specific characteristic of BTH is that it exerts hydrolase activity as well as trans-
glycosylase activity. According to Cramer et al.25, transglycosylation reactions 
occur as long as HA oligosaccharides with 6 to 12 monomer units are available 
resulting in saturated HA oligosaccharides with N-acetylglucosamine at the re-
ducing end. This is in contrast to the aforementioned formation of smaller frag-
ments. The transglycosylase activity of BTH is dependent on the pH value and 
the salt content of the incubation buffer. Saitoh et al.53 showed that the optimal 
pH value for transglycosylation reaction is at pH 7 whereas hydrolysis appears 
to be optimal at pH values below 5. The presence of NaCl negatively affects the 
transglycosylase activity. Nearly complete inhibition was found at NaCl concen-
trations above 0.5 M.53. 
                                                                                                            Introduction 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 9 
Different pH optima of hyaluronidase activity are reported in the literature de-
pending on the mostly heterogeneous enzyme composition of the BTH prepara-
tions, the source of substrate, the applied hyaluronidase assay54 and the incu-
bation conditions1,54-56. 
The bee venom hyaluronidase (BVH), a member of the hyaluronate 4-glycano-
hydrolases like BTH, was found to share 30% sequence identity with the mam-
malian PH-20. Compared to the human and the bovine hyaluronidases, in BVH 
a C-terminal domain of about 120-150 amino acid residues is lacking, but the 
active site residues are conserved32,57. The recent structural elucidation of a 
BVH-HA tetrasaccharide complex provides insights into the mode of substrate 
binding and the catalytic mechanism57,58. 
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Fig. 1.3: Double-displacement substrate assisted mechanism of bee venom hyaluronidase. The 
saccharide in subsite59 -1* (1) binds in boat conformation, and catalysis is proposed to occur via 
a formation of a covalent oxazolinium ion intermediate 2 to the product 3. Adapted from Mark-
ovic-Housley and Schirmer58. 
 
Generally, glycosidases act via a double or single nucleophilic displacement 
mechanism which results in either retention or inversion of the configuration of 
the anomeric carbon atom58,60. In the case of BVH, an acid-base catalytic 
mechanism is suggested in which Glu113 serves as the proton donor and the 
N-acetyl group of the substrate is the nucleophile as illustrated in Fig. 1.3. It is 
assumed that the hydrolysis of BTH operates in this double-displacement sub-
strate assisted mechanism as described for BVH. The acid-base catalyst 
Glu113 of BVH corresponds to Glu149 of BTH as a sequence alignment of BTH 
and BVH clearly showed61. 
 
                                            
* By convention, the sugar residue subsites are labelled from –n to +n, with –n at the non-
reducing end and +n at the reducing end of the substrate. Cleavage occurs between the -1 and 
+1 subsites. 
Chapter 1 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 10 
1.2.4 Hyaluronidases from prokaryotes 
The bacterial enzymes capable of breaking down hyaluronan were reviewed by 
Suzuki27 and Hynes and Walton28. The amino acid sequences of a variety of 
hyaluronidases from prokaryotes are known62. Among the bacterial hyaluroni-
dases, the hyaluronate lyases from Streptococcus pneumoniae and from S. 
agalactiae (group B streptococcus, GBS) are the best characterized ones26,63,64. 
Both enzymes are cleaving the β-1,4-glycosidic bond of hyaluronan between D-
glucuronic acid and N-acetyl-D-glucosamine in a β-elimination reaction resulting 
in the unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-ene-
pyranosyluronic acid)-D-glucose1,22,26,65. Due to the elucidation of the crystal 
structures of hyaluronate lyase from S. pneumoniae and from S. agalactiae 
strain 3502 (hylB3502) by X-ray analysis in the recent years more detailed infor-
mation on the catalytic sites is available63,64,66-68. Considering the active site of 
S. agalactiae hylaruonate lyase there are two important parts. The three cata-
lytic residues His479, Tyr488 and Asn429 are responsible for the substrate deg-
radation and the aromatic patch comprising Trp371, Trp372 and Phe423 selects 
the cleavage sites on the HA chain and anchors these sites exactly in the deg-
radation position within the cleft. In addition, the highly positively charged en-
zymatic cleft facilitates the binding of the negatively charged polymeric sub-
strate chain66. 
The mechanism of hyaluronan binding and degradation, termed proton accep-
tance and donation (PAD), was proposed based on crystal structure of the na-
tive enzyme as well as the structure of the enzyme in complex with the disac-
charide product of degradation66 and in complex with hyaluronate hexasaccha-
ride69. Additionally, the PAD mechanism is supported by a homology model of 
the enzyme in complex with the hyaluronate tetrasaccharide, site-directed 
mutagenesis studies26 and the comparison with the related hyaluronate lyase 
from S. pneumoniae (hylSpn)66,67,70. In the first step, the negatively charged 
hyaluronan binds to the positively charged enzymatic cleft. Three disaccharide 
units can be accommodated in the cleft (see Fig. 1.4, only two, HA1 and HA2, 
of the three units are drawn). In the second step, the aromatic patch of the ac-
tive site stabilizes and precisely positions HA1 and HA2 in a way that is optimal 
for degradation. In the next step, the glucuronic acid of HA1 is deprotonated at 
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C5 by His479 (Fig.1.4). Simultaneously, Tyr488, located at the bottom of the 
cleft and interacting with the O4 oxygen atom of the glycosidic linkage provides 
a proton to this glycosidic oxygen. The glycosidic bond is cleaved by 1,2-elimi-
nation forming the unsaturated final product (fourth step). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Mechanism of hyaluronan degradation by S. agalactiae hyaluronate lyase strain 3502 
according to Li and Jedrzejas 66. Schematic representation of hyaluronic acid with HA1 and HA2 
as disaccharide units and the position of the side chains of Tyr488, His 479 and Asn429 relative 
to the substrate. 
 
In the final step, the catalytic residues are regenerated: His479 is deprotonated 
and Tyr488 is protonated by a water molecule. 
Supported by elucidation of 3D structures of S. pneumoniae and S. agalactiae 
strain 3502 hyaluronidases in complex with hyaluronan fragments of various 
lengths, the PAD mechanism has been supposed to result in a processive 
mode of degradation of the polymeric substrate69,71. Furthermore, chondroitin 
and chondroitin sulfate were exposed to hyaluronate lyases. Hyaluronate lyase 
of GBS was found to cleave chondroitin and chondroitin-6-sulfate but not chon-
droitin-4-sulfate72,73. This profile of action is in accordance with the X-ray struc-
ture of hylSpn in complex with chondroitin and chondroitin sulfate disaccha-
rides74. 
The three catalytic residues, Asn429, His479 and Tyr488 in hyaluronate lyase 
of S. agalactiae strain 3502, are conserved among all known bacterial hyalu-
ronidases, but the aromatic patch residues, including Trp371, Trp372 and 
Phe423, are only partly conserved66. The difference in the aromatic patch com-
O
NH2O
N
NH
Asn429
His479
Tyr488
HA1
HA2
O
HN
HO
O
O
OH
O
O
HO
COOH
HO
O
O
OH
HO
H
O
HN
HO
O
O
OH
O O
H
OH
5
1 3
41
Chapter 1 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 12 
position may explain the different enzymatic activities of the hyaluronate lyases. 
The bacterial enzymes containing the complete aromatic patch like hylB3502 and 
hylSpn act in a processive way and produce the disaccharide only whereas 
bacterial enzymes possessing Trp371 and Trp372 but not Phe423 operate in a 
nonprocessive degradation pattern and differ in their enzymatic products, e.g. 
Streptomyces hyalurolyticus hyaluronate lyase produces a mixture of tetra- and 
hexasaccharides and no disaccharides75,76. By contrast, Kuhn et al.77 found that 
hylB4755 degrades HA via a nonprocessive way since at all stages of digestion a 
mixture of oligosaccharides of different size were present. 
Bacterial hyaluronate lyases are considered as virulence factors that facilitate 
the spreading of bacteria in host tissues by degradation of hyaluronan78,79. Hu-
man infection by S. agalactiae is one of the major causes of meningitis and 
septicaemia and many other serious diseases leading to death in neo-
nates28,80,81. To study the role of hyaluronan and hyaluronidases in bacterial 
infection, the design and development of hyaluronate lyase inhibitors become 
more and more important. 
In this study, hyaluronidases from bovine testis and from S. agalactiae strain 
4755 (hylB4755) were used to determine the inhibitory potency of the synthesized 
putative inhibitors. HylB4755 shows sequence identities of 98% with the homolo-
gous enzyme of S. agalactiae strain 350282 and of 53% with S. pneumoniae 
hyaluronidase83. 
 
 
1.3 Medical applications of hyaluronan and hyaluroni-
dases 
 
HA has found applications in various medical and pharmaceutical areas owing 
to its high water-binding capacity and the viscoelasticity of its solutions. In the 
late 1950s, hyaluronan was probably applied for the first time to humans, in fact 
as vitreous humor supplement/replacement during eye surgery, an application 
which has proved therapeutically useful up to now (e.g. in cataract surgery)84. 
Since HA retains moisture it is used in some cosmetics to keep skin young and 
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fresh-looking85. Sodium hyaluronate and a covalently cross-linked form of hyalu-
ronan are successfully applied for the treatment of osteoarthritis86. Anabolic ef-
fects of HA on degraded bovine articular cartilages suppress their degenera-
tion87. Moreover, HA normalizes the properties of synovial fluids88 and produces 
an analgesic effect89,90. A rapid increase of hyaluronan levels can occur in many 
clinical situations, e.g. shock incidents, septicaemia and in burn patients91. 
The therapeutical benefit of hyaluronidases is based on the cleavage of hyalu-
ronan in tissues resulting in increased membrane permeability, a reduced vis-
cosity and a facilitated diffusion of injected fluids. These phenomena are re-
ferred to as spreading effect of hyaluronidases. The ability to promote penetra-
tion and spread are used to accelerate and increase absorption of injected 
drugs, e.g. antibiotics, to promote resorption of excess fluids, to improve the 
effectiveness of local anaesthesia and to diminish pain due to subcutaneous or 
intramuscular injection of fluids13,52. For many years, hyaluronidases, especially 
BTH preparations, are widely used in many fields like orthopaedia, surgery, 
ophthalmology, internal medicine, oncology, dermatology and gynaecology52,92-
94. Because of the BSE risk the supply of BTH preparations was stopped. As a 
consequence, a number of cases of iatrogenic strabismus have been observed 
after cataract surgeries95. With respect to this shortage, pharmaceutical prepa-
rations with bacterial54 or ovine96 hyaluronidase are suggested as replacement 
of BTH. Sperm hyaluronidase is involved as a key player in successful fertiliza-
tion in most mammalians, including humans97,98. 
Hyaluronidase has been investigated as an additive to chemotherapeutic drugs 
for augmentation of the anticancer effect56,99-101. There is evidence that hyalu-
ronidase may have intrinsic anticancer effects and can suppress tumor progres-
sion. Furthermore, Zahalka et al.102 showed in an animal model of T cell lym-
phoma that hyaluronidase blocks lymph node invasion by tumor cells. However, 
the findings are rather inconsistent. The specific function of Hyal1 and Hyal2 in 
different tumors is still contradictory and also the angiogenic effect of HA frag-
ments must be regarded. 
Selective and potent hyaluronidase inhibitors are not available so far. On one 
hand such compounds could be of potential therapeutical value as drugs. On 
the other hand hyaluronidase inhibitors are required as pharmacological tools to 
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investigate the physiological and pathophysiological role of the enzyme and its 
substrate hyaluronan. 
 
 
1.4 Inhibitors of hyaluronidases 
 
The first studies documenting the existence of hyaluronidase inhibitors emerged 
half a century ago103-105. Already in 1952, inhibitory effects on bovine testicular 
hyaluronidase were reported for iron, copper and zinc salts, heparin, polyphe-
nols and flavonoids106. Based on the structural similarity to HA, heparin and 
heparan sulfate have been investigated as inhibitors of hyaluronidase but inhi-
bition was observed only at concentrations much higher than physiological lev-
els107-109. Inhibition of hyaluronidases was also described for other structurally 
related compounds, for instance, alginic acids comprising L-glucuronic acid and 
D-mannuronic acid110, O-sulfated glycosaminoglycans in which fully sulfated 
substances showed the highest inhibitory activity111, fully O-sulfated HA oligo-
saccharides112 or dextran sulfate113. 
Further examples of inhibitors can be found in many classes of substances. For 
instance, some flavones and flavone analogs like apigenin and kaempferol in-
hibit hyaluronidase114-119, but not selectively and only at millimolar concentra-
tions120. Other natural products like saponins and sapogenins121, norlignans122 
and extracts of plants or feces109,123-128 reveal likewise weak inhibitory activity. 
Furthermore, it is well known that various anti-allergic drugs such as disodium 
cromoglycate (DSCG), tranilast and traxanox possess inhibitory effects on hya-
luronidase119,129. Moreover, the anti-inflammatory drug indomethacin was found 
to inhibit hyaluronidase in vivo130. Other anti-inflammatory agents like glycyr-
rhizin131, phenylbutazone and oxyphenbutazone132 are also mentioned to 
weakly inhibit hyaluronidases. Recently, vitamin C133, L-arginine derivatives134 
and cis-unsaturated fatty acids135 were reported to inhibit a streptococcal hyalu-
ronidase with IC50 values at (sub)millimolar concentration whereas 
lanostanoids136 revealed IC50 values in the micromolar range. According to the 
literature, DSCG was one of the most potent inhibitors (IC50 value 29 µM119) of 
bovine testicular hyaluronidase. However, when we investigated DSCG as a 
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reference substance in our test system by using a turbidimetric assay (see 
chapter 3 and 5.5.3), the compound proved to be much less active on BTH with 
50% inhibition at a concentration of 5.6 mM. Moreover, IC50 values of 1.5 mM 
(at pH 5) and 4.3 mM (at pH 7.4) were determined on the hyaluronate lyase of 
S. agalactiae strain 4755. 
A comparison of the published data (% inhibition and IC50 values) of all afore-
mentioned compounds is impossible because of differences in the applied test 
systems (e.g. incubation conditions, enzymes, enzyme concentrations and sub-
strate concentrations). Owing to the increasing interest in hyaluronan and hyalu-
ronidases, their physiological and pathophysiological role and their clinical ap-
plications selective and potent inhibitors are required as pharmacological tools 
and potential drugs as well, e.g. as new anti-fertility agent or as antimicrobial 
agent against penicillin-resistant bacteria like S. pneumoniae137,138. But it is ap-
parent that the systematic search for inhibitors has barely begun. 
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Chapter 2 
Objectives 
To date, potent and selective inhibitors of hyaluronidases are not known. Such 
compounds are needed as pharmacological tools to study the physiological and 
pathophysiological role of hyaluronan and hyaluronidases. Moreover, such 
agents might be useful as drugs in the treatment of various diseases, e.g. can-
cer, arthroses or bacterial infections, or as contraceptives. The main goal of this 
thesis was the synthesis of hyaluronidase inhibitors starting either from struc-
tures suggested by molecular modeling or from already known putative inhibi-
tors. The inhibitory effects of the considered molecules should be investigated 
on hyaluronate lyase from S. agalactiae and on the bovine testicular hyaluroni-
dase as main representatives of the bacterial and mammalian enzymes, re-
spectively. 
Vitamin C, known to bind to the active site of bacterial hyaluronidase from S. 
pneumoniae, was envisaged as a core structure for potential hyaluronidase in-
hibitors. The first part of this doctoral project comprises the synthesis and 
pharmacological investigation of various ascorbic acid derivatives with in-
creased lipophilicity. To gain insight into the enzyme-inhibitor interaction on a 
molecular level the crystal structure of vitamin C derivatives co-crystallized with 
the hyaluronate lyase of S. pneumoniae should be enlightened in cooperation 
with the group of Dr. Jedrzejas†. 
These days, one of the most promising strategies for the design and develop-
ment of enzyme inhibitors is Computer-Aided Drug Design (CADD). CADD is 
                                            
† The co-crystallization experiments have been carried out by Dr. Mark J. Jedrzejas (Children’s 
Hospital Oakland Research Institute, Oakland, California 94609, USA) and Dr. Daniel J. Rigden 
(National Centre of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, D.F. 
70770-900, Brazil). 
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accelerating the discovery of new lead compounds and their structural optimi-
zation. The elucidation of the three-dimensional structures of two bacterial hya-
luronidases enabled a rational de novo design approach identifying 1,3-diace-
tylbenzimidazole-2-thione as a lead structure‡. Thus, the second part of this 
project deals with the optimization of the benzimidazole lead structure by struc-
tural modification and investigation of the inhibitory activities. 
Recently, the binding mode of an alkyl-2-phenylindole, 1-decyl-2-(4-sulfamoyl-
oxyphenyl)-1H-indol-6-yl-sulfamate, co-crystallized with S. pneumoniae hyalu-
ronate lyase was determined by means of X-ray analysis†. By comparison of 
this binding mode with known structure-activity relationships of 2-phenylindoles, 
the putative binding mode of benzoxazole-2-thiones as bacterial hyaluronidase 
inhibitors was suggested‡. To verify this hypothesis a set of benzoxazole deriva-
tives was synthesized and tested for inhibitory activity in the third part of this 
doctoral project. Additionally, the structure-activity relationships should be dis-
cussed in order to get more information for further developing inhibitors. 
The fourth part of the project based on the binding mode of the 2-phenylindole 
as well. Derived from this model of molecular interaction substituted indole de-
rivatives were prepared and pharmacologically investigated. 
 
 
 
 
 
 
 
 
 
 
                                            
‡ Molecular modeling studies have been carried out by Alexander Botzki as part of his PhD 
project, Universität Regensburg, 2004. 
 19 
Chapter 3 
Methods for the determination of 
hyaluronidase activity 
3.1 Introduction 
 
Since the discovery of the hyaluronidases in the year 192819, various methods 
for the determination of their enzymatic activity were devised. Many of them 
seem to be rarely used and are sparsely discussed in literature. Hynes and Fer-
retti139 gave an overview on the applied methods, which should be applicable to 
hyaluronidases from either microbial or mammalian sources. They classified the 
different assays into spectrophotometric, radiochemical, fluorogenic, enzymo-
immunological, plate (solid media) assays as well as chemical, physicochemical 
and zymographic analyses. Stern and Stern140 discussed the advantages and 
limitations of the conventional methods in their article about an ELISA-like as-
say for hyaluronidase and hyaluronidase inhibitors. Recently, new assay meth-
ods were described for rapid determination of hyaluronidase activity. For in-
stance, a combination of fluorescently labeled HA and gel filtration on high-per-
formance liquid chromatography (HPLC) was used to examine the degree of 
digestion141. Moreover, a flow cytometric method detecting the decrease in fluo-
rescence of substrate-coated beads142, a fluorimetric Morgan-Elson assay143 
and quartz crystal impedance technique144 were reported for measuring hyalu-
ronidase activity. 
All compounds synthesized within this doctoral project were investigated for 
their inhibitory effect on the enzymatic activity of S.agalactiae hyaluronate lyase 
strain 4755 and Neopermease®, a commercially available preparation of bovine 
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testicular hyaluronidase. A turbidimetric assay and/or a colorimetric assay were 
used to determine the inhibitory potency of the test compounds. The principles 
of both assays are described in the following. 
 
 
3.2 Turbidimetric assay 
 
According to the classification of Hynes and Ferretti139 this assay is subsumed 
under the group of physicochemical assays. In general, the procedure is based 
on the turbidity, which results from addition of different reagents forming insolu-
ble complexes with HA and their degradation products. Afterwards the optical 
density was photometrically determined. 
In 1956 Di Ferrante145 described a turbidimetric method for the determination of 
hyaluronidase activity. This procedure is based on the formation of insoluble 
complexes between cetyltrimethylammonium bromide (CTAB) and the residual 
high molecular weight substrate (mw > 8 kDa) after incubation with enzyme 
(Fig. 3.1). 
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Fig. 3.1: Principle of the turbidimetric method described by Di Ferrante145 for the determination 
of hyaluronidase activity 
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The turbidity is proportional to the amount of high molecular weight HA frag-
ments. Therefore, the enzymatic activity can be quantified by turbidimetric 
measurements at 600 nm by means of reference samples. The assay is highly 
reproducible, fast and easy to perform. Moreover, the precipitation reagent is 
stable. This is in contrast to the classical turbidimetric method described by 
Kass and Seastone146, who used unstable reagents including proteins. Further-
more, the CTAB reagent stops the enzymatic reaction and produces the turbid-
ity at the same time. The detailed procedure of the modified method of Di Fer-
rante145, which is established at our laboratory, as well as the calculation of the 
inhibitory activity of the examined compounds are described in the experimental 
part (see 5.5.3). 
 
 
3.3 Morgan-Elson assay 
 
For investigation of the potential enzyme inhibitors the hyaluronidase activity 
was quanitified using a colorimetric assay (Morgan-Elson assay). This assay, a 
chemical assay according to the classification by Hynes and Ferretti139, is based 
on the methods of Gacesa et al.147 and Reissig et al.148 and reported in detail by 
Muckenschnabel et al.149. The reaction of terminal N-acetyl-D-glucosamine with 
p-dimethylaminobenzaldehyde (Ehrlich’s reagent) results in a red colored prod-
uct, which can be photometrically detected at 586 nm. Consequently, the hyalu-
ronidase activity is determined by quantitation of the N-acetyl-D-glucosamine 
residues at the reducing ends of hyaluronan and HA fragments produced by 
enzymatic degradation. 
Based on HPLC-MS studies Muckenschnabel et al.149 suggested a mechanism 
for the Morgan-Elson reaction and a structure of the red colored product (Fig. 
3.2). Under the reactions conditions (100 °C, pH 9) N-acetyl-D-glucosamine at 
the reducing end is cleaved off forming the chromogens I (α-configuration) and 
II (β-configuration). Subsequently, treatment with concentrated hydrochloric acid 
and glacial acid leads to an elimination of water. Finally, the chromogen III re-
acts with p-dimethylaminobenzaldehyde (Ehrlich’s reagent) to form the reso-
nance-stabilized product possessing absorbance maxima at 545 nm and 586 
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nm. This red colored compound is sensitive to light and chemically rather un-
stable (t1/2 < 1 min). 
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Fig. 3.2: Mechanism of the Morgan-Elson reaction – reaction of N-acetyl-D-glucosamine with 
p-dimethylaminobenzaldehyde resulting in the red colored product postulated by Muckenschna-
bel et al.149 
 
This method is not applicable to the investigation of those hyaluronidase inhibi-
tors which are reactive towards Ehrlich’s reagent. For instance, the products 
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formed by reaction of indoles (cf. chapter 7.3) with dimethylaminobenzaldehyde 
are also detectable at 590 nm, so that the quantification of the red colored 
product of the Morgan-Elson assay is falsified. For details of the experimental 
procedure and the calculation of the inhibitory activity of the investigated com-
pounds see section 4.5.3. 
 
 
3.4 General conditions applied to the assays 
 
3.4.1 Effect of organic solvent on enzymatic activity 
Both the turbidimetric assay and the Morgan-Elson assay were performed in a 
buffered aqueous solution. Many of the tested potential inhibitors are poorly 
soluble under this conditions unless organic solvent is added. Therefore, differ-
ent solvents like DMF, DMSO, ethanol or methanol, in which the compounds 
are readily soluble, were investigated for their influence on the enzymatic activ-
ity of the hyaluronidases. Salmen120 determined the activity of hyaluronidase 
depending on the portion of organic solvent in the buffer. The effects of the 
aforementioned solvents on a bovine testicular hyaluronidase were negligible 
up to concentrations of 4%. Higher concentrations resulted in a weak to strong 
inhibition of the enzyme depending on the type of solvent. The effects of 
methanol, ethanol and DMSO on the bacterial enzyme hylB4755 were also negli-
gible at concentrations up to 4%, whereas the inhibitory effect of DMF was al-
ready significant at a concentration of 3%120. 
The effects of DMSO, DMF, methanol, ethanol and acetonitrile on the activity of 
hyaluronate lyase from S. agalactiae strain 4755 in the turbidimetric assay are 
illustrated in Figs. 3.3 and 3.4. At the pH optimum of hylB4755 it is obvious that 
3.7 % of DMSO or the two alcohols are well-tolerated as solvent (see Fig 3.3). 
By contrast, DMF and acetonitrile already exhibit a significant inhibition effect on 
the enzymatic activity at concentrations of 3%. The same tendency was ob-
served for the influence of the five solvents on hylB4755 at physiological pH as 
shown in Fig. 3.4. 
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Fig. 3.3: Inhibitory effect of DMSO, DMF, methanol, ethanol and acetonitrile on hylB4755  at pH 5 
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Fig. 3.4: Effect of DMSO, DMF, methanol, ethanol and acetonitrile on the activity of the bacte-
rial hyaluronidase hylB4755 at physiological pH (7.4) 
With the exception of DMF, the investigated organic solvents were inactive on 
the activity of Neopermease®, a bovine testicular hyaluronidase, up to concen-
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trations of 3.7 % as shown in Fig. 3.5. For the investigation of all hyaluronidase 
inhibitors described in this thesis, a percentage of 3.7 % of organic solvent in 
the buffer was used in the turbidimetric assay. DMSO was chosen as solvent 
since the test compounds were readily soluble in this solvent. Moreover, DMSO 
had no remarkable influence on the enzymatic activity of the two enzymes. 
 
(v/v) organic solvent in %
0 1 2 3 3,7 5 10 15
en
zy
m
at
ic
 a
ct
iv
ity
 in
 %
0
20
40
60
80
100 DMSO
DMF
MeOH
EtOH
CH3CN
 
Fig. 3.5: Influence of DMSO, DMF, methanol, ethanol and acetonitrile on the activity of bovine 
testicular hyaluronidase (Neopermease®) at pH 5 
 
In spite of the addition of DMSO to the buffer not all compounds remained com-
pletely dissolved during the assays at the applied concentrations. Hence, the 
results of the turbidimetric and colorimetric measurements to determine the en-
zymatic activity can be adulterated since the effective concentration of the test 
compounds may be lowered by precipitation, and undissolved compounds can 
cause a turbidity of the solution. Therefore, the solubilities of the inhibitors were 
tested in a separated experiment (cf. solubility tests in 5.5.3) and the maximum 
concentrations of the compounds in the assay were adapted accordingly to pre-
vent precipitation. 
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3.4.2 Influence of the pH value on the enzymatic activity 
The activities of the two hyaluronidases from different sources (bovine testis, 
Streptococcus agalactiae) are dependent on the pH value. Both aforementioned 
assays were applied to determine the enzyme activity under comparable condi-
tions as a function of pH. As shown in Fig. 3.6, the results from both assays 
were in good agreement for the hyaluronate lyase. The bacterial enzyme exhib-
its maximum activity at pH 5 and markedly reduced activity at physiological pH. 
 
 
Fig. 3.6: pH-profile of hyaluronate lyase from S.agalactiae strain 4755 measured by the 
colorimetric and the turbidimetric assay150 
 
By contrast, the pH profile of the bovine testicular hyaluronidase is almost in-
verted comparing the colorimetric and the turidimetric assay (see Fig. 3.7). This 
phenomenon can be ascribed to three enzymatically active fractions contained 
in the preparation Neopermease®150. 
To determine the enzyme selectivity the compounds were tested at the same 
pH value on the two enzymes: the inhibition was measured at pH 5, the pH op-
timum of hylB4755, since both BTH and hylB4755 exhibit a sufficiently high activity 
under these conditions. Additionally, the synthesized compounds were tested 
for inhibition of hylB4755 at physiological pH. 
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Fig. 3.7: Effect of pH on the activity of bovine testicular hyaluronidase (Neopermease®) as a 
function of the type of assay150 
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Chapter 4 
Vitamin C derivatives as hyaluronidase 
inhibitors 
4.1 Introduction 
 
The biological importance of L-ascorbic acid (vitamin C) was initially associated 
with scurvy, the symptoms of vitamin deficiency. Insights into the biochemistry 
of ascorbic acid revealed its key role in a variety of physiological processes in-
cluding, for example, the production of collagen151 or the function as an antioxi-
dant and free radical scavenger. It plays also an important role in activating 
peptide hormones, regulating cell division and growth133. Furthermore, it acts as 
an electron donor for several enzymatic reactions, is implicated in host defense 
mechanisms152 and is discussed to be involved in the prevention of various dis-
eases151. Moreover, vitamin C and its derivatives are reported to possess antitu-
mor and antiviral activities153. Abell et al.154 found that L-ascorbic acid is an in-
hibitor of various α-amylases. But, the mechanisms of vitamin C interaction with 
proteins and enzymes are still largely unknown. The first observed protein-
ascorbic acid interaction at the molecular level was found in the crystal structure 
of D-xylose isomerase (pdb-file: 1XID)155. 
Vitamin C was reported to be an inhibitor of bovine testicular hyaluronidase51. 
Recently, Li et al.133 elucidated the crystal structure of the bacterial hyaluroni-
dase hylSpn in complex with L-ascorbic acid (pdb-file: 1F9G). It was confirmed 
that vitamin C binds to the active site of the hylSpn. However, the hyaluronidase 
inhibitory activity is rather low (IC50 value of approximately 5.8 mM133). The 
bound compound provided 25 interactions with 7 amino acid residues of the 
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R1 = H, alkyl, benzyl
R2 = alkyl, benzyl
enzyme. Trp292 and Tyr408, which is one of the three key catalytic residues in 
the hyaluronan degradation, formed the most 
interactions confirming that the aromatic patch 
and the catalytic group of the active center are 
involved in binding of vitamin C. Moreover, it 
was indicated that hydrophobic interactions play 
an important role inside the active site. Thus, 
vitamin C derivatives with increased 
hydrophobicity could be stronger inhibitors of 
bacterial hyaluronidase. This prompted us to 
synthesize various ascorbic acid derivatives with lipophilic substituents (see Fig. 
4.1). 
 
 
4.2 Chemistry 
 
The 6-O-acylated ascorbic acid derivatives 4.18-4.24 were accessible via the 
synthetic route illustrated in Schemes 4.1 and 4.2. Using L-ascorbic acid as 
starting material, the four hydroxyl groups must be protected in a way which 
allows selective deprotection followed by 6-O-acylation. Therefore, an inverse 
protecting strategy was chosen by initially protecting the diol moiety in positions 
5 and 6 as acetonide. Afterwards, the enediol system was protected by etherifi-
cation with protecting groups (PG), which are stable under the acidic conditions 
used to cleave the isopropylidene PG. In the next step, the ester group was se-
lectively introduced by selective esterification at the primary alcohol group. At 
last, the PG of the enediol system was cleaved to obtain the various 6-O-acy-
lated ascorbic acids. 
Ascorbic acid derivatives 4.9-4.11 were synthesized according to a modified 
four-step reaction sequence following a procedure described by Sanders156 as 
shown in Scheme 4.1. In the first step, ascorbic acid was converted into 4.2 by 
stirring in anhydrous acetone in the presence of catalytic amounts of acetyl 
chloride. The different PGs of the enediol system were introduced with the ap-
propriate halo compounds using potassium carbonate as base in DMF. In the 
Fig. 4.1: Target compounds 
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case of 4.4, the nucleophilic substitution worked only when using the more re-
active benzyl bromide at 40 °C instead of benzyl chloride at 60 °C. By treatment 
with acetic acid (50 %) in methanol at 80 °C for several hours, the isopro-
pylidene protecting group was removed yielding the vitamin C derivatives 4.6-
4.8. 
O
HO
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O O
HO
OH
O
O
O
O
O
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O
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R'
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OH
OH
O
R'
R
O
O
O
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R'
R
(CH2)14CH3
O
4.1 4.2
4.3-4.54.6-4.8
4.9-4.11
i
ii
iv
iii
R     R'
Me   Me
Bn    Bn
CH2-CH2
4.3, 4.6, 4.9
4.4, 4.7, 4.10
4.5, 4.8, 4.11
Reagents: i) abs. acetone, AcCl(cat.); ii) K2CO3, RI or RBr or 1,2-dibromo-
ethane, DMF; iii) 50% HAc, MeOH, 80 °C; iv) pyridine, CH3(CH2)14COCl, 
DMAP(cat.)
 
Scheme 4.1: Synthetic pathway to various 6-O-palmitoyl ascorbic acid derivatives 
 
Finally, the O-acylation at the primary alcohol function was performed in di-
chloromethane with palmitoyl chloride and pyridine as base in the presence of 
the acylation catalyst DMAP resulting in the 6-O-palmitoyl ascorbic acid deriva-
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tives 4.9-4.11. For the synthesis of 4.11, pyridine was used both as solvent and 
as base since 4.8 was only weakly soluble in dichloromethane. 
Various 6-O-acylated ascorbic acids were accessible following the strategy de-
picted in Scheme 4.2. For this purpose, the enediol system was benzyl-pro-
tected since the solubility of the starting compound 4.7 in dichloromethane 
(DCM) was improved compared to 4.6 and 4.8. Benzyl-protected ascorbic acid 
4.7 was converted into 6-O-acylated derivatives 4.12-4.17 via two methods. Ei-
ther 4.7 was treated with the pertinent acid chloride, pyridine (as base) and 
catalytic amounts of DMAP in anhydrous DCM, or the corresponding carboxylic 
acid was treated with 4.7 in anhydrous DCM using CDI as coupling reagent. 
The benzyl ether was cleaved by hydrogenolysis (H2/Pd-C) resulting in high 
yields of the 2-O-,3-O-deprotected ascorbic acid derivatives 4.18-4.23. 
O
HO
OH
OH
O
O
R
O
O
BnO
OBn
OH
OH
O
4.7
O
BnO
OBn
OH
O
O
R
O
4.12: R = C(CH3)3
4.13: R = (CH2)2CH3
4.14: R = (CH2)4CH3
4.15: R = (CH2)10CH3
4.10: R = (CH2)14CH3
4.16: R = (CH2)16CH3
4.17: R = Ph
4.18: R = C(CH3)3
4.19: R = (CH2)4CH3
4.20: R = (CH2)10CH3
4.21: R = (CH2)14CH3
4.22: R = (CH2)16CH3
4.23: R = Ph
i
ii
Reagents: i) Method A:
RCOCl, pyridine, DMAP
(cat.), DCM; Method B:
RCOOH, CDI, DCM; 
ii) 10% Pd/C, H2, 5 bar,
EtOH
Scheme 4.2: Conversion of 4.7 into 6-O-acylated ascorbic acids 
 
4.3 Results and discussion 
 
The inhibitory effect of the L-ascorbic acid derivatives on the activity of the hya-
luronidases were examined both in a turbidimetric assay and in the Morgan-El-
son assay (see chapter 3). To investigate the selectivity of these compounds 
both assays were performed with a bacterial hyaluronidase from S.agalactiae 
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(hylB4755) and either Hylase Dessau® or Neopermease®, which are hyaluroni-
dase preparations from bovine testis. 
 
4.3.1 Inhibitory activity of L-ascorbic acid derivatives on hyalu-
ronidases determined with a turbidimetric assay 
The turbidimetric method was used to determine the inhibitory activity of the 
vitamin C derivatives on hylB4755 at pH optimum (pH 5) and at pH 7.4. 
Table 4.1: Inhibitory effect of L-ascorbic acid derivatives on hyaluronate lyase from S.agalactiae 
strain 4755 and bovine testicular hyaluronidase (Neopermease®) (turbidimetric assay) 
 
 
 
 
 
No. R R’ R1 hylB4755, IC50 [µM] or %a BTHa 
    pH = 5.0 pH = 7.4 pH = 5.0 
4.1 H H H 6100 ± 100 inactiveb inactivec 
4.6 CH3 CH3 H inactived inactived inactived 
4.7 Bn Bn H 355.1 ± 59.2 1114 ± 72 inactived 
4.8 CH2-CH2 H 24 % (2000) inactived inactived 
4.9 CH3 CH3 CO(CH2)14CH3 5 % (160) inactivee inactivee 
4.10 Bn Bn CO(CH2)14CH3 inactivee inactivee inactivee 
4.11 CH2-CH2 CO(CH2)14CH3 32 % (190) 49.34±6.6 inactivee 
4.18 H H COC(CH3)3 43 % (1100) 13 % (1100) inactivef 
4.19 H H CO(CH2)4CH3 475 ± 16.1 1077 ± 27 inactived 
4.20 H H CO(CH2)10CH3 6.71 ± 0.28 14.40 ± 1.37 219.0 ± 10.7 
4.21 H H CO(CH2)14CH3 4.22 ± 0.13 6.57 ± 0.07 56.5 ± 1.31 
4.22 H H CO(CH2)16CH3 0.93 ± 0.11 3.35 ± 0.25 38.6 ± 1.10 
4.23 H H COPh 131.6 ± 5.9 459.6 ± 12.8 33 % (1430) 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at inhibitor con-
centration given in parentheses; highest tested concentrations were dependent on the solubility 
of the compounds, b at concentrations ≤ 13 mM, c at concentrations ≤ 100 mM, d at concentra-
tions ≤ 2 mM, e at concentrations ≤ 200 µM, f at concentrations ≤ 1.1 mM. 
OO
O
O R'
R O
OH
R1
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Furthermore, in order to check the selectivity of the L-ascorbic acid derivatives 
for the bacterial enzyme, the inhibitory activity of the compounds was also 
tested on bovine testicular hyaluronidase using the preparation Neopermease® 
at pH 5. 
Recently, vitamin C (4.1), reported to inhibit the bovine testicular hyaluroni-
dase52, was found to be also a weak inhibitor of the hyaluronate lyase from S. 
pneumoniae (IC50 value: 5.8 mM)133. It was confirmed by X-ray analysis that L-
ascorbic acid binds to the active site of the bacterial hyaluronidase from S. 
pneumoniae. Hydrophobic interactions of 4.1 with two residues, Trp292 and 
Tyr408, within the catalytic cleft of S. pneumoniae play an important role for 
binding of 4.1. Since hydrophobic interactions have a great influence on the 
substrate-enzyme interaction in aqueous solution as well5 various L-ascorbic 
acid derivatives with increased lipophilicity were synthesized as potential hyalu-
ronidase inhibitors (see Table 4.1). 
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Fig. 4.2: Enzymatic activity of hyaluronate lyase of S.agalactiae in the presence of compounds 
4.19-4.23 at optimum pH (5) 
In contrast to Farr et al.52, but in accordance with Li et al.133., we found that vita-
min C at concentrations up to 100 mM did not inhibit the bovine testicular hyalu-
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ronidase (BTH) in the turbidimetric assay. However, the bacterial enzyme 
(hylB4755) was weakly inhibited by 4.1 at pH 5, whereas at physiological pH no 
inhibitory effect was found at concentrations ≤ 13 mM. Interestingly, vitamin C 
appeared to be an activator of hylB4755 at concentrations higher than 4 mM at 
physiological pH. In opposition to results of Okorukwu and Vercruysse157, vita-
min C (4.1) did not affect the degradation of HA under our test conditions. 
Structural modifications of the enediol system as in 4.6 and 4.8 were not toler-
ated whereas the 2-O-,3-O-dibenzylated analog 4.7 was more active than 4.1. 
4.7 is an inhibitor of the hyaluronate lyase from S. agalactiae both at optimum 
pH and at physiological pH (IC50 values of 355 µM, and about 1.1 mM, respec-
tively). This is in agreement with the hypothesis that the potency of hyaluroni-
dase inhibitors derived from vitamin C may be increased by additional hydro-
phobic interactions with amino acids in the active site. By contrast, the bovine 
enzyme was not affected by 4.7 at concentrations up to 2 mM. The structurally 
related compounds 4.6 and 4.8 showed no notable inhibition of BTH and of 
hylB4755 up to the denoted concentrations. 
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Fig. 4.3: Inhibitory effect of 4.20-4.23 on hylB4755 at physiological pH (7.4) 
At the optimum pH of hylB4755, the L-ascorbic acid derivatives 4.19-4.23 proved 
to be inhibitors with IC50 values in the lower micromolar range (IC50 values of 
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475 µM (4.19), 6.7 µM (4.20), 4.2 µM (4.21), 0.9 µM (4.22) and 131 µM (4.23); 
see Fig. 4.2). Compound 4.18 induced 43 % inhibition at a concentration of 1.1 
mM. The extension of the acyl residue in position 6 (4.19-4.23) further in-
creased the inhibitory potency compared to vitamin C – presumably as the re-
sult of additional hydrophobic interactions with the enzyme. This tendency was 
confirmed at pH 7.4, although the inhibitory activity of the vitamin C derivatives 
4.18-4.23 was a little weaker than at pH 5 (IC50 values: 1.1 mM (4.19), 14.4 µM 
(4.20), 6.6 µM (4.21), 3.4 µM (4.22) and 460 µM (4.23); see Table 4.1 and Fig. 
4.3). 
When tested on the bovine testicular hyaluronidase at pH 5 the vitamin C de-
rivatives 4.18 and 4.19 did not affect the enzyme activity at the concentrations 
used. For compounds 4.20-4.22 bearing longer alkanoyl chains at position 6-O 
of the vitamin C skeleton, IC50 values of 219 µM (4.20), 57 µM (4.21) and 39 µM 
(4.22) were determined (see Table 4.1 and Fig. 4.4). 
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Fig. 4.4: Inhibition of bovine testicular hyaluronidase (Neopermease®) by compounds 4.20-4.22 
Obviously, the length of the alkanoyl chain can regulate the selectivity of the 
inhibitors for the bacterial enzyme vs. BTH. For instance, compound 4.20 was 
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about 33-fold more potent on hylB4755 compared to BTH, whereas the shorter 
homologs were inactive at BTH. For vitamin C benzoate (4.23) only a rather 
weak inhibition by 33% was determined at a concentration of 1.4 mM. 
Structural modifications at the hydroxy groups of the enediole system of the 
strong hyaluronidase inhibitor 4.21 (see 4.9-4.11) abolished the inhibitory effect 
on BTH (the inhibitor concentrations were limited by the solubility of 4.9-4.11 in 
the buffer). Neither at optimum pH nor at physiological pH compounds 4.9 and 
4.10 inhibited hylB4755. Compound 4.11, in which the oxygens of the enediole 
moiety are linked by an ethan-1,2-diyl group, represents an exception among 
the vitamin C derivatives listed in Table 4.1: 4.11 is the only compound with 
higher activity at pH 7.4 (IC50 value: 49 µM) than at pH 5 (32 % at a concentra-
tion of 190 µM). Compared to 4.21, the inhibitory effect of 4.11 on hylB4755 de-
creased, e.g. 4.11 showed a 7-fold weaker inhibitory activity against hylB4755 at 
physiological pH. 
Among the vitamin C derivatives compound 4.22 induced the most potent inhi-
bition of hylB4755 with an IC50 value of 0.9 µM at optimum pH. It was about 6500 
times more active than the reference compound vitamin C and represents one 
of the most potent inhibitors of bacterial and bovine hyaluronidases described 
so far. 
 
Bovine testicular hyaluronidase and hylB4755 are very different enzymes, for in-
stance, in terms of molecular mass, enzymatic mechanism and turnover. In or-
der to obtain comparable data for the inhibition of the bacterial and the bovine 
enzyme and to gain information on the enzyme selectivity of the compounds the 
hyaluronidase assays had to be carried out at equimolar enzyme concentra-
tions. Therefore, prior to the screening of the new hyaluronidase inhibitors, in-
vestigations were performed to identify equimolar concentrations of the bacterial 
enzyme (hylB4755) and the bovine enzyme under the same reaction conditions. 
Moreover, at equimolar concentrations of the enzymes the incubation period 
was adjusted to obtain about the same substrate degradation over time. The 
assay was carried out at pH 5, the pH optimum of hylB4755, since the BTH 
showed a sufficient activity at this pH (see chapter 3 for pH profiles). Equimolar 
amounts of hylB4755 (11.4 ng) and Neopermease® (8 ng) were incubated at 7.5 
min and 51 h, respectively, to give comparable substrate conversion. After set-
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ting the test conditions of the turbidimetric assay to equiactive and equimolar 
amounts of BTH and hylB4755 the potent inhibitor 4.21 was investigated. As 
shown in Table 4.2, the enzyme selectivity of compound 4.21 for hylB4755 vs. 
BTH slightly dropped from a 13-fold to 6-fold selectivity under equimolar con-
centrations compared to equiactive enzyme concentrations. 
 
Table 4.2: Inhibitory potency of 4.21 in the turbidimetric assay determined at equiactive enzyme 
concentrations of hylB4755 and BTH or under equimolar concentrations of enzymes at pH 5 
 
Enzyme concentration hylB4755, IC50 [µM]a BTH, IC50 [µM]a 
equiactive  4.22 ± 0.13 56.5 ± 1.31 
equimolar 6.29 ± 0.18 36.7 ± 1.44 
a inhibition of enzyme was expressed as IC50 ± SEM in µM, n = 4 
 
The differences in the IC50 values obtained under equiactive and equimolar 
conditions were in good agreement. The more convenient assay under equiac-
tive conditions was used in this doctoral thesis to determine enzyme selectivity. 
 
4.3.2 Inhibition of hyaluronidases by L-ascorbic acid deriva-
tives in the Morgan-Elson assay 
In addition to the investigation of all L-ascorbic acid derivatives in the turbidimet-
ric assay selected compounds were also investigated for inhibition of the hyalu-
ronidases in the colorimetric assay to allow for a comparison of data from both 
experimental procedures. 
In agreement with the results from the turbidimetric assay the purported inhibi-
tory effect51 of vitamin C (4.1) on the bovine enzyme was confirmed. At high 
concentrations (4.1 mM) compound 4.1 decreased the activity of the bacterial 
hyaluronate lyase only by approximately 25 % at pH 5. As also found for the tur-
bidimetric assay, 4.1 acts as an activator of hylB4755 at concentrations above 4 
mM at physiological pH. 
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Fig. 4.5: Inhibitory activities of 4.20-4.22 determined on the bacterial enzyme (hylB4755) at pH 5 
(Morgan-Elson assay) 
 
As summarized in Table 4.3, the inhibitory effect on hylB4755 at optimum pH in-
creased with the extension of the chain length from compound 4.20 to 4.22 
(4.20: 69.1 µM, 4.21: 5.5 µM, 4.22: 1.6 µM; see Fig. 4.5). This is in accordance 
with the data from the turbidimetric assay. However, the IC50 values of 4.20-
4.22 determined with the Morgan-Elson assay at pH 5 were higher than those 
found in the turbidimetric assay, whereas the opposite was found at physiologi-
cal pH. The vitamin C derivatives 4.20-4.22 were about equipotent (IC50 values: 
1.10 µM (4.20), 1.56 µM (4.21) and 1.50 µM (4.22)) at pH 7.4. Comparing the 
two assays at optimum pH, similar results were found for 4.18 and 4.23 which 
were nearly inactive in the Morgan-Elson assay on hylB4755, whereas at 
physiological pH a stronger inhibition compared to the turbidimetric method was 
determined with IC50 values of 182 µM (4.23) and 188 µM (4.18). 
The 6-O-acylated L-ascorbic acid derivatives 4.18 and 4.20-4.23 are much 
more potent inhibitors of the bacterial enzyme compared to the parent molecule, 
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for instance, the esters 4.20-4.22 are at least 1000 times more potent than vi-
tamin C in the Morgan-Elson assay. 
 
Table 4.3: Inhibitory activities in the Morgan-Elson assay determined on the S. agalactiae 
hyaluronate lyase at both physiological pH (7.4) and pH 5, and on bovine testicular hyaluroni-
dase (Hylase Dessau®) at optimum pH (3.6) and physiological pH 
 
 
 
 
 
No. R R’ R1 
hylB4755, IC50 [µM] or 
% a 
BTH, IC50 [µM]a 
    pH = 5.0 pH = 7.4 pH = 3.6 pH = 7.4 
4.1 H H H 25% (4100) inactiveb inactiveb n.d. 
4.9 CH3 CH3 CO(CH2)14CH3 10% (160) 44% (160) inactivec inactivec 
4.10 Bn Bn CO(CH2)14CH3 inactived 67% (150) inactived inactivec 
4.11 CH2-CH2 CO(CH2)14CH3 n.d. n.d. n.d. n.d. 
4.18 H H COC(CH3)3 inactivee 187.9±28 inactivee inactivee 
4.20 H H CO(CH2)10CH3 69.1±2.5 1.10±0.43 105±5 643±30 
4.21 H H CO(CH2)14CH3 5.50±0.90 1.56±0.84 60% (290) 120±60 
4.22 H H CO(CH2)16CH3 1.57±0.17 1.50±0.33 82.8±10 inactivec 
4.23 H H COPh inactivef 181.9± inactivef inactivef 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at inhibitor con-
centration given in parentheses; highest tested concentrations were dependent on the solubility 
of the compounds, b at concentrations ≤ 15 mM, c at concentrations ≤ 200 µM, d at concentra-
tions ≤ 50 µM, e at concentrations ≤ 2.5 mM, f at concentrations ≤ 1.5 mM. 
 
Neither 4.18 nor 4.23 induced an inhibitory effect on the activity of Hylase Des-
sau® at both physiological and optimum pH up to the denoted concentrations. 
Compounds 4.20-4.22 were equipotent at optimum pH of the BTH. Due to lim-
ited solubility complete inhibition of hyaluronidase could not be achieved by 
compound 4.21. Therefore, only a percentage inhibition was indicated. 
OO
O
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Fig. 4.6: Enzyme selectivity of 4.22; inhibitory effect on BTH and hylB4755 at physiological pH 
(7.4) and at optimum pH (BTH: pH 3.6; hylB4755: pH 5.0) (data from Morgan-Elson assay) 
 
At physiological pH, IC50 values of 643 µM (4.20) and 120 µM (4.21) were ob-
tained. Surprisingly, compound 4.22 showed no inhibitory effect on Hylase Des-
sau® up to 200 µM indicating highest activity to reside in compounds bearing a 
hexadecanoyl residue in position 6-O of the vitamin C structure. The sub-
stances 4.9 and 4.10 were inactive on the BTH and exhibited only very weak 
and incomplete inhibition of hylB4755 at pH 7.4 and pH 5. 
The examined compounds 4.18 and 4.20-4.23 proved to be selective for 
hylB4755 vs. BTH (see Table 4.3). As shown for compound 4.22 in Fig. 4.6, the 
selectivity is more pronounced when the assay is performed at pH 7.4 instead 
of optimum pH values. 
In general, the results obtained with the two different assays were in good 
agreement and revealed the same tendencies, although one has to take into 
consideration the different principles of the two methods and the slightly differ-
ing enzyme concentration. 
 
Chapter 4 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 42 
4.3.3 Structural elucidation of L-ascorbic acid-6-hexadecanoate 
– a potent hyaluronidase inhibitor 
Most parts of this section were included in a recent publication by Botzki et 
al.61.§ Supported by X-ray analysis of the hylSpn-L-ascorbic acid complex133 
hydrophobic interactions with Trp292 and Tyr408 were supposed to play an im-
portant role for binding of vitamin C (4.1) in the catalytic site of the bacterial 
hyaluronidase from S. pneumoniae (hylSpn). Hence, vitamin C derivatives with 
increased hydrophobic properties should lead to stronger inhibitors. This hy-
pothesis was confirmed as demonstrated in chapters 4.3.1 and 4.3.2. Subse-
quently, the potent inhibitor of hylB4755 L-ascorbic acid-6-hexadecanoate (4.21), 
a highly effective antioxidant158 and glutathione-S-transferase inhibitor159, was 
investigated on its inhibitory effect on hylSpn and in cooperation with the work 
group of M. J. Jedrzejas a crystal structure of S. pneumoniae hyaluronate lyase, 
co-crystallized with 4.21 was determined at a 1.65 Å resolution (pdb-file: 
1W3Y)61. The X-ray structure should shed light on the enzyme-inhibitor interac-
tions resulting in proposals for more potent inhibitors. The crystallization ex-
periments were performed by M. Nukui and M. J. Jedrzejas (Children’s Hospital 
Oakland Research Institute, Oakland, California 94609, USA). The X-ray struc-
ture of the complex was solved by D. Rigden (National Center of Genetic Re-
sources and Biotechnology, Cenargen/Embrapa, Basília, D.F. 70770-900, Bra-
zil). 
 
4.3.3.1 Inhibition of hyaluronidases caused by L-ascorbic acid and L-
ascorbic acid-6-hexadecanoate: a comparison 
 
As already mentioned, it was reported that L-ascorbic acid inhibited the activitiy 
of hyaluronate lyase of S. pneumoniae (hylSpn) with an IC50 value of about 6 
mM but no inhibitory effect could be observed on the bovine testicular hyalu-
ronidase measured under the same reaction conditions133. These results were 
revised using our slightly different turbidimetric assay protocol using Neoper-
mease®, a bovine testicular hyaluronidase, hylSpn and additionally, the bacte-
                                            
§ Note: The author of this doctoral thesis made substantial contribution and is co-author of this 
publication by Botzki et al. 
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rial hyaluronidase from S. agalactiae strain 4755, the bacterial enzyme prefer-
entially used in this doctoral project. At first, we had to standardize the experi-
ments for all three enzymes by performing the turbidimetric assay with equiac-
tive concentrations of all enzymes at pH 5. The enzyme activities in presence of 
4.1 and 4.21 were determined as described elsewhere61. 
In agreement with the result described in the previous sections, the bacterial en-
zymes were weakly inhibited by vitamin C (4.1) with IC50 values of 6 mM for 
hylB4755 and 35 mM for hylSpn, respectively, and 4.1 was inactive on the bovine 
enzyme up to concentrations of 100 mM. Consequently, vitamin C turned out to 
be a weak and selective inhibitor of the bacterial enzymes under the used reac-
tion conditions. As depicted in Fig. 4.7, vitamin C ester 4.21 displayed a strong 
inhibitory effect on hylB4755 with an IC50 value of 4 µM. On the related bacterial 
enzyme hylSpn and the bovine testicular hyaluronidase IC50 values of 100 µM 
and 56 µM, respectively, were determined. Compared to the parent compound 
4.1, 6-O-palmitoyl-L-ascorbic acid (4.21) is an up to 1500 times more potent 
inhibitor of bacterial and bovine hyaluronidases (see Table 4.4). 
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Fig. 4.7: Inhibition of hylB4755, hylSpn and Neopermease® (BTH) by L-ascorbic acid-6-hexa-
decanoate (4.21) 
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Table 4.4: IC50 values ± SEM of vitamin C (4.1) and L-ascorbic acid-6-hexadecanoate (4.21) 
determined on equiactive concentrations of S. pneumoniae hyaluronate lyase, S. agalactiae 
hyaluronate lyase strain 4755 and BTH (Neopermease®) using a turbidimetric assay at pH 5 
 
Compound hylB4755, IC50 [µM] hylSpn, IC50 [µM] BTH, IC50 [µM] 
4.1 6100±100 34800±300 inactive (< 100 mM) 
4.21 4.2±0.13 100.0±2.00 56.5±0.13 
 
Furthermore, 4.21 is about 25-fold more active on hylB4755 than on hylSpn 
whereas 4.1 revealed only a 6-fold selectivity. Moreover, the selectivity of 4.21 
for the bacterial enzyme vs. BTH is only weak. With respect to the selectivity for 
the enzymes further explorations are necessary since the obvious selectivity 
cannot be quantitatively confirmed without the data for the Km values of the ap-
plied HA substrate. 
Finally, it can be concluded that additional hydrophobic enzyme-inhibitor inter-
actions enhance the inhibitory effect as confirmed by the distinctly higher in-
hibitory activity of 4.21 on all investigated enzymes compared to 4.1. 
 
4.3.3.2 The binding mode of 6-O-palmitoyl-L-ascorbic acid to S. pneumo-
niae hyaluronidase 
 
In order to determine the binding mode of compound 4.21 the X-ray structure of 
hylSpn co-crystallized with L-ascorbic acid-6-hexadecanoate was determined at 
1.65 Å resolution (pdb-file: 1W3Y)61. This information should be useful to create 
a model for the interactions of the inhibitor with amino acid residues inside the 
active site of the enzyme and should facilitate the further development of more 
potent inhibitors. The hylSpn part of the complex structure contains an N-termi-
nal α-domain and a C-terminal β-domain connected by a 10-residue linker and 
has only slight changes when compared with the native hylSpn68 and the vita-
min C-hylSpn133 crystal structures. The active site of the enzyme is situated in 
the predominant cleft between α- and the β-domains. The catalytic mechanism 
as proposed79,160-162 has been supported by structural determinations66,67,71,160 
and mutagenesis studies67,71,163. Catalysis is implemented at the narrowest part 
of the catalytic cleft in which Asn349, His399 and Tyr408 are mainly responsible 
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for it. Additionally, a hydrophobic patch consisting of Trp291, Trp292 and 
Phe343 contributes to precise positioning of the substrate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The electron density at the binding site enabled the satisfactory localization of 
4.21 within the active site of hylSpn as shown in Fig. 4.8. The final X-ray struc-
ture offered additional difference electron density and elevated B-factors of the 
inhibitor (Table 4.3) suggesting the possibility of alternative binding modes of 
4.21. However, despite repeated attempts, only the conformation shown was 
well supported by the density. Surprisingly, the lactone ring of the inhibitor 
seems to bind in a ring-opened form which was evident from electron density, 
although the vitamin C portion of 4.21 binds to the same region as intact vitamin 
C133. Possibly, the ring-opened form was emerged during the crystallization time 
(Fig. 4.8). It is well-known that oxidation of L-ascorbic acid (4.1) gives L-dehy-
droascorbic acid, which is rapidly degraded under physiological conditions (pH 
7.4) via L-diketogulonate to yield L-erythrulose and oxalate164. It is suggested 
that 4.21 is modified in a similar manner, but only the hydrolyzed lactone moiety 
was modeled into the electron density. However, it is unlikely that ring-opening 
Y408 
H399 
T400 
F343 
W291 
W292 
N290 
Fig. 4.8: Binding mode of L-ascorbic acid-6-hexadecanoate (4.21) at the active site of 
hylSpn. Distances for possible Hydrogen Bonds: N290-O5: 1.65 Å; Y408-COO: 1.78 Å 
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occurs during the performance of the enzymatic assay with respect to the much 
shorter time needed for the assay. 
As shown in Fig. 4.8, 4.21 binds within the catalytic site of hylSpn explaining the 
inhibitory activity. With the exceptions of a hydrogen bond between the carb-
oxylate group of the inhibitor and the hydroxyl of Tyr408 and others between the 
hydroxy groups at C-4 and C-5 and Asn290 the majority of protein-inhibitor in-
teractions are hydrophobic. The hydrophobic face of the vitamin C portion lies 
flat on the side chain of Trp292, a member of the hydrophobic patch. Such an 
arrangement is quite common in complexes of carbohydrate-binding proteins 
with their ligands165. The palmitoyl moiety fits in a mainly hydrophobic surface 
crevice. With the exception of three terminal carbon atoms for which density did 
not permit modeling the aliphatic chain matches very well with the existent 
electron density. The palmitoyl group forms hydrophobic interactions with 
Trp291 and Phe343, both contributing to the hydrophobic patch along with 
His399 and Thr400. 
 
H399 Y408 
N290 
W291 
W292 
Fig. 4.9: Illustration of the binding site of 4.21 (carbon atoms are colored in yellow, oxygen 
atoms are colored in red and nitrogen atoms are illustrated in white) with Connolly surface 
(sample radius: 1.4 Å). The color encoding range from brown (high lipophilicity) to blue 
(polar). 
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None of the interactions is sufficiently close and geometrically suitable to be 
considered as a weak hydrogen bond involving methylene carbons of the 
palmitoyl group. Comparing the binding modes of 4.21 with that of a substrate-
based hexasaccharide (pdb-file:1LOH)70 there is an obvious overlapping of the 
binding sites. But the surface cleft that accommodates the palmitoyl group is not 
directly involved in substrate binding. Interestingly, one of the three well-ordered 
cryoprotectant xylitol molecules bound to hylSpn fits close to the end of the 
palmitoyl moiety. The distance between the penultimate resolved carbon of the 
palmitoyl group and atom O5 of xylitol is only 4.0 Å (Fig. 4.9). This position of 
the bound xylitol suggests that the affinity of the present inhibitor might be en-
hanced through addition of matching groups at the aliphatic end of the palmitoyl 
moiety. 
 
 
4.4 Conclusions 
 
L-Ascorbic acid (4.1), reported to inhibit the bovine testicular hyaluronidase, 
was described recently as a weak inhibitor of hyaluronate lyase of S. pneumo-
niae (hylSpn). It was confirmed by X-ray analysis that vitamin C binds to the 
active site of the bacterial enzyme suggesting that additional hydrophobic inter-
actions might increase the inhibitory effect. Thus, a series of L-ascorbic acid 
derivatives, including compounds with increased lipophilic properties, was suc-
cessfully synthesized and investigated for its inhibitory activity against hyaluro-
nate lyase of S. agalactiae (hylB4755) and bovine testicular hyaluronidase. 
The 6-O-acyl derivatives of L-ascorbic acid, compounds 4.19-4.23, exhibit a 
substantial inhibitory potency against hyaluronidases with preference for the 
bacterial enzyme. At optimum pH the IC50 values for inhibition of hylB4755 range 
from 0.9 µM to 475 µM with highest activity residing in the esters of the long 
chain alkanoic acids. Compared with the inhibition at optimum pH, the IC50 val-
ues at physiological pH are slightly weaker but they reveal the same inhibitory 
tendency. Since the inhibitory effect increases by lengthening the alkyl chains of 
the inhibitors the hypothesis that additional hydrophobic interactions with the 
enzyme are crucial for enhancing the inhibitory affinity could be approved. Con-
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sidering the bovine testicular hyaluronidase only the vitamin C derivatives 4.20-
4.22 displayed a high inhibitory activity on the enzyme with IC50 values in the 
lower micromolar range. Among the studied vitamin C derivatives L-ascorbic 
acid-6-octadecanoat (4.22) proved to be the most potent inhibitor of hyaluroni-
dases. 4.22 is up to 6500 times more potent than the parent compound 4.1 and 
is the most potent hyaluronate lyase inhibitor known to date. The aforemen-
tioned inhibitory data was obtained by using a turbidimetric assay for determin-
ing the enzyme activity. When using a colorimetric method which based on the 
Morgan-Elson reaction similar inhibitory effects were found for the vitamin C 
derivatives. Additionally, the elucidation of the X-ray structure of compound 4.21 
provided new insights into enzyme-inhibitor interactions at the molecular level. 
This information should be useful for further development of more potent and 
selective inhibitors of hyaluronidases. 
 
 
4.5 Experimental section 
 
4.5.1 General conditions 
Starting materials and solvents were purchased from Acros Organics (Belgium), 
Lancaster Synthesis GmbH (Germany), Sigma-Aldrich Chemie GmbH (Ger-
many) or Merck (Germany). THF was distilled from NaH. Commercially avail-
able petroleum ether (60-80 °C) was distilled before use and dichloromethane 
was either predried over CaCl2 or distilled from P2O5. All other solvents used 
were of analytical grade. 
Nuclear Magnetic Resonance (1H-NMR and 13C-NMR) spectra were recorded 
on a Bruker AC-250, ARX-300 or ARX-400 NMR spectrometer with per-deuter-
ated dimethyl sulfoxide (DMSO-d6) or deuterated chloroform (CDCl3). The 
chemical shift δ is given in parts per million (ppm) with reference to the chemical 
shift of the residual protic solvent compared to tetramethylsilane (TMS, δ = 0 
ppm). “s” indicates a singlet, “d” a doublet, “dd” a doublet of doublet, “t” a triplet, 
“q” a quartet, “m” a multiplet and “br” a broad peak. 2D-NMR (H-H and C-H) 
COSY techniques were used in a few cases to support interpretation of 1D 
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spectra. The multiplicity of carbon atoms (13C-NMR) were determined by DEPT 
135 and DEPT 90 (distortionless enhancement by polarization transfer): “+” 
primary and tertiary carbon atom (positive DEPT 135 signal), “-“ secondary car-
bon atom (negative DEPT 135 signal), “Cquart” quaternary carbon atom. Mass 
spectrometry analysis (MS) was performed on a Finnigan MAT 95 (PI-EIMS 70 
eV, HR-MS), a Finnigan SSQ 710A (PI-EIMS 70 eV, CI-MS (NH3)) and on a 
Finnigan ThermoQuest TSQ 7000 (ESI-MS, APCI-MS) spectrometer. The peak-
intensity is indicated relatively to the strongest signal in %. Infrared spectra (IR) 
were recorded on a BRUKER TENSOR 27 spectrophotometer. The wave num-
ber is given in cm-1. Melting points (Mp) were measured on a BÜCHI 530 elec-
trically heated copper block apparatus using an open capillary and are uncor-
rected. Column chromatography was carried out using Merck silica gel SI 60 
(0.063-0.200) and Merck silica gel 60 (0.040-0.063) for flash column chromatog-
raphy. The department of microanalysis Regensburg carried out elemental 
analysis. Compounds were dried in vacuo (0.1-1Torr) at room temperature or 
with heating up to 50 °C for at least 24 h prior to submission for elemental 
analysis. Reactions were routinely monitored by thin layer chromatography 
(TLC) on Merck silica gel 60 F254 aluminum sheets and spots were visualized 
with UV light at 254 nm. 
 
4.5.2 Chemistry 
5-O-,6-O-Isopropylidene-L-ascorbic acid (4.2) 
To L-ascorbic acid (4.1) (25.0 g, 141.95 mmol), dissolved in absolute acetone 
(160 ml), was added acetyl chloride (2.35 ml, 32.93 mmol). After stirring for 
4.5 h at room temperature in a flask closed with a drying tube, the mixture was 
stored for 20 h in the refrigerator to get fully crystallization. The precipitated 
product was collected and washed thoroughly with cold acetone for three times. 
Drying over potassium carbonate remains a white solid. 
Yield: 22.96 g (106.20 mmol, 75 %, white solid) 
Mp: 193-195 °C (Lit. 201-203 °C166) 
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1H-NMR (DMSO-d6): δ [ppm] = 1.26 (s, 6H, C(CH3)2), 3.88 (dd, 1H, 2J = 8.3 Hz, 
3J = 6.3 Hz, CH2O-), 4.10 (dd, 1H, 2J = 8.3 Hz, 3J = 7.1 Hz, CH2O-), 4.22-4.30 
(m, 1H, CHO-), 4.70 (d, 1H, 3J = 3.0 Hz, H-5), 8.47 (br, 1H, OH), 11.28 (br, 1H, 
OH) 
C9H12O6 (216.19) 
 
2-O-,3-O-Dimethyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid (4.3) 
A solution of 5-O-,6-O-isopropylidene-L-ascorbic acid (4.2) (10.65 g, 
49.26 mmol), potassium carbonate (7.6 g, 54.99 mmol) and iodomethane 
(6.8 ml, 109.23 mmol) in anhydrous DMF (150 ml) was heated under stirring at 
60 °C for 7 h. The solvent was removed and the oily residue was picked up in 
dichloromethane (300 ml). The organic phase was washed with water (60 ml 
and 30 ml), dried over magnesium sulfate and evaporated in vacuo. The or-
ange-brown oil was recrystallized from ethanol. After slow crystallization in the 
refrigerator, the precipitated product was collected, washed with a little amount 
of cold ethanol and dried in vacuo. 
Yield: 4.66 g (19.08 mmol, 39 %, white, yellow shimmering needles) 
Mp: 94 °C (Lit. 97 °C156) 
1H-NMR (DMSO-d6): δ [ppm] = 1.25 (s, 6H, C(CH3)2), 3.71 (s, 3H, OCH3), 3.88 
(dd, 1H, 2J = 8.3 Hz, 3J = 5.6 Hz, CH2O-), 4.08 (s, 3H, OCH3), 4.10 (dd, 1H, 2J = 
8.3 Hz, 3J = 7.1 Hz, CH2O-), 4.27 (ddd, 1H, 3J = 7.1 Hz, 3J = 5.6 Hz, 3J = 2.5 Hz, 
CHO-), 4.87 (d, 1H, 3J = 2.5 Hz, H-5) 
MS (CI-MS, NH3): m/z (%) = 262 ([M + NH4] +, 100), 245 ([M + H] +, 7) 
C11H16O6 (244.25) 
 
2-O-,3-O-Dibenzyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid (4.4) 
A solution of 5-O-,6-O-isopropylidene-L-ascorbic acid (4.2) (5.48 g, 
25.35 mmol), potassium carbonate (3.88 g, 28.07 mmol), benzyl bromide 
(6.6 ml, 55.56 mmol) and DMF (75 ml) was stirred at 40 °C for 4 h. The reaction 
mixture was diluted with water (120 ml) and extracted three times with di-
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chloromethane (60 ml). The combined organic layers were dried over magne-
sium sulfate and concentrated in vacuo. The red-brown oil was recrystallized 
from methanol. After slow crystallization in the refrigerator, the precipitated 
product was collected, washed with a little cold methanol and dried under re-
duced pressure to obtain white needles. 
Yield: 6.14 g (15.49 mmol, 61 %, white needles) 
Mp: 118-120 °C (Lit. 123-125 °C156) 
1H-NMR (DMSO-d6): δ [ppm] = 1.28 (s, 3H, C(CH3)2), 1.29 (s, 3H, C(CH3)2), 
3.87 (dd, 1H, 2J = 8.5 Hz, 3J = 5.9 Hz, CH2O-), 4.08 (dd, 1H, 2J = 8.5 Hz, 3J = 
7.1 Hz, CH2O-), 4.27 (ddd, 1H, 3J = 7.1 Hz, 3J = 5.9 Hz, 3J = 2.5 Hz, CHO-), 
4.94 (d, 1H, 2J = 11.2 Hz, CH2Ph), 4.95 (d, 1H, 3J = 2.5 Hz, H-5), 5.01 (d, 1H, 2J 
=11.2 Hz, CH2Ph), 5.16 (d, 1H, 2J = 11.8 Hz, CH2Ph), 5.25 (d, 1H, 2J = 11.8 Hz, 
CH2Ph), 7.27-7.43 (m, 10H, Ar-H) 
MS (CI-MS, NH3): m/z (%) = 414 ([M + NH4] +, 100), 397 ([M + H] +, 10) 
C23H24O6 (396.44) 
 
2-O-,3-O-Ethan-1,2-diyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid (4.5) 
Potassium carbonate (3.04 g, 21.99 mmol) was provided on a three-neck flask 
together with DMF (20 ml). 5-O-,6-O-Isopropylidene-L-ascorbic acid (4.2) 
(4.32 g, 19.98 mmol), dissolved in DMF (20 ml), and 1,2-dibromoethane 
(1.80 ml, 20.89 mmol), dissolved in DMF (20 ml), were dropped simultaneously 
during a period of 1h at 60 °C under continuously stirring. After further stirring at 
60 °C for 2 h, water (120 ml) was added and the reaction mixture was extracted 
with dichloromethane (3x60 ml). The combined organic phases were dried over 
magnesium sulfate and concentrated in vacuo. The yellow-brown colored oil 
was recrystallized from methanol to give a white solid. 
Yield: 1.96 g (8.09 mmol, 40 %, white solid) 
Mp: 125-126 °C (Lit. 133-134 °C156) 
1H-NMR (DMSO-d6): δ (ppm) = 1.27 (s, 3H, C(CH3)2), 1.28 (s, 3H, C(CH3)2), 
3.89 (dd, 1H, 2J = 8.5 Hz, 3J = 5.8 Hz, CH2O-), 4.11 (dd, 1H, 2J = 8.5 Hz, 3J = 
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7.1 Hz, CH2O-), 5.07 (d, 1H, 3J = 3.6 Hz, H-5), 4.14-4.30 (m, 3H, OCH2CH2O, 
CHO-), 4.32-4.45 (m, 2H, OCH2CH2O) 
MS (CI-MS, NH3): m/z (%) = 260 ([M + NH4] +, 100), 243 ([M + H] +, 4) 
C11H14O6 (242.23) 
 
2-O-,3-O-Dimethyl-L-ascorbic acid (4.6) 
2-O-,3-O-Dimethyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid (4.3) (5.72 g, 
23.42 mmol) was dissolved in methanol (58 ml) and aqueous acetic acid (50%, 
144 ml) at 60 °C for 9.5 h. The solvent was removed and the yellow oil was re-
crystallized from ethyl acetate/ether to give a hygroscopic white solid. 
Yield: 3.60 g (17.63 mmol, 75 %, white solid) 
Mp: 56-58 °C 
1H-NMR (DMSO-d6): δ (ppm) = 3.35-3.49 (m, 2H, CH2OH), 3.61-3.68 (m, 1H, 
CHOH), 3.70 (s, 3H, OCH3), 4.08 (s, 3H, OCH3), 4.81 (d, 1H, 3J = 1.3 Hz, H-5), 
4.88 (dd, 1H, 3J = 6.3 Hz, 3J = 5.1 Hz, CH2OH), 5.06 (d, 1H, 3J = 6.1 Hz, CHOH) 
MS (CI-MS, NH3): m/z (%) = 222 ([M + NH4] +, 100), 205 ([M + H] +, 6) 
C8H12O6 (204.18) 
 
2-O-,3-O-Dibenzyl-L-ascorbic acid (4.7) 
A solution of 2-O-,3-O-dibenzyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid (4.4) 
(6.14 g, 15.49 mmol), methanol (62 ml) and aqueous acetic acid (50 %, 155 ml) 
was stirred at 90 °C for 4 h. The solvent was evaporated and the oily yellow 
residue was absorbed in ethyl acetate (125 ml). After extraction with a saturated 
solution of sodium carbonate (3x10 ml), the combined organic layers were 
washed with water (10 ml). The organic phase was dried over magnesium sul-
fate and removed under reduced pressure. This crude product was purified by 
column chromatography on silica gel eluting with a 3:1 (v/v) mixture of ethyl 
acetate and petroleum ether (60-80 °C) to obtain a yellow oil which gave after a 
few days a white crystalline solid. 
Yield: 5.34 g (14.98 mmol, 97 %, white solid) 
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Mp: 70-72 °C (Lit. 67-69 °C156) 
1H-NMR (DMSO-d6): δ (ppm) = 3.36-3.51 (m, 2H, CHOH, CH2OH), 3.66-3.73 
(m, 1H, CH2OH), 4.88 (dd, 1H, 3J = 6.1 Hz, 3J = 4.8 Hz, CH2OH), 4.90 (d, 1H, 3J 
= 1.4 Hz, H-5), 4.94 (d, 1H, 2J = 11.3 Hz, CH2Ph), 4.98 (d, 1H, 2J = 11.3 Hz, 
CH2Ph), 5.15 (d, 1H, 3J = 6.3 Hz, CHOH), 5.20 (d, 1H, 2J = 11.5 Hz, CH2Ph), 
5.26 (d, 1H, 2J = 11.5 Hz, CH2Ph), 7.29-7.45 (m, 10H, Ar-H) 
MS (APCI-MS, CH3CN/H2O+1%HOOCH): m/z (%) = 357 ([M + H] +, 100), 180 
([2C6H5 - CH] +, 65) 
C20H20O6 (356.38) 
 
2-O-,3-O-Ethan-1,2-diyl-L-ascorbic acid (4.8) 
A solution of 2-O-,3-O-ethan-1,2-diyl-(5-O-,6-O-isopropylidene)-L-ascorbic acid 
(4.5) (1.00 g, 4.13 mmol), methanol (17 ml) and aqueous acetic acid (50%, 
43 ml) was stirred at 80 °C for 5 h. The solvent was removed and the remaining 
light-yellow oil was treated with ethyl acetate (10 ml). The resulting solid was 
analytically pure. 
Yield: 0.80 g (3.96 mmol, 96 %, white solid) 
Mp: 126.5-127.5 °C (Lit. 127-128 °C156) 
1H-NMR (DMSO-d6): δ (ppm) = 3.41-3.52 (m, 2H, CH2OH), 3.63-3.71 (m, 1H, 
CHOH), 4.17-4.22 (m, 2H, CH2), 4.31-4.44 (m, 2H, CH2), 4.90 (t, 1H, 3J = 5.6 
Hz, CH2OH), 5.02 (d, 1H, 3J = 1.9 Hz, H-5), 5.13 (d, 1H, 3J = 6.0 Hz, CHOH) 
MS (CI-MS, NH3): m/z (%) = 220 ([M + NH4] +, 100), 203 ([M + H] +, 4) 
C8H10O6 (202.16) 
 
2-O-,3-O-Dimethyl-6-O-hexadecanoyl-L-ascorbic acid (4.9) 
2-O-,3-O-Dimethyl-L-ascorbic acid (4.6) (0.60 g, 2.94 mmol), dissolved in di-
chloromethane (20 ml, dried over CaCl2), and pyridine (0.31 ml, 3.84 mmol) 
were annealed with an ice bath. After adding catalytic amounts of DMAP 
(40 mg), palmitoyl chloride (1.15 ml, 3.81 mmol) was slowly added. The tem-
perature of the solution was maintained at 0 °C for 1h under stirring. Afterwards, 
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the solution was stirred at room temperature for 26 h. The reaction was 
quenched with a saturated solution of sodium bicarbonate (20 ml). The mixture 
was extracted with dichloromethane (3x15 ml) and the combined organic layers 
were dried over magnesium sulfate. After filtration, the solvent was removed 
under reduced pressure. The oily crude product was purified by column chro-
matography on silica gel eluting with a 1:1 (v/v) mixture of ethyl acetate and pet-
roleum ether (60-80 °C). To get analytical pure substance the obtained product 
was recrystallized with methanol. 
Yield: 0.68 g (1.54 mmol, 52 %, white solid) 
Mp: 73-73.5 °C 
1H-NMR (DMSO-d6): δ (ppm) = 0.85 (t, 3H, 3J = 6.5 Hz, (CH2)14CH3), 1.19-1.30 
(m, 24H, (CH2)12CH3), 1.44-1.59 (m, 2H, COCH2CH2-), 2.31 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 3.70 (s, 3H, OCH3), 3.85-4.12 (m, 3H, CH2O-, CHOH), 4.08 (s, 3H, 
OCH3), 4.80 (d, 1H, 3J = 1.6 Hz, H-5), 5.47 (d, 1H, 3J = 5.5 Hz, CHOH) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CH3), 22.1 (-, CH2), 24.3 (-, CH2), 28.4 
(-, CH2), 28.7 (-, 2CH2), 28.9 (-, CH2), 29.0 (-, 6CH2), 31.3 (-, CH2), 33.3 (-, 
CH2), 59.2 (+, OCH3), 60.3 (+, OCH3), 64.0 (-, CH2), 65.6 (+, CHOH), 74.8 (+, 
CH), 122.4 (Cquart, C2), 157.8 (Cquart, C3), 168.9 (Cquart, lactone CO), 172.7 
(Cquart, CO(CH2)14-) 
MS (CI-MS, NH3): m/z (%) = 460 ([M + NH4] +, 100) 
C24H42O7 (442.59) 
 
2-O-,3-O-Dibenzyl-6-O-hexadecanoyl-L-ascorbic acid (4.10) 
To an ice-cold solution of 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (1.00 g, 
2.81 mmol), pyridine (0.25 ml, 3.10 mmol) and previously dried dichloromethane 
(25 ml) were added catalytic amounts of DMAP (55 mg). Palmitoyl chloride 
(0.93 ml, 3.08 mmol) was added dropwise and the solution was stirred at 0 °C 
for 1 h. After stirring at room temperature for additional 23 h, the reaction was 
quenched with a solution of saturated sodium bicarbonate (20 ml). The mixture 
was extracted with dichloromethane (3x15 ml) and the combined organic 
phases were dried over magnesium sulfate. The solvent was removed in vacuo. 
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The product was purified by chromatography on a silica gel column eluting with 
a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.99 g (1.66 mmol, 59 %, white crystalline solid) 
Mp: 62.5-63.5 °C 
1H-NMR (DMSO-d6): δ (ppm) = 0.85 (t, 3H, 3J = 6.5 Hz, CH3), 1.15-1.30 (m, 
24H, (CH2)12CH3), 1.44-1.56 (m, 2H, COCH2CH2-), 2.30 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 3.88-4.15 (m, 3H, CH2O-, CHOH), 4.90 (d, 1H, 3J = 1.2 Hz, H-5), 4.94 
(d, 1H, 2J = 11.5 Hz, CH2Ph), 4.99 (d, 1H, 2J = 11.5 Hz, CH2Ph), 5.19 (d, 1H, 2J 
= 11.9 Hz, CH2Ph), 5.25 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.55 (d, 1H, 3J = 6.3 Hz, 
CHOH), 7.28-7.44 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CH3), 22.1 (-, CH2), 24.3 (-, CH2), 28.4 
(-, CH2), 28.7 (-, 2CH2), 28.8 (-, CH2), 29.0 (-, 6CH2), 31.3 (-, CH2), 33.3 (-, 
CH2), 64.1 (-, CH2O-), 65.8 (+, CHOH), 72.7 (-,C3OCH2), 73.6 (-,C2OCH2), 75.1 
(+, CH), 120.8 (Cquart, C2), 127.7 (+, 2Ar-C), 128.4 (+, 6Ar-C), 128.7 (+, 2Ar-C), 
135.6 (Cquart, C3OCH2Ph), 136.1 (Cquart, C2OCH2Ph), 157.4 (Cquart, C3), 169.0 
(Cquart, lactone CO), 172.7 (Cquart, CO(CH2)14-) 
MS (ES-MS, DCM/MeOH+10mmol/l NH4Ac): m/z (%) = 612 ([M + NH4] +, 100), 
595 ([M + H] +, 72) 
C36H50O7 (594.78) 
 
2-O-,3-O-Ethan-1,2-diyl-6-O-hexadecanoyl-L-ascorbic acid (4.11) 
A solution of 2-O-,3-O-ethan-1,2-diyl-L-ascorbic acid (4.8) (0.40 g, 1.98 mmol) 
and pyridine (10 ml) was cooled down to 0 °C with an ice bath. Catalytic 
amounts of DMAP (40 mg) and palmitoyl chloride (0.66 ml, 2.18 mmol) were 
added under a nitrogen atmosphere. The solution was stirred overnight and di-
luted with dichloromethane (25 ml). Then, the mixture was extracted with hydro-
chloric acid (3 M, 3x25 ml) and washed with water (10 ml). The combined or-
ganic layers were dried over magnesium sulfate, filtrated and concentrated in 
vacuo. The product was purified by column chromatography on silica gel eluting 
with a 1:1 (v/v) mixture of ethyl acetate and petroleum ether (60-80 °C) to obtain 
a white powder. 
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Yield: 0.54 g (1.23 mmol, 62 %, white solid) 
Mp: 96-97 °C 
1H-NMR (DMSO-d6): δ (ppm) = 0.85 (t, 3H, 3J = 6.8 Hz, CH3), 1.18-1.33 (m, 
24H, (CH2)12CH3), 1.46-1.58 (m, 2H, COCH2CH2-), 2.31 (t, 2H, 3J = 7.4 Hz, 
COCH2-), 3.87-3.96 (m, 1H, CHOH), 4.06-4.10 (m, 2H, CH2), 4.18-4.22 (m, 2H, 
CH2), 4.32-4.44 (m, 2H, CH2O-), 5.02 (d, 1H, 3J = 2.3 Hz, H-5), 5.53 (d, 1H, 3J = 
6.2 Hz, CHOH) 
13C-NMR (DMSO-d6): δ [ppm] = 13.8 (+, CH3), 22.0 (-, CH2), 24.3 (-, CH2), 28.4 
(-, CH2), 28.6 (-, 2CH2), 28.8 (-, CH2), 28.9 (-, 6CH2), 31.2 (-, CH2), 33.3 (-, 
CH2), 64.0 (-, CH2), 64.7 (-, CH2), 65.8 (+, CHOH), 67.2 (-, CH2), 75.1 (+, CH), 
122.7 (Cquart, C2), 153.6 (Cquart, C3), 165.2 (Cquart, lactone CO), 172.6 (Cquart, 
CO(CH2)14-) 
MS (ES-MS, DCM/MeOH+10mmol/l NH4Ac): m/z (%) = 458 ([M + NH4] +, 100) 
C24H40O7 (440.58) 
 
Preparation of 2-O-,3-O-dibenzyl-6-O-acyl-L-ascorbic acid derivatives 4.12-
4.17 
General procedures 
Method A. To an ice-cold solution of 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) 
(1 eq), pyridine (1.1 eq) and previously dried dichloromethane (20 ml) were 
added catalytic amounts of DMAP (40-55 mg) under an inert atmosphere. Acid 
chloride (1.1 eq) was added dropwise and the solution was stirred at 0 °C for 1 
h. After stirring at room temperature for additional 24 h, the reaction was 
quenched with a solution of saturated sodium bicarbonate (20 ml). The mixture 
was extracted with dichloromethane (3x15 ml) and the combined organic 
phases were dried over magnesium sulfate. The solvent was removed in vacuo. 
The product was purified by column chromatography on a silica gel. 
Method B. Carboxylic acid (1 eq) was dissolved in dry dichloromethane (8-
15 ml) under a nitrogen atmosphere and CDI (1 eq) was added at ambient tem-
perature. After the development of gas was not recognizable any more (ap-
proximately 10 min) the solution was chilled in an ice bath. 2-O-,3-O-Dibenzyl-L-
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ascorbic acid (4.7) (1 eq), dissolved in dry dichloromethane (8-10 ml), was 
added dropwise and the mixture was stirred at room temperature for further 
24 h. After concentrating the mixture in vacuo, water (10 ml) was added and the 
aqueous phase was extracted with dichloromethane (3x10 ml). The combined 
organic phases were dried over magnesium sulfate, the solvent was removed 
and the residue was purified by column chromatography on a silica gel. 
 
2-O-,3-O-Dibenzyl-6-O-(2,2-dimethylpropanoyl)-L-ascorbic acid (4.12) 
Method A: Reaction of 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (1.20 g, 
3.37 mmol), pyridine (0.30 ml, 3.72 mmol) and pivaloyl chloride (0.46 ml, 
3.74 mmol); chromatography on a silica gel column, elution with a 3:1 (v/v) mix-
ture of chloroform and ethyl acetate. 
Yield: 0.89 g (2.02 mmol, 60 %, white solid) 
Mp: 88.5-90 °C 
1H-NMR (DMSO-d6): δ (ppm) = 1.14 (s, 9H, C(CH3)3), 3.94-3.97 (m, 1H, 
CHOH), 4.02-4.13 (m, 2H, CH2O-), 4.89 (d, 1H, 3J = 1.6 Hz, H-5), 4.94 (d, 1H, 
2J = 11.1 Hz, C2OCH2Ph), 4.98 (d, 1H, 2J = 11.1 Hz, C2OCH2Ph), 5.20 (d, 1H, 
2J = 11.8 Hz, C3OCH2Ph), 5.27 (d, 1H, 2J = 11.8 Hz, C3OCH2Ph), 5.56 (d, 1H, 
3J = 6.3 Hz, CHOH), 7.29-7.44 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 26.7 (+, C(CH3)3), 64.3 (-, CH2), 65.8 (+, 
CHOH), 72.7 (-, C3OCH2), 73.5 (-, C2OCH2), 75.1 (+, CH), 120.9 (Cquart, C2), 
127.6 (+, 2Ar-C), 128.3 (+, 2Ar-C), 128.4 (+, 4Ar-C), 128.6 (+, 2Ar-C), 135.6 
(Cquart, C3OCH2Ph), 136.1 (Cquart, C2OCH2Ph), 157.3 (Cquart, C3), 169.0 (Cquart, 
lactone CO), 177.1 (Cquart, COC(CH3)3) 
MS (ES-MS, DCM/MeOH+10mmol/l NH4Ac): m/z (%) = 458 ([M + NH4] +, 100), 
441 ([M + H] +, 77) 
C25H28O7 (440.49) 
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2-O-,3-O-Dibenzyl-6-O-butanoyl-L-ascorbic acid (4.13) 
Method A: Reaction of 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (1.20 g, 
3.37 mmol), pyridine (0.30 ml, 3.72 mmol) and butyryl chloride (0.39 ml, 
3.77 mmol); chromatography on a silica gel column, elution with a 3:1 (v/v) mix-
ture of chloroform and ethyl acetate. 
Yield: 0.99 g (2.32 mmol, 69 %, colorless oil) 
1H-NMR (DMSO-d6): δ (ppm) = 0.87 (t, 3H, 3J = 7.1 Hz, CH3), 1.46-1.62 (m, 2H, 
CH2CH2CH3), 2.30 (t, 2H, 3J = 7.2 Hz, COCH2-), 3.88-4.15 (m, 3H, CH2O-, 
CHOH), 4.91 (d, 1H, 3J = 1.6 Hz, H-5), 4.94 (d, 1H, 2J = 11.5 Hz, CH2Ph), 4.99 
(d, 1H, 2J = 11.5 Hz, CH2Ph), 5.19 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.26 (d, 1H, 2J 
= 11.9 Hz, CH2Ph), 5.55 (d, 1H, 3J = 6.3 Hz, CHOH), 7.29-7.44 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.4 (+, CH3), 17.8 (-, CH2), 35.2 (-, CH2), 64.1 
(-, CH2O-), 65.8 (+, CHOH), 72.7 (-, C3OCH2), 73.6 (-, C2OCH2), 75.1 (+, CH), 
120.8 (Cquart, C2), 127.7 (+, 2Ar-C), 128.4 (+, 6Ar-C), 128.7 (+, 2Ar-C), 135.6 
(Cquart, C3OCH2Ph), 136.1 (Cquart, C2OCH2Ph), 157.4 (Cquart, C3), 169.0 (Cquart, 
lactone CO), 172.6 (Cquart, CO(CH2)2-) 
MS (CI-MS, NH3): m/z (%) = 444 ([M + NH4] +, 100), 427 ([M + H] +, 1), 354 ([M 
+ NH4 - C7H6] +, 10)  
C24H26O7 (426.46) 
 
2-O-,3-O-Dibenzyl-6-O-hexanoyl-L-ascorbic acid (4.14) 
Method B: Reaction of hexanoic acid (0.29 ml, 2.32 mmol), CDI (0.38 g, 
2.34 mmol) and 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (0.84 g, 2.36 mmol); 
purification by chromatography on a silica gel column, elution with a 3:1 (v/v) 
mixture of chloroform and ethyl acetate. 
Yield: 0.55 g (1.21 mmol, 52 %, colorless oil) 
1H-NMR (DMSO-d6): δ (ppm) = 0.84 (t, 3H, 3J = 6.7 Hz, CH3), 1.15-1.32 (m, 4H, 
CH2(CH2)2CH3), 1.45-1.59 (m, 2H, COCH2CH2-), 2.31 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 3.88-4.15 (m, 3H, CH2O-, CHOH), 4.91 (d, 1H, 3J = 1.6 Hz, H-5), 4.94 
(d, 1H, 2J = 11.1 Hz, CH2Ph), 4.99 (d, 1H, 2J = 11.1 Hz, CH2Ph), 5.19 (d, 1H, 2J 
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= 11.9 Hz, CH2Ph), 5.25 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.55 (d, 1H, 3J = 6.3 Hz, 
CHOH), 7.28-7.44 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.7 (+, CH3), 21.7 (-, CH2), 24.0 (-, CH2), 30.6 
(-, CH2), 33.3 (-, CH2), 64.1 (-, CH2O-), 65.8 (+, CHOH), 72.7 (-,C3OCH2), 73.6 
(-,C2OCH2), 75.1 (+, CH), 120.8 (Cquart, C2), 127.7 (+, 2Ar-C), 128.4 (+, 6Ar-C), 
128.7 (+, 2Ar-C), 135.6 (Cquart, C3OCH2Ph), 136.1 (Cquart, C2OCH2Ph), 157.4 
(Cquart, C3), 169.0 (Cquart, lactone CO), 172.7 (Cquart, CO(CH2)4-) 
C26H30O7 (454.51) 
 
2-O-,3-O-Dibenzyl-6-O-dodecanoyl-L-ascorbic acid (4.15) 
Method B: Reaction of lauric acid (0.57 g, 2.85 mmol), CDI (0.46 g, 2.84 mmol) 
and 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (1.00 g, 2.81 mmol); purification by 
chromatography on a silica gel column, elution with a 3:1 (v/v) mixture of petro-
leum ether (60-80 °C) and ethyl acetate; product was crystallized with methanol 
to get an analytically pure sample as a white solid. 
Yield: 0.75 g (1.39 mmol, 50 %, white solid) 
Mp: 49.5-50 °C 
1H-NMR (DMSO-d6): δ (ppm) = 0.85 (t, 3H, 3J = 6.9 Hz, CH3), 1.21-1.25 (m, 
16H, (CH2)8CH3), 1.48-1.53 (m, 2H, COCH2CH2-), 2.30 (t, 2H, 3J = 7.4 Hz, 
COCH2-), 3.90-4.13 (m, 3H, CH2O-, CHOH), 4.90 (d, 1H, 3J = 1.6 Hz, H-5), 4.95 
(d, 1H, 2J = 11.2 Hz, CH2Ph), 4.99 (d, 1H, 2J = 11.2 Hz, CH2Ph), 5.20 (d, 1H, 2J 
= 11.8 Hz, CH2Ph), 5.25 (d, 1H, 2J = 11.8 Hz, CH2Ph), 5.54 (d, 1H, 3J = 6.5 Hz, 
CHOH), 7.30-7.43 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CH3), 22.1 (-, CH2), 24.3 (-, CH2), 28.4 
(-, CH2), 28.6 (-, 2CH2), 28.9 (-, 3CH2), 31.3 (-, CH2), 33.3 (-, CH2), 64.1 (-, 
CH2O-), 65.8 (+, CHOH), 72.7 (-,C3OCH2), 73.6 (-,C2OCH2), 75.1 (+, CH), 
120.8 (Cquart, C2), 127.7 (+, 2Ar-C), 128.3 (+, 2Ar-C), 128.4 (+, 4Ar-C), 128.6 (+, 
2Ar-C), 135.6 (Cquart, C3OCH2Ph), 136.1 (Cquart, C2OCH2Ph), 157.3 (Cquart, C3), 
169.0 (Cquart, lactone CO), 172.7 (Cquart, CO(CH2)10-) 
MS (CI-MS, NH3): m/z (%) = 556 ([M + NH4] +, 100), 466 ([M + NH4 - C7H6] +, 9) 
C32H42O7 (538.67) 
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2-O-,3-O-Dibenzyl-6-O-octadecanoyl-L-ascorbic acid (4.16) 
Method B: Reaction of stearic acid (0.80 g, 2.81 mmol), CDI (0.46 g, 
2.84 mmol) and 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (1.00 g, 2.81 mmol); 
purification by chromatography on a silica gel column, elution with a 3:1 (v/v) 
mixture of chloroform and ethyl acetate. 
Yield: 0.66 g (1.06 mmol, 38 %, white solid) 
Mp: 69-70 °C 
1H-NMR (DMSO-d6): δ (ppm) = 0.85 (t, 3H, 3J = 6.9 Hz, CH3), 1.18-1.28 (m, 
28H, (CH2)14CH3), 1.44-1.56 (m, 2H, COCH2CH2-), 2.30 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 3.89-4.14 (m, 3H, CH2O-, CHOH), 4.90 (d, 1H, 3J = 1.6 Hz, H-5), 4.94 
(d, 1H, 2J = 11.2 Hz, CH2Ph), 4.98 (d, 1H, 2J = 11.2 Hz, CH2Ph), 5.19 (d, 1H, 2J 
= 11.6 Hz, CH2Ph), 5.25 (d, 1H, 2J = 11.6 Hz, CH2Ph), 5.55 (d, 1H, 3J = 6.4 Hz, 
CHOH), 7.29-7.44 (m, 10H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CH3), 22.0 (-, CH2), 24.2 (-, CH2), 28.3 
(-, CH2), 28.6 (-, 2CH2), 28.8 (-, CH2), 28.9 (-, 8CH2), 31.2 (-, CH2), 33.2 (-, 
CH2), 64.0 (-, CH2O-), 65.7 (+, CHOH), 72.6 (-,C3OCH2), 73.5 (-,C2OCH2), 75.0 
(+, CH), 120.8 (Cquart, C2), 127.6 (+, 2Ar-C), 128.3 (+, 2Ar-C), 128.4 (+, 4Ar-C), 
128.6 (+, 2Ar-C), 135.5 (Cquart, C3OCH2Ph), 136.0 (Cquart, C2OCH2Ph), 157.3 
(Cquart, C3), 169.0 (Cquart, lactone CO), 172.6 (Cquart, CO(CH2)16-) 
MS (ES-MS, DCM/MeOH+10mmol/l NH4Ac): m/z (%) = 640 ([M + NH4] +, 100), 
623 ([M + H] +, 83) 
C38H54O7 (622.84) 
 
2-O-,3-O-Dibenzyl-6-O-benzoyl-L-ascorbic acid (4.17) 
Method A: Reaction of 2-O-,3-O-dibenzyl-L-ascorbic acid (4.7) (0.80 g, 
2.24 mmol), pyridine (0.25 ml, 3.10 mmol) and benzoyl chloride (0.34 ml, 
2.93 mmol); chromatography on a silica gel column eluting with a 4:1 (v/v) mix-
ture of petroleum ether (60-80 °C) and ethyl acetate; product was crystallized 
with methanol to get an analytically pure sample as a white solid. 
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Yield: 0.50 g (1.09 mmol, 48 %, colorless oil) 
Mp: 89.5-92 °C 
1H-NMR (DMSO-d6): δ (ppm) = 4.08-4.17 (m, 1H, CHOH), 4.29-4.42 (m, 2H, 
CH2O-), 4.96 (d, 1H, 2J = 11.1 Hz, CH2Ph), 5.01 (d, 1H, 2J = 11.1 Hz, CH2Ph), 
5.07 (d, 1H, 3J = 1.6 Hz, H-5), 5.21 (d, 1H, 2J = 11.9 Hz, CH2Ph), 5.27 (d, 1H, 2J 
= 11.9 Hz, CH2Ph), 5.70 (d, 1H, 3J = 6.3 Hz, CHOH), 7.30-7.45 (m, 10H, Ar-H), 
7.49-7.57 (m, 2H, Ar-H), 7.63-7.72 (m, 1H, Ar-H), 7.99-8.06 (m, 2H, Ar-H)  
13C-NMR (DMSO-d6): δ [ppm] = 65.2 (-, CH2), 65.9 (+, CHOH), 72.8 (-
,C3OCH2), 73.6 (-,C2OCH2), 75.3 (+, CH), 120.9 (Cquart, C2), 127.7 (+, 2Ar-C), 
128.4 (+, 2Ar-C), 128.5 (+, 4Ar-C), 128.7 (+, 4Ar-C), 129.4 (+, 2Ar-C), 129.5 
(Cquart, Ar-C), 133.4 (+, Ar-C), 135.6 (Cquart, C3OCH2Ph), 136.1 (Cquart, 
C2OCH2Ph), 157.5 (Cquart, C3), 165.5 (Cquart, COPh), 169.1 (Cquart, lactone CO)  
MS (CI-MS, NH3): m/z (%) = 478 ([M + NH4] +, 100), 388 ([M + NH4- C7H6] +, 26) 
C27H24O7 (460.48) 
 
Synthesis of 6-O-acyl-L-ascorbic acid derivatives 4.18-4.23 
General procedure 
The appropriate 2-O-,3-O-dibenzyl-6-O-acyl-L-ascorbic acid derivative (1 eq) 
was dissolved in ethanol (8-10 ml) and treated with 10% Pd-C catalyst (55-
65 mg). Hydrogenolysis was performed in an autoclave under a pressure of 5 
bar at room temperature for 24 h. Insoluble material was filtered off and was 
washed with ethanol, and the filtrate was concentrated in vacuo. 
 
6-O-(2,2-Dimethylpropanoyl)-L-ascorbic acid (4.18) 
Reaction of 2-O-,3-O-dibenzyl-6-O-(2,2-dimethylpropanoyl)-L-ascorbic acid 
(4.12) (0.39 g, 0.89 mmol); crystallization from ethanol/chloroform/hexane. 
Yield: 0.20 g (0.77 mmol, 87 %, white solid) 
Mp: >167 °C (decomposition) 
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1H-NMR (DMSO-d6): δ [ppm] = 1.15 (s, 9H, C(CH3)3), 3.92-4.12 (m, 3H, CH2O-, 
CHOH), 4.65 (d, 1H, 3J = 1.4 Hz, H-5), 5.33 (d, 1H, 3J = 5.9 Hz, CHOH), 8.41 
(br, 1H, OH), 11.12 (br, 1H, OH) 
MS (CI-MS, NH3): m/z (%) = 278 ([M + NH4] +, 100) 
C11H16O7 (260.24) 
 
6-O-Hexanoyl-L-ascorbic acid (4.19) 
Reaction of 2-O-,3-O-dibenzyl-6-O-hexanoyl-L-ascorbic acid (4.14) (0.39 g, 
0.86 mmol); crystallization from chloroform/hexane. 
Yield: 0.16 g (0.58 mmol, 68 %, pale yellow oil) 
1H-NMR (DMSO-d6): δ [ppm] = 0.86 (t, 3H, 3J = 7.0 Hz, CH3), 1.21-1.32 (m, 4H, 
COCH2CH2(CH2)2CH3), 1.47-1.60 (m, 2H, COCH2CH2-), 2.32 (t, 2H, 3J = 7.4 
Hz, COCH2-), 3.92-4.11 (m, 3H, CH2O-, CHOH), 4.68 (d, 1H, 3J = 1.8 Hz, H-5), 
5.31 (d, 1H, 3J = 5.5 Hz, CHOH), 8.40 (br, 1H, OH), 11.11 (br, 1H, OH) 
MS (ESI-MS, DCM/MeOH+10mmol/l NH4Ac): m/z (%) = 273 ([M - H] +, 100) 
C12H18O7 (274.27) 
 
6-O-Dodecanoyl-L-ascorbic acid (4.20) 
Reaction of 2-O-,3-O-dibenzyl-6-O-dodecanoyl-L-ascorbic acid (4.15) (0.30 g, 
0.56 mmol); crystallization from chloroform/hexane. 
Yield: 0.13 g (0.50 mmol, 66 %, white solid) 
Mp: 95-97 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.86 (t, 3H, 3J = 6.5 Hz, CH3), 1.15-1.33 (m, 
16H, (CH2)8CH3), 1.43-1.60 (m, 2H, COCH2CH2-), 2.32 (t, 2H, 3J = 7.1 Hz, 
COCH2-), 3.92-4.15 (m, 3H, CH2O-, CHOH), 4.67 (d, 1H, 3J = 1.6 Hz, H-5), 5.32 
(br, 1H, OH), 8.42 (br, 1H, OH), 11.15 (br, 1H, OH) 
MS (CI-MS, NH3): m/z (%) = 376 ([M + NH4] +, 100) 
HR-MS (CI-MS, NH3): calculated for [M+H] +: 359.20698 
 found 359.20705 
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C18H30O7 (358.43) 
 
6-O-Hexadecanoyl-L-ascorbic acid (4.21) 
Reaction of 2-O-,3-O-dibenzyl-6-O-hexadecanoyl-L-ascorbic acid (4.10) (0.46 g, 
0.77 mmol); crystallization from hexane. 
Yield: 0.24 g (0.58 mmol, 74 %, white solid) 
Mp: 109.5 °C-111.5 °C (Lit. 111-112 °C167) 
1H-NMR (DMSO-d6): δ [ppm] = 0.85 (t, 3H, 3J = 6.7 Hz, CH3), 1.18-1.34 (m, 
24H, (CH2)12CH3), 1.44-1.61 (m, 2H, COCH2CH2-), 2.31 (t, 2H, 3J = 7.4 Hz, 
COCH2-), 3.91-4.15 (m, 3H, CH2O-, CHOH), 4.67 (d, 1H, 3J = 1.6 Hz, H-5), 5.32 
(br, 1H, OH), 8.39 (br, 1H, OH), 11.14 (br, 1H, OH) 
C22H38O7 (414.53) 
 
6-O-Octadecanoyl-L-ascorbic acid (4.22) 
Reaction of 2-O-,3-O-dibenzyl-6-O-octadecanoyl-L-ascorbic acid (4.16) (0.31 g, 
0.50 mmol); crystallization from hexane. 
Yield: 0.17 g (0.38 mmol, 77 %, white solid) 
Mp: 105-106.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.85 (t, 3H, 3J = 6.9 Hz, CH3), 1.18-1.31 (m, 
28H, (CH2)14CH3), 1.46-1.58 (m, 2H, COCH2CH2-), 2.31 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 3.92-4.12 (m, 3H, CH2O-, CHOH), 4.67 (d, 1H, 3J = 1.6 Hz, H-5), 5.32 
(br, 1H, OH), 8.40 (br, 1H, OH), 11.11 (br, 1H, OH) 
MS (CI-MS, NH3): m/z (%) = 460 ([M + NH4] +, 100), 442 ([M + H] +, 43) 
C24H42O7 (442.59) 
 
6-O-Benzoyl-L-ascorbic acid (4.23) 
Reaction of 2-O-,3-O-dibenzyl-6-O-benzoyl-L-ascorbic acid (4.17) (0.29 g, 
0.63 mmol); recrystallization from chloroform. 
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Yield: 0.14 g (0.50 mmol, 79 %, white-grey solid) 
Mp: >140 °C (decomposition) 
1H-NMR (DMSO-d6): δ [ppm] = 4.11-4.15 (m, 1H, CH2O-), 4.28-4.39 (m, 2H, 
CH2O-, CHOH), 4.82 (d, 1H, 3J = 1.8 Hz, H-5), 5.44 (d, 1H, 3J = 6.4 Hz, CHOH), 
7.51-7.56 (m, 2H, Ar-H), 7.65-7.69 (m, 1H, Ar-H), 8.01-8.05 (m, 2H, Ar-H), 8.40 
(br, 1H, OH), 11.10 (br, 1H, OH) 
MS (CI-MS, NH3): m/z (%) = 298 ([M + NH4] +, 100) 
HR-MS (CI-MS, NH3): calculated for [M+H] +: 281.06613 
 found 281.06601 
C13H12O7 (280.23) 
 
4.5.3 Pharmacological methods 
 
Materials 
Hyaluronan (hyaluronic acid) from Streptococcus zooepidemicus was pur-
chased from Aqua Biochem (Dessau, Germany). Bovine serum albumin (BSA) 
was obtained from Serva (Heidelberg, Germany). The investigated hyaluroni-
dases were enzyme preparations from different sources. Stabilized hyaluronate 
lyase, i.e. 200,000 units** (0.572 mg from S.agalactiae strain 4755 plus 2.2 mg 
of BSA and 37 mg of Tris-HCl per vial) of lyophilized hyaluronate lyase, was 
kindly provided by id-Pharma (Jena, Germany). Lyophilized hyaluronidase from 
bovine testis (Neopermease®) (200,000 units**; 4 mg plus 25 mg of gelatine per 
vial) was a gift from Sanabo (Vienna, Austria). Hylase Dessau®, 1 500 units** of 
lyophilized bovine testicular hyaluronidase (stabilized with gelafusal (partially 
hydrolyzed gelatin)), was kindly provided by Pharma Dessau (Dessau, Ger-
many). Streptococcus pneumoniae hyaluronate lyase67,161,168 has been pro-
duced as described previously169.The enzyme was concentrated to 5 mg/ml in 
10 mM Tris-HCl buffer, 150 mM NaCl, 1 mM DTT, pH 7.4 using centrifugal spin 
devices with 50 kDa molecular weight cutoff (Millipore, Billerica, USA) and was 
used for the inhibition studies and for crystallization experiments. The enzyme 
                                            
** according to the declaration of the supplier 
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concentration was determined photometrically at 280 nm using a calculated 
molar absorption coefficient of 127,090 L·mol-1·cm-1 68,169 according to Pace et 
al.170. All other chemicals were of analytical grade and were received from 
Merck or Sigma. 
 
Estimation of the aqueous solubility of the test compounds 
To determine the solubility of the test compounds, a sample containing 600 µl of 
citrate-phosphate buffer (pH 5 and pH 7.4), 396 µl of water, 300 µl of BSA solu-
tion (0.2 mg/ml in water) and a solution of 54 µl of the respective test compound 
(dissolved in DMSO) of various concentrations was measured at 600 nm. A cu-
vette filled with water served as reference. Compounds were tested for inhibi-
tory activity at concentrations, where no turbidity was measured. 
 
Determination of enzyme inhibition 
The inhibitory potency of the prepared vitamin C derivatives on the enzymatic 
activities of hyaluronidases was determined both in a turbidimetric assay and in 
the Morgan-Elson assay (see chapter 3). The turbidimetric method was devel-
oped in our laboratory, based on the method of Di Ferrante145 as described in 
section 5.5.3. Following a procedure of Muckenschnabel et al.149, which is 
based on the method of Gacesa et al.147 and Reissig et al.148, a modified Mor-
gan-Elson test was implemented. The reported protocol from Muckenschnabel 
et al.149 was scaled down to minimize the required amounts of test compound 
and enzyme as described in the following. 
 
The test compounds (0.2 µM - 100 mM), dissolved in DMSO (7 µl), were incu-
bated at 37 °C in an incubation mixture containing 80 µl of McIlvaine’s buffer 
(solution A: 0.2 M Na2HPO4, 0.1 M NaCl, solution B: 0.1 M citric acid, 0.1 M 
NaCl; solution A and B were mixed in appropriate portions to adjust the required 
pH), 20 µl of BSA solution (0.2 mg/ml in water), 20 µl of HA solution (5 mg/ml in 
water), 33 µl of water and 20 µl of an enzyme solution (equiactive concentra-
tion: 8 IU Hylase Dessau® (pH 3.6), 40 IU Hylase Dessau® (pH 7.4), hylB4755 
(1.14 ng, pH 5.0 and 7.4)). According to the different applied pH conditions in 
the assay equiactive concentrations of BTH and hylB4755 were incubated for 2 h 
at optimum pH (BTH: pH 3.6, hylB4755: pH 5) whereas at physiological pH the 
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samples were incubated for 4 h (hylB4755) or 48 h (BTH). The final DMSO con-
centration was 3.9% (v/v). 
The enzyme reaction was stopped by addition of 45 µl of alkaline borate solu-
tion and subsequent heating for 4.5 min at 100 °C. The alkaline borate solution 
was prepared immediately before use from a borate solution (17.3 g H3BO4 and 
7.8 g KOH in 100 ml water) and a potassium carbonate solution (8.0 g K2CO3 in 
10 ml water). After cooling on ice for 1 min 600 µl of N,N-dimethylaminobenzal-
dehyde (20.0 g N,N-dimethylaminobenzaldehyde dissolved in 25 ml concen-
trated and 75 ml glacial acid; the solution was diluted with 4 volumes of glacial 
acid immediately before use) was added and the mixture was incubated at 37 
°C for 20 min. The samples (sample solution was separated into 2 plate holes 
(in each case 300 µl)) were transferred to a 96-well microtiter plate and the ab-
sorbance of the colored product was measured photometrically with an automa-
tized EL312E (BIO-TEKR Instruments INC., Highland Park, Winooski) mi-
croplate reader at 590 nm. As reference for 100% enzyme activity the formation 
of the red colored product of a sample without inhibitor (7 µl of DMSO was used 
instead) was quantified. In absence of both enzyme and inhibitor (20 µl of BSA 
solution and 7 µl of DMSO, respectively, was used instead) a reference for 0% 
enzyme activity could be measured. 
 
Quantification of inhibitory activity 
The enzyme activity was calculated from the formation of the red colored prod-
uct measured at 590 nm. The effect of the test compounds on the enzymatic 
activity was calculated according to the equation: 
                                   (Asample – Aenzyme) 
relative activity [in %] = –––––––––––––––––––––  · 100 % 
                                (Ainhibitor – Aboth) 
where Aenzyme is the absorbance of the reference sample without enzyme (20 µl 
of BSA (0.2 mg/ml) solution was used instead), Ainhibitor is the absorbance of the 
reference sample without inhibitor (7 µl of DMSO was used instead) and Aboth is 
the absorbance without both enzyme and inhibitor. 
The enzyme activities were plotted against the logarithm of the inhibitor con-
centration. The IC50 values (50% inhibition of equiactive enzyme concentrations) 
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± SEM were calculated fitting the experimental data with the standard curves 
analysis of Sigma Plot 8.0 (SPSS Inc., Chicago, IL) in a sigmoidal concentra-
tion-dependent manner and are the means of at least two independent experi-
ments performed in duplicate. 
 
4.5.4 Crystallization of the L-ascorbic acid-6-hexadecanoate-
hylSpn complex 
 
The crystallization experiments were carried out by Masatoshi Nukui and Mark 
J. Jedrzejas (Children’s Hospital Oakland Research Institute, Oakland, Califor-
nia 94609, USA). For crystallization experiments, L-ascorbic acid-6-hexa-
decanoate was dissolved in 5% DMSO (v/v) and 10 mM Tris-HCl buffer, 150 
mM NaCl, 11mM DTT, pH=7.4 to the final concentration of 50 mM. The hanging 
drop vapour diffusion171 using Linbro culture plates (Hampton Research Inc.) at 
room temperature was used to grow the crystals of the enzyme-inhibitor com-
plex. Equal volumes of protein, reservoir solution (1µl each) and various 
amounts of inhibitor solutions (0.1, 0.5 and 1.0 µl) were mixed and equilibrated 
against 1 ml of the reservoir solution. The reservoir solution contained saturated 
ammonium sulphate, 0.2 M NaCl, 2% dioxane and 0.1 M sodium citrate buffer 
(pH 6.0) as reported for the native enzyme crystallization68. 
 
4.5.5 X-ray diffraction 
The X-ray diffraction experiments were performed by Masatoshi Nukui and 
Mark J. Jedrzejas (Children’s Hospital Oakland Research Institute, Oakland, 
California 94609, USA). The crystals of the enzyme-inhibitor complex were 
cryoprotected using 30% xylitol (w/v), 3.5 M ammonium sulphate and 0.1 M so-
dium citrate buffer (pH 6.0) as described for the native crystals67 and frozen in 
liquid nitrogen. Standard fiber loops (Hampton Research Inc.) of a suitable size 
were used to pick up and mount the frozen crystals under a nitrogen flow at -
180 °C. The X-ray diffraction data for enzyme-inhibitor complex was collected 
using rotation (oscillation) photography and a Quantum 4u CCD detector. The 
crystallographic setup of beamline 5.0.1 of the Berkeley Center for Structural 
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Biology, Advanced Light Source, Lawrence Berkeley National Laboratory was 
used. The collected data was analyzed, indexed, integrated and scaled using 
the HKL2000 software package172. The crystals were isomorphous to the native 
S. pneumoniae hyaluronate lyase crystals68. The statistics of the native diffrac-
tion data were analyzed. 
 
4.5.6 Structure solution and refinement 
Structure solution and refinement were carried out by Daniel J. Rigden (National 
Center of Genetic Resources and Biotechnology, Cenargen/Embrapa, Brasília, 
D.F. 70770-900, Brazil). 
The structure was solved by isomorphous replacement and rigid body-refine-
ment in CNS173 using the 1.56 Å crystal structure of S. pneumoniae hyaluronate 
lyase (pdb-file: 1EGU133) as a starting point. Refinement employed alternating 
cycles of computational refinement with CNS173 and manual rebuilding using the 
program O174. All data was used throughout with no intensity or sigma-based 
cut-offs applied. SigmaA-weighted map coefficients175 were used throughout. 
An Rfree value173, calculated from 5% of reflections set aside at the outset, was 
used to monitor the progress of refinement. Water molecules were placed into 
3σ positive peaks in |Fo-Fc| maps when density was also evident in |2Fo-Fc| 
maps and suitable hydrogen bonding partners were available. The ligand L-
ascorbic acid-6-hexadecanoate (4.21) was modeled into the catalytic site ac-
cording to the strong, immediately evident difference density. Sulfate and xylitol 
molecules, deriving from the crystallization and cryo-cooling solutions, respec-
tively, were modeled into suitably shaped regions of electron density. Final sta-
tistics for the model are shown in Table 4.5. 
Programs of the CCP4 package176 were applied to manipulations and structural 
superpositions made with LSQMAN177. PyMOL178 was used to create illustra-
tions. 
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Table 4.5: Crystallographic data and refinement statistics 
 
Space group P212121 
Unit Cell (Å)  
 a 84.13 
 b 102.71 
 c 102.4 
Low resolution diffraction limit (Å) 45.9 
High resolution diffraction limit (Å) 1.65 
Completenessa (%) 99.9 (99.0) 
I/σ (I)a 22.8 (1.3) 
Multiplicitya (%) 5.8 (5.7) 
Rmergea (%) 7.3 (87.5) 
Non-hydrogen protein atoms 5835 
Sulfate atoms 25 
Non-hydrogen atoms xylitol 30 
Non-hydrogen atoms compound 4.21 27 
Non-hydrogen atoms solvent 564 
Number of reflectionsa 106633 (9620) 
R (%)a 19.2 (30.5) 
Rfree (%)a 21.1 (31.4) 
Mean temperature all atoms 23.9 
B-factor (Å2)  
 Protein 22.2 
 Protein main chain 21.2 
 Protein side chain 22.5 
 Sulfate 46.4 
 Xylitol 38.1 
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 Compound 4.21 54.9 
  Vitamin C moiety 56.5 
  Palmitoyl moiety 46.8 
 Solvent 31.1 
r.m.s.b deviation from ideal values  
 Bond lengths (Å) 0.005 
 Bond angles (°) 1.2 
aValues in parentheses are for the highest resolution shell, 1.65-1.71 Å. 
b Root mean square. 
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Chapter 5 
Benzimidazole-type hyaluronate lyase 
inhibitors: Synthesis and pharmacological 
investigation 
5.1 Introduction 
The recent elucidation of the three-dimensional X-ray crystal structures of two 
hyaluronate lyases from Streptococcus species, one from S. pneumoniae (pdb-
file: 1EGU)68 and the other one from S. agalactiae strain 3502 (pdb-file: 
1F1S)63, enabled the rational design of new ligands for S. agalactiae hyaluro-
nate lyase from strain 4755 (hylB4755) by creating a model by means of partially 
superimposing corresponding domains of the aforementioned crystal structures 
using Sybyl 6.8 (Tripos Inc., St. Louis). Subsequent LUDI calculations based on 
this model resulted in different proposals. The aim of this de novo design ap-
proach of new hyaluronate lyase inhibitors was to identify 
promising leads, which should be small molecules and 
easily accessible. 1,3-Diacetylbenzimidazol-2-thione (5.1, 
Fig. 5.1) was discovered as a hit83. The investigation of 
5.1 for inhibition of hylB4755 revealed IC50 values of 5 µM 
(at physiological pH 7.4) and 160 µM (at optimum pH 
5.0) in a turbidimetric assay (see chapter 3)120. Starting 
from lead compound 5.1, we decided to investigate structurally diverse ben-
zimidazole derivatives for inhibition of the bacterial hyaluronate lyase hylB4755 in 
order to obtain more information about the binding mode. Therefore, benzimi-
Fig. 5.1: Lead structure 
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dazole derivatives, as depicted in Figure 5.2, were defined as target com-
pounds. 
 
 
 
 
 
 
 
 
5.2 Chemistry 
The preparation of 1-(2-sulfanyl-1H-benzo[d]imidazol-1-yl)ethanone (5.3) was 
performed according to the procedure described by Saxena et al.179 (method A), 
whereas the N-monoacylated benzimidazol-2-thione derivatives 5.4-5.8 were 
accessible by a slightly modified protocol (method B) using benzimidazol-2-
thione 5.2 as starting material and acid chlorides or acid anhydrides as acylat-
ing reagents (Scheme 5.1). Pyridine was used as solvent and base and the 
workup process was altered. 
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Scheme 5.1: Synthesis of N-monoacylated benzimidazol-2-thione 
derivatives 
Fig. 5.2: Various benzimidazole derivatives as target compounds 
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5.12: R = CH2CH3
5.13: R = (CH2)6CH3
5.14: R = CH2Ph
5.15: R = CH2-p-MeOC6H4
NaH, RX,
DMF
5.3
The benzimidazol-2-thione structure offers two reactive positions due to the two 
possible tautomeric forms. Both the sulfur atom and the nitrogen atom can be 
deprotonated by base. According to the HSAB concept an alkylation with bro-
moalkanes should preferentially take place at the soft sulfur atom whereas the 
acylation should be favored at the hard nitrogen atom. Actually, the alkylation of 
5.2 with bromoethane and sodium hydride gave compound 5.9 and no alkyla-
tion at the nitrogen atom. 
The attempt to prepare 5.3 by hydrogenation of 2-nitroacetanilide over 10 % Pd-
C catalyst under pressure, followed by ring closure with 1,1’-thiocarbonyldi-
imidazole (TCDI) failed as the acetyl group was cleaved off resulting in 2-sul-
fanylbenzimidazole (Scheme 5.2). 
 
Various S-alkylated benzimidazole derivatives 5.12-5.15 were synthesized from 
N-monoacetylated 5.3 by treatment with sodium hydride (1.5 eq) and alkyl hal-
ide (1 eq) in DMF (Scheme 5.3). 
 
 
As expected according to the HSAB concept and confirmed by NMR studies 
(NOESY, HMBC) the alkylation took place preferentially at the soft sulfur atom 
of 5.3 under these reaction conditions, yielding compounds 5.12-5.15. 
Scheme 5.3: Preparation of the 2-alkylsulfanylbenzimidazoles 
NO2
NH
O
NH2
NH
O
N
H
H
N
S
N
H
N
O
S
i
ii
5.11 5.3
5.2
5.10
Reagents: i) H2, 10% Pd/C, MeOH,
3 bar; ii) TCDI, CH2Cl2/THF
Scheme 5.2: Attempted alternative synthesis of compound 5.3 
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The diacylated compound 5.16 was obtained by treating 5.6 with acetyl chloride 
and triethylamine in dry THF (Scheme 5.4). Isolation and purification of the 
product is difficult because of the low stability against hydrolysis during the 
workup. Therefore, the yield was very low. 
 
 
 
 
 
 
 
Simple variations of the functional groups of the lead structure were realized as 
depicted in Schemes 5.5 and 5.6. The oxo analog of the lead, 1,3-diacetyl-1H-
benzo[d]imidazol-2(3H)-one (5.18), was synthesized according to the method 
described by Chung et al.180. Compound 5.18 is described as “a versatile and 
selective acetylating agent with many advantages due to its facile preparation, 
good reactivity, stability and easy work-up process”180. From the chemical point 
of view 5.18 is an interesting reagent, but probably, it cannot be used as an en-
zyme inhibitor due to its high reactivity towards nucleophiles, although it is more 
stable than the corresponding thio analogs. 
In order to increase the chemical stability of the molecule and to investigate the 
role of the carbonyl groups in binding to the enzyme, the acetyl groups of the 
lead compound should be replaced with ethyl residues. Treating 2-sulfanylben-
zimidazole with two equivalents of bromoethane is inappropriate to synthesize 
1,3-diethyl-1H-benzo[d]imidazol-2(3H)-thione (5.19) as, according to the HSAB 
concept, the halo compound reacts preferentially with the soft sulfur atom in-
stead of the hard nitrogen atom. Therefore, a different strategy was chosen. In 
the first step, 2-hydroxybenzimidazole (5.17) was converted to the oxo analog 
of 5.20 following a well established procedure described by Vernin et al.181 for 
the preparation of symmetrically and unsymmetrically 1,3-dialkylated benzimi-
dazol-2-ones. The alkylation was performed under phase transfer catalysis 
conditions with an excess of alkyl halide, 50 % aqueous sodium hydroxide, 
N
H
N
S
O
(CH2)4CH3
N
N
S
O
(CH2)4CH3
5.6 5.16
AcCl, Et3N
THF
O
Scheme 5.4: Synthesis of 1-(3-acetyl-1,2-dihydro-2-thioxobenzo[d]imidazol-1-
yl)hexan-1-one (5.16) 
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benzene as the organic solvent and tetrabutylammonium chloride (TEBAC) as 
the catalyst. When treated with Lawesson’s reagent in pyridine as solvent 1,3-
diethyl-1H-benzo[d]imidazol-2(3H)-one (5.19) was not converted to the desired 
thio analog. Variation of the reaction conditions (reaction temperature up to 140 
°C, longer reaction time (2 days)) remained unsuccessful: the starting material 
was always nearly quantitatively recovered. 
 
This required a new synthetic route. Therefore, a two step synthesis was cho-
sen, in which the first step should be the N,N’-dialkylation of o-phenylendiamine 
followed by ring closure to obtain the corresponding benzimidazol-2-thione. o-
Phenylenediamine (5.21) was alkylated with bromoethane (2 eq), sodium hy-
dride (2.2 eq) as base in DMF at 60 °C for 2 hours yielding both the diethylated 
compound (21 %) and the monoethylated substance (38 %). According to the 
literature the cyclisation of 1,2-diaminobenzene to benzimidazoles is often per-
formed with carbon disulphide182,183 under heat in an alkaline alcoholic me-
dium184,185,186. A convenient and mild procedure can be envisaged with the re-
agent TCDI. Therefore, 5.22 and 5.23 were stirred with TCDI in dry THF over-
night at ambient temperature resulting in moderate and high yields of 5.20 
NH
N
OH
5.19
N
N
O
N
N
S
i ii
5.20
5.18
N
N
O
O
O
iii
5.17
Reagents: i) BrCH2CH3, TEBAC, 50% 
NaOH, benzene; ii) LR, pyridine, heat; 
iii) Ac2O, reflux, 6h
Scheme 5.5: Attempted synthetic route to 1,3-diethyl-1H-benzo[d]imidazol-2(3H)-
thione (5.20) and synthesis of 1,3-diacetyl-1H-benzo[d]imidazol-2(3H)-one (5.18) 
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(37%) and 5.24 (93%), respectively. 5.24 was converted to 5.25 by acylation 
with acetyl chloride in anhydrous THF in the presence of triethylamine. 
The introduction of an additional substituent at the benzene ring of the benzimi-
dazole scaffold was achieved by a ring closing reaction of methyl 3,4-diamino-
benzoate (5.26) with TCDI in dry THF. Compound 5.27 was obtained in high 
yield (Scheme 5.7). 
 
 
 
 
 
 
The new 2-methylbenzimidazole derivative 5.29 was synthesized by analogy 
with the aforementioned procedures as illustrated in Scheme 5.8. 
NH2
NH2
5.23
H
N
NH
NH2
NH
i
5.22
+
5.20 5.24
N
N
S
NH
N
S
5.25
N
N
S
O
iii
ii
5.21
Reagents: i) BrCH2CH3 (2 eq), NaH (2.2 eq), DMF, 60 °C, 2h;
ii) TCDI (1.1 eq), THF; iii) AcCl, Et3N, THF
Scheme 5.6: Synthetic pathway to mono- and dialkylated benzimidazol- 
2-thione derivatives 
NH2
NH2
TCDI, THF
MeO2C
N
H
H
N
S
MeO2C
5.275.26
Scheme 5.7: Synthesis of methyl 2-thioxo-3H-benzo[d]imidazole-5-carboxylate 
(5.27) 
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5.3 Results and Discussion 
 
The synthesized compounds were investigated for inhibitory activity on the 
bacterial hyaluronidase from S. agalactiae strain 4755 at both pH 7.4 and pH 5, 
and on a hyaluronidase from bovine testis at pH 5 by using a turbidimetric as-
say according to a modified protocol from Di Ferrante145 (see chapter 3). 
In general, all compounds inhibited the bacterial enzyme but were inactive on 
the bovine testicular hyaluronidase. Therefore, only the inhibitory effects on 
hylB4755 are elaborated on below. At the physiological pH, the affinity of the 
substrate HA is lower than at pH optimum probably facilitating the displacement 
of HA. In agreement with the pH dependency of the substrate affinity150 the ben-
zimidazoles were more potent at physiological pH. 
 
5.3.1 N-Acylated benzimidazol-2-thiones 
Starting from the lead structure 5.1 that bears two acetyl groups at the nitrogen 
atoms, a series of mono- and diacylated benzimidazol-2-thiones was synthe-
sized and tested to prove the role of the acyl groups (Table 5.1). All monoacy-
lated compounds (5.3-5.8) showed only weak inhibition of hylB4755 at pH 5 at 
highest possible concentrations (dependent on the solubility of the compounds). 
Higher inhibitory potency was found at physiological pH. 
 
N
N
O
N
H
N H3CCH2COCl,
Et3N, THF
5.29
5.28
Scheme 5.8: Acylation of 2-methylbenzimidazole (5.28) 
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Table 5.1: Inhibitory activities of acylated benzimidazoles on hyaluronidase from S. agalactiae 
at pH 5 and pH 7.4, respectively, and bovine testicular hyaluronidase at pH 5 (data determined 
in a turbidimetric assay) 
 
 
 
 
 
Compd. R X Y hylB4755, IC50 [µM] or %a BTHa 
    pH = 5.0 pH = 7.4 pH = 5.0 
5.1b COCH3 NCOCH3 S 160 5 n.d. 
5.2 H NH S 1148 ± 50 1862±117 25 % (4000) 
5.3 COCH3 NH S 20 % (460) 17 ± 1 inactivec 
5.4 COCH2CH3 NH S 4 % (180) 26 ± 3 inactived 
5.5 CO(CH2)2CH3 NH S 7 % (190) 20 ± 2 inactived 
5.6 CO(CH2)4CH3 NH S 14 % (170) 16 ± 1 inactived 
5.7 CO(CH2)2Ph NH S 5 % (100) 29 ± 5 inactivee 
5.8 CO-m-ClC6H4 NH S 16 % (400) 70 ± 10 inactivef 
5.16 CO(CH2)4CH3 NCOCH3 S 50 % (49) 12 ± 1 inactiveg 
5.18 COCH3 NCOCH3 O inactived 10 % (200) inactived 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as percent inhibition at the inhibi-
tor concentration (µM) given in parentheses; highest tested concentrations were dependent on 
the solubility of the compounds, b data according to Salmen120, c at concentrations ≤ 460 µM, d 
at concentrations ≤ 200 µM, e at concentrations ≤ 100 µM, f at concentrations ≤ 400 µM, g at 
concentrations ≤ 50 µM. 
 
Compounds 5.3-5.7 were about equipotent: IC50 values of 17 µM (5.3), 26 µM 
(5.4), 20 µM (5.5), 16 µM (5.6) and 29 µM (5.7) were determined (see Fig. 5.3). 
Compound 5.8 revealed a weaker inhibition with an IC50 of 70 µM. This may be 
interpreted as a hint that the benzoyl residue of 5.8 is too rigid. In contrast to the 
ascorbic acid derivatives described in chapter 4 an increase in hydrophobicity 
did not result in an increase in inhibitory activity; the extension of the alkanoyl 
chain of monoacylated benzimidazol-2-thiones had no influence on the inhibi-
tory activity. However, for N,N’-diacylated compounds derived from 5.1 an ex-
tension of one of the alkanoyl chains by 4 methylene groups (5.16) resulted in 
N
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R
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about 3-fold higher inhibitory activity compared to 5.1 (IC50 = 160 µM) at opti-
mum pH. 
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Fig. 5.3: Enzyme activity of hylB4755 in the presence of the acylated benzimidazol-2-thiones 5.5, 
5.8 and 5.16 at physiological pH (7.4) 
 
Due to the low solubility of 5.16 no IC50 value could be determined, but 50 % 
inhibition of the enzyme activity at a concentration of 49 µM could be measured. 
At physiological pH, the compounds 5.1 and 5.16 were the most potent ones 
(e.g., 5.16: IC50 = 12 µM) within the whole benzimidazole set. The difference in 
activity depending on pH was most pronounced for the monoacylated benzimi-
dazol-2-thiones. This could be explained by the protonated or unprotonated 
state of amino acid residues in the active site of hylB4755 and of the inhibitors as 
well as the pH dependency of the substrate affinity. Lead structure 5.1 was sig-
nificantly more potent than the corresponding oxo analog 5.18. Further investi-
gations of the promising N,N’-diacylated benzimidazol-2-thiones were not car-
ried out because of the instability of such compounds resulting in a difficult 
synthesis with very low yields and doubtful results from pharmacological inves-
tigations due to (partial or total) decomposition during incubation in the turbidi-
metric assay. 
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5.3.2 S-Alkylated benzimidazole derivatives 
Based upon the results shown in Table 5.1, we decided to continue with more 
stable S-substituted benzimidazole derivatives selecting either 2-sulfanylben-
zimidazole or compound 5.3 as core skeleton. 
 
Table 5.2: Inhibitory activities of S-alkylated benzimidazole derivatives on hylB4755 at pH 5 and 
pH 7.4, respectively and on BTH at pH 5 
 
 
 
 
 
Compd. R1 R2 hylB4755, IC50 [µM] or %a BTHa 
    pH = 5.0 pH = 7.4 pH = 5.0 
5.9 H CH2CH3 18 % (2000) 8 % (2000) inactiveb 
5.12 COCH3 CH2CH3 4 % (420) 5 % (420) inactivec 
5.13 COCH3 (CH2)6CH3 inactived inactivee inactived 
5.14 COCH3 CH2Ph 4 % (100) 12 % (100) inactivef 
5.15 COCH3 CH2-pMeOC6H4 inactivef inactiveg inactivef 
a inhibition of enzyme expressed as IC50 ± SEM in µM or as percent inhibition at the inhibitor 
concentration (µM) given in parentheses; highest tested concentrations were dependent on the 
solubility of the compounds, b at concentrations ≤ 2 mM, c at concentrations ≤ 420 µM, d at con-
centrations ≤ 140 µM, e at concentrations ≤ 270 µM, f at concentrations ≤ 100 µM, g at concen-
trations ≤ 120 µM. 
 
Therefore, several 2-(alkylsulfanyl)benzimidazole derivatives were prepared 
and tested for inhibitory activity on hyalB4755 and bovine testicular hyaluroni-
dase. As summarized in Table 5.2 the inhibitory activity of compounds 5.9 and 
5.12-5.15 on the bacterial hyaluronidase range from very weak to inactive. At 
optimum pH and at physiological pH a decrease in inhibitory activity on hylB4755 
was found for compound 5.9 compared to 5.2 and for compounds 5.12-5.15 
compared to 5.3. 
 
 
 
N
N
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5.3.3 N-Alkylated benzimidazole derivatives 
Since the S-alkylation of N-monoacylated 5.3 and non-acylated benzimidazole 
5.2 did not result in higher inhibitory potency it was attempted to stabilize the 
lead structure 5.1 by replacing the acetyl groups with ethyl groups. Considering 
compounds 5.1, 5.20 and 5.25 the stepwise replacement of the acetyl groups 
by alkyl residues resulted in a gradual loss of inhibitory activity on hylB4755 to the 
point of complete inactivity (at physiological pH, Table 5.3). 
 
Table 5.3: Inhibitory activities of various benzimidazole derivatives determined on hylB4755 at 
both pH optimum and physiological pH and on BTH at pH 5 
 
 
 
 
 
Compd. R X Y hylB4755, IC50 [µM] or %a BTHa 
    pH = 5.0 pH = 7.4 pH = 5.0 
5.1b COCH3 NCOCH3 S 160 5 n.d. 
5.19 CH2CH3 NCH2CH3 O 40 % (4900) inactivec inactivec 
5.20 CH2CH3 NCH2CH3 S inactived inactived inactived 
5.24 H NCH2CH3 S 19 % (4200) 28 % (4200) inactivee 
5.25 COCH3 NCH2CH3 S 10 % (380) 19 ± 1 inactivef 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as percent inhibition at the inhibi-
tor concentration (µM) given in parentheses; highest tested concentrations were dependent on 
the solubility of the compounds, b data from Salmen120, c at concentrations ≤ 4.9 mM, d at con-
centrations ≤ 100 µM, e at concentrations ≤ 4.2 mM, f at concentrations ≤ 380 µM. 
 
Moreover, the oxo analog 5.19 of 5.20 did not show an improved inhibitory ef-
fect. As found for the N,N’-diacetylated lead 5.1 in comparison to the alkylated 
analogs, the N-monoacetylated benzimidazol-2-thione 5.3 was likewise much 
more active than its corresponding ethyl analog 5.24. At least one amide bond 
seems to be essential for the inhibitory effect of this class of compounds. 
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5.3.4 Substituted benzimidazole derivatives 
An additional functional group was introduced at the anellated benzene moiety 
of benzimidazole to broaden the possibilities for derivatization and structural 
variation, respectively, and to improve the solubility of these compounds at the 
same time. This was achieved with the synthesis of compound 5.27 bearing a 
methoxycarbonyl group in position 5. 
 
Table 5.4: Enzymatic activity of bovine testicular hyaluronidase and hyaluronate lyase of S. 
agalactiae in the presence of compounds 5.2 and 5.27-5.29 
 
 
 
 
 
No. R1 R2 R3 hylB4755, IC50 [µM] or %a BTHa 
    pH = 5.0 pH = 7.4 pH = 5.0 
5.2 H SH H 1148 ± 50 1862 ± 117 25 % (4000) 
5.27 H SH CO2CH3 25 % (4500) 53 % (4500) inactiveb 
5.28 H CH3 H inactivec 6 % (4000) 10 % (4000) 
5.29 COCH2CH3 CH3 H 12 % (2000) inactived inactived 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as percent inhibition at the inhibi-
tor concentration (µM) given in parentheses; highest tested concentrations were dependent on 
the solubility of the compounds, b at concentrations ≤ 4.5 mM, c at concentrations ≤ 4 mM, d at 
concentrations ≤ 2 mM. 
 
Actually, the solubility in aqueous buffer was improved, however, the benzimi-
dazol-5-carboxylic acid ester 5.27 was a less active hyaluronidase inhibitor than 
compound 5.2 (Table 5.4). Finally, the thione group in position 2 of 5.2 was re-
placed by a methyl group (5.28). This modification caused a distinct loss of in-
hibitory activity on the bacterial enzyme both at physiological and optimum pH. 
Moreover, in contrast to 2-sulfanylbenzimidazole the introduction of a propanoyl 
residue in position 1 of 2-methylbenzimidazole was inappropriate to increase 
the inhibitory potency (see 5.28 vs. 5.29, Table 5.4, and 5.2 vs. 5.4, Table 5.1). 
Thus, the thione group in position 2 of the benzimidazole moiety seems to be 
crucial for inhibition of the bacterial hyaluronidase. 
R3
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5.4 Summary 
 
The synthesized N-monoacylated and N,N’-diacylated benzimidazol-2-thiones 
proved to be inhibitors of hyaluronate lyase from S. agalactiae strain 4755 
(hylB4755). The compounds are selective for the bacterial enzyme, whereas bo-
vine testicular hyaluronidase is not affected. Compared to the lead compound 
1,3-diacetylbenzimidazol-2-thione (5.1) only 1-acetyl-3-hexanoylbenzimidazol-2-
thione (5.16) displayed IC50 values in low micromolar range. Although the N,N’-
diacylated derivatives 5.1 and 5.16 are potent inhibitors of hylB4755 at both pH 
optimum and physiological pH they cannot be used for further investigations 
owing to their very high instability against hydrolysis. The much more stable N-
monoacylated derivatives 5.3-5.8 revealed likewise IC50 values in the low µM 
range but only at physiological pH. The difference in activity depending on pH 
was most obvious for the monoacylated benzimidazoles. An exchange of the 
acyl residues by ethyl groups resulted in a strong decrease in inhibitory activity. 
Thus, an amide bond appears to be essential for binding to the active site of the 
enzyme. Moreover, the thioxo function in position 2 of the benzimidazoles is 
favorable to increase the inhibitory activity. The thiones were significantly more 
potent than the oxo analogs, and a methyl group in position 2 led to a marked 
decrease in inhibitory activity. 
 
 
5.5 Experimental section 
 
5.5.1 General conditions 
See section 4.5.1 for general methods. 
5.5.2 Chemistry 
Synthesis of the monoacylated benzimidazoles 5.3-5.8 
General procedures 
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Method A. 2-Sulfanylbenzimidazole (5.2) (1 eq) and acid anhydride (1.1 eq) 
were dissolved in pyridine (4.4 eq) under a nitrogen atmosphere. The reaction 
mixture was stirred overnight at room temperature. The formed precipitate was 
removed by suction and washed with a small amount of dichloromethane. The 
crude product was purified as stated below. 
Method B. 2-Sulfanylbenzimidazole (5.2) (1 eq) and acid chloride or acid anhy-
dride (1.1 eq) were dissolved in pyridine (4.4 eq) under a nitrogen atmosphere. 
The reaction mixture was stirred overnight at room temperature. After quench-
ing with water (10-25 ml), ethyl acetate (30-45 ml) was added. The organic 
phase was extracted with 3M hydrochloric acid (3 x 25 ml), dried over magne-
sium sulfate and concentrated under reduced pressure. The crude product was 
purified as stated below. 
 
1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) 
Method A: Reaction of 2-sulfanylbenzimidazole (5.2) (4.02 g, 26.76 mmol), 
acetic anhydride (3.00 ml, 31.74 mmol) and pyridine (9.70 ml, 120.18 mmol); 
recrystallization from ethyl acetate. 
Yield: 3.80 g (19.77 mmol, 74 %, white solid) 
Mp: 193-194 °C (Lit. 198-200 °C179) 
1H-NMR (DMSO-d6): δ [ppm] = 3.00 (s, 3H, CH3), 7.16-7.33 (m, 3H, Ar-H), 7.97-
8.02 (m, 1H, Ar-H), 13.31 (br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 192 ([M•+], 20), 150 ([M - CH2CO] +, 100) 
Analysis: C9H8N2OS (192.24) 
 calculated C: 56.23 H: 4.19 N: 14.57 
 found C: 56.27 H: 4.23 N: 14.89 
 
1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)propan-1one (5.4) 
Method B: Reaction of 2-sulfanylbenzimidazole (5.2) (1.03 g, 6.86 mmol), pro-
panoyl chloride (0.64 ml, 7.33 mmol) and pyridine (2.40 ml, 29.73 mmol); re-
crystallization from ethyl acetate. 
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Yield: 0.78 g (3.79 mmol, 55 %, white flakes) 
Mp: 176-177.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.19 (t, 3H, 3J = 7.1 Hz, CH2CH3), 3.56 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 7.17-7.34 (m, 3H, Ar-H), 7.97-8.02 (m, 1H, Ar-H), 13.29 
(br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 206 ([M•+], 6), 150 ([M - CH3CHCO] +, 100) 
Analysis: C10H10N2OS (206.05) 
 calculated C: 58.23 H: 4.89 N: 13.58 S: 15.55 
 found C: 58.43 H: 5.09 N: 13.26  S: 15.20 
 
1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)butan-1-one (5.5) 
Method B: Reaction of 2-sulfanylbenzimidazole (5.2) (1.00 g, 6.66 mmol), bu-
tyric anhydride (1.20 ml, 7.32 mmol) and pyridine (2.40 ml, 29.73 mmol); crude 
product was treated with a 2:1 (v/v) mixture of petroleum ether (boiling point 
range 60-80 °C) and ethyl acetate to separate pure product; analytically pure 
product was obtained by column chromatography on silica gel eluting with a 4:1 
(v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.98 g (4.45 mmol, 67 %, white solid) 
Mp: 152-153 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.98 (t, 3H, 3J = 7.4 Hz, (CH2)2CH3), 1.67-1.81 
(m, 2H, CH2CH2CH3), 3.56 (t, 2H, 3J = 7.3 Hz, COCH2-), 7.17-7.34 (m, 3H, Ar-
H), 7.95-8.00 (m, 1H, Ar-H), 13.29 (br, 1H, NH) 
13C-NMR (DMSO-d6): δ [ppm] = 13.3 (+, CH3), 17.6 (-, CH2), 40.7 (-, CH2), 
109.4 (+, Ar-C), 115.0 (+, Ar-C), 123.3 (+, Ar-C), 125.2 (+, Ar-C), 130.9 (Cquart, 
Ar-C), 131.0 (Cquart, Ar-C), 169.4 (Cquart, CS), 175.1 (Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 220 ([M•+], 13), 150 ([M - C4H9CHCO]+, 100) 
Analysis: C11H12N2OS (220.30) 
 calculated C: 59.97 H: 5.49 N: 12.72 S: 14.56 
 found C: 60.06 H: 5.50 N: 12.56  S: 14.66 
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1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)hexan-1-one (5.6) 
Method B: Reaction of 2-sulfanylbenzimidazole (5.2) (1.02 g, 6.79 mmol), hex-
anoic anhydride (1.80 ml, 7.81 mmol) and pyridine (2.40 ml, 29.73 mmol); puri-
fication by column chromatography on silica gel, elution with a 4:1 (v/v) mixture 
of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.58 g (2.34 mmol, 34 %, white solid) 
Mp: 132.5-133 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.89 (t, 3H, 3J =7.0 Hz, (CH2)4CH3), 1.28-1.40 
(m, 4H, (CH2)2CH3), 1.67-1.78 (m, 2H, COCH2CH2-), 3.57 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 7.17-7.33 (m, 3H, Ar-H), 7.94-7.99 (m, 1H, Ar-H), 13.29 (br, 1H, NH) 
13C-NMR (DMSO-d6): δ [ppm] = 13.7 (+, CH3), 21.8 (-, CH2), 23.7 (-, CH2), 30.5 
(-, CH2), 38.7 (-, CH2), 109.5 (+, Ar-C), 115.0 (+, Ar-C), 123.3 (+, Ar-C), 125.2 
(+, Ar-C), 130.9 (Cquart, Ar-C), 131.1 (Cquart, Ar-C), 169.4 (Cquart, CS), 175.2 
(Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 248 ([M•+], 9), 150 ([M - C4H9 - CHCO]+, 100) 
Analysis: C13H16N2OS (248.35) 
 calculated C: 62.87 H: 6.49 N: 11.28 S: 12.91 
 found C: 62.91 H: 6.49 N: 11.05  S: 12.60 
 
1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)-3-phenylpropan-1-one (5.7) 
Method B: Reaction of 2-sulfanylbenzimidazole (5.2) (0.50 g, 3.33 mmol), 3-
phenylpropanoyl chloride (0.50 ml, 3.33 mmol) and pyridine (2.20 ml, 
26.98 mmol); purification by flash column chromatography on silica gel, elution 
with a 5:2 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.46 g (1.63 mmol, 49 %, white solid) 
Mp: 161-162.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 3.05 (t, 2H, 3J = 7.8 Hz, COCH2CH2Ph), 3.90 (t, 
2H, 3J = 7.8 Hz, COCH2CH2Ph), 7.16-7.34 (m, 8H, Ar-H), 7.96-7.99 (m, 1H, Ar-
H), 13.33 (br, 1H, NH) 
                                                   Benzimidazole-type hyaluronate lyase inhibitors 
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13C-NMR (DMSO-d6): δ [ppm] = 30.0 (-, CH2), 40.7 (-, CH2), 109.5 (+, Ar-C), 
115.1 (+, Ar-C), 123.3 (+, Ar-C), 125.3 (+, Ar-C), 126.0 (+, Ar-C), 128.3 (+, 4Ar-
C), 130.9 (Cquart, Ar-C), 131.1 (Cquart, Ar-C), 140.5 (Cquart, Ar-C), 169.4 (Cquart, 
CS), 174.4 (Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 282 ([M•+], 6), 249 ([M - SH]+, 19), 150 ([M - 
C6H5CH2CHCO] +, 100), 91 ([C7H7]+, 28) 
Analysis: C16H14N2OS (282.37) 
 calculated C: 68.06 H: 5.00 N: 9.92 S: 11.36 
 found C: 67.95 H: 5.07 N: 9.92  S: 11.18 
 
(3-Chlorophenyl)(2-thioxo-1H-benzo[d]imidazol-1-yl)methanone (5.8) 
Method B: Reaction of 2-sulfanylbenzimidazole (5.2) (0.30 g, 2.00 mmol), m-
chlorobenzoyl chloride (0.26 ml, 2.00 mmol) and pyridine (3.50 ml, 42.92 mmol); 
purification by flash column chromatography on silica gel, elution with dichloro-
methane. 
Yield: 0.13 g (0.45 mmol, 23 %, pale yellow solid) 
Mp: 170-172 °C 
1H-NMR (DMSO-d6): δ [ppm] = 7.21-7.35 (m, 3H, benzimidazole-H), 7.45-7.48 
(m, 1H, benzimidazole-H), 7.55 (ddd, 1H, 3J = 8.1 Hz, 3J = 7.7 Hz, 5J = 0.4 Hz, 
H-5), 7.75 (ddd, 1H, 3J = 8.1 Hz, 4J = 2.1 Hz, 5J = 1.1 Hz, H-4/6), 7.80 (ddd, 1H, 
3J = 7.7 Hz, 4J = 1.7 Hz, 5J = 1.1 Hz, H-4/6), 7.91 (ddd, 1H, 4J = 2.1 Hz, 4J = 1.7 
Hz, 5J = 0.4 Hz, H-2), 13.29 (br, 1H, NH) 
13C-NMR (DMSO-d6): δ [ppm] = 110.0 (+, Ar-C), 112.1 (+, Ar-C), 123.2 (+, Ar-
C), 124.9 (+, Ar-C), 128.8 (+, Ar-C), 129.7 (+, Ar-C), 130.5 (+, Ar-C), 131.3 
(Cquart, Ar-C), 131.9 (Cquart, Ar-C), 133.1 (Cquart, Ar-C), 133.5 (+, Ar-C), 134.8 
(Cquart, Ar-C), 168.5 (Cquart, CO), 169.5 (Cquart, CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 288 ([M•+], 41), 139 ([ClC6H4CO]+, 100), 111 
([ClC6H4]+, 47) 
C14H9ClN2OS (288.75) 
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2-(Ethylsulfanyl)-1H-benzo[d]imidazole (5.9) 
A solution of 2-sulfanylbenzimidazole (5.2) (1.03 g, 6.86 mmol), bromoethane 
(0.50 ml, 6.70 mmol) and DMF (15 ml) was cooled down in an ice-bath under an 
inert atmosphere. Sodium hydride (0.24 g, 10.0 mmol) was added in small por-
tions and the reaction was stirred overnight. After quenching the reaction with 
methanol (20 ml), the mixture was stirred for 30 min and concentrated under 
reduced pressure. The residue was taken up in ethyl acetate. After addition of 
water (20 ml), the phases were separated and the aqueous phase was ex-
tracted with ethyl acetate (2x15 ml). The combined organic phases were 
washed with water (15 ml) and dried over sodium sulfate. Then the solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography on silica gel eluting with a 2:1 (v/v) mixture of petroleum ether 
(60-80 °C) and ethyl acetate. 
Yield: 0.60 g (3.37 mmol, 49 %, white flakes) 
Mp: 165-166 °C (Lit. 172-173 °C187) 
1H-NMR (DMSO-d6): δ [ppm] = 1.36 (t, 3H, 3J = 7.3 Hz, CH2CH3), 3.27 (q, 2H, 
3J = 7.3 Hz, CH2CH3), 7.07-7.14 (m, 2H, Ar-H), 7.31-7.39 (m, 1H, Ar-H), 7.47-
7.54 (m, 1H, Ar-H), 12.49 (br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 178 ([M•+], 96), 163 ([M - CH3]+, 28), 150 ([M - 
C2H4]+, 100), 145 ([M-SH] +, 72) 
Analysis: C9H10N2S (178.25) 
 calculated C: 60.64 H: 5.65 N: 15.72 
 found C: 60.69 H: 5.56 N: 15.83 
 
N-(2-Aminophenyl)acetamide (5.11) 
To 2-nitroacetanilide (5.10) (1.80 g, 10.0 mmol), dissolved in absolute methanol 
(40 ml), 10 % Pd-C catalyst (100 mg) and 15 drops of glacial acetic acid were 
added. After hydrogenation in an autoclave at 3 bar at room temperature for 25 
h, the solution was filtrated, washed with methanol and concentrated in vacuo. 
The crude product was recrystallized from methanol. 
Yield: 0.76 g (5.06 mmol; 51%, creamy solid) 
                                                   Benzimidazole-type hyaluronate lyase inhibitors 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 89 
Mp: 127-128 °C (Lit. 130-131 °C188) 
1H-NMR (DMSO-d6): δ (ppm) = 2.03 (s, 3H, CH3), 4.84 (br, 2H, NH2), 6.52 (ddd, 
1H, 3J = 7.8 Hz, 3J = 7.2 Hz, 4J = 1.5 Hz, H-5), 6.70 (dd, 1H, 3J = 7.9 Hz, 4J = 
1.5 Hz, H-3), 6.88 (ddd, 1H, 3J = 7.9 Hz, 3J = 7.2 Hz, 4J = 1.5 Hz, H-4), 7.14 (dd, 
1H, 3J =7.8 Hz, 4J = 1.5 Hz, H-6), 9.11 (br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 150 ([M•+], 64), 108 ([M - CH2CO]+, 100) 
C8H10N2O (150.18) 
 
Synthesis of the 1-(2-alkylsulfanyl-1H-benzo[d]imidazol-1-yl)ethanones 
5.12-5.15 
General procedure. 1-(2-Thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) 
(1 eq) was dissolved in DMF (10-15 ml) and treated with the pertinent alkyl hal-
ide (1 eq) under a nitrogen atmosphere. After cooling with an ice-bath, sodium 
hydride (60 % suspension in paraffin oil) (1.5 eq) was added in small portions. 
The reaction mixture was stirred overnight at room temperature. Afterwards the 
reaction was stopped with methanol (10 ml) to destroy excess sodium hydride. 
After stirring for a few minutes, water (20-40 ml) and ethyl acetate (20-35 ml) 
were added. The separated aqueous phase was extracted twice with ethyl 
acetate (15 ml). The combined organic layers were dried over sodium sulfate 
and the solvent was removed under reduced pressure. The crude product was 
purified as stated below. 
 
1-[2-(Ethylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone (5.12) 
Reaction of 1-(2-thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) (0.70 g, 
3.64 mmol), bromoethane (0.28 ml, 3.75 mmol) and sodium hydride (0.24 g, 
6.00 mmol); purification by column chromatography on silica gel, elution with a 
2:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.50 g (2.27 mmol, 62 %, white solid) 
Mp: 108-109 °C 
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1H-NMR (DMSO-d6): δ [ppm] = 1.38 (t, 3H, 3J = 7.4 Hz, SCH2CH3), 2.81 (s, 3H, 
COCH3), 3.23 (q, 2H, 3J = 7.4 Hz, SCH2CH3), 7.26-7.36 (m, 2H, Ar-H), 7.59-
7.65 (m, 1H, Ar-H), 7.77-7.84 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 220 ([M•+], 65), 178 ([M - CH2CO] +, 51), 163 
([M - CH2CO - CH3] +, 27), 150 ([M - CH2CO - C2H4] +, 100) 
Analysis: C11H12N2OS (220.30) 
 calculated C: 59.97 H: 5.49 N: 12.72 
 found C: 60.19 H: 5.58 N: 12.30 
 
1-[2-(Heptylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone (5.13) 
Reaction of 1-(2-thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) (0.72 g, 
3.75 mmol), 1-bromoheptane (0.58 ml, 3.69 mmol) and sodium hydride (0.25 g, 
6.25 mmol); purification by column chromatography on silica gel, elution with a 
7:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.35 g (1.21 mmol, 33 %, white solid) 
Mp: 42-43 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.86 (t, 3H, 3J = 6.9 Hz, (CH2)6CH3), 1.21-1.48 
(m, 8H, (CH2)4CH3), 1.67-1.79 (m, 2H, SCH2CH2-), 2.81 (s, 3H, COCH3), 3.22 
(t, 2H, 3J = 7.3 Hz, SCH2-), 7.26-7.36 (m, 2H, Ar-H), 7.57-7.63 (m, 1H, Ar-H), 
7.77-7.83 (m, 1H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CH3), 22.0 (-, CH2), 26.2 (+, COCH3), 
28.0 (-, CH2), 28.2 (-, CH2), 28.3 (-, CH2), 31.1 (-, CH2), 31.4 (-, CH2), 114.1 (+, 
Ar-C), 118.1 (+, Ar-C), 123.1 (+, Ar-C), 124.1 (+, Ar-C), 132.9(Cquart, Ar-C), 
143.5 (Cquart, Ar-C), 154.7 (Cquart, Ar-C), 169.4 (Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 290 ([M•+], 15), 248 ([M - CH2CO]+, 3), 150 ([M 
- CH2CO - C7H14]+, 100) 
Analysis: C16H22N2OS (290.42) 
 calculated C: 66.17 H: 7.64 N: 9.65 
 found C: 66.36 H: 7.34 N: 9.42 
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1-(2-(Benzylsulfanyl)-1H-benzo[d]imidazol-1-yl)ethanone (5.14) 
Reaction of 1-(2-thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) (0.70 g, 
3.64 mmol), benzyl bromide (0.45 ml, 3.79 mmol) and sodium hydride (0.24 g, 
6.00 mmol); purification by column chromatography on silica gel, elution with 
dichloromethane. 
Yield: 0.45 g (1.59 mmol, 44 %, white solid) 
Mp: 119-120 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.81 (s, 3H, COCH3), 4.51 (s, 2H, CH2), 7.24-
7.38 (m, 5H, Ar-H), 7.47-7.52 (m, 2H, Ar-H), 7.63-7.67 (m, 1H, Ar-H), 7.78-7.84 
(m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 282 ([M•+], 54), 240 ([M - CH2CO]+, 80), 207 
([M - CH2CO - SH]+, 48), 91 ([C6H5CH2]+, 100) 
Analysis: C16H14N2OS (282.36) 
 calculated C: 68.06 H: 5.00 N: 9.92 
 found C: 68.26 H: 5.17 N: 9.81 
 
1-[2-(4-Methoxybenzylsulfanyl)-1H-benzo[d]imidazol-1-yl]ethanone (5.15) 
Reaction of 1-(2-thioxo-1H-benzo[d]imidazol-1-yl)ethanone (5.3) (0.50 g, 
2.60 mmol), 4-methoxybenzylchloride (0.37 ml, 2.73 mmol; stabilized in 1% 
K2CO3) and sodium hydride (0.16 g, 4.00 mmol); extraction with dichloro-
methane instead of ethyl acetate; purification by column chromatography on 
silica gel, elution with dichloromethane; analytical pure sample was obtained by 
recrystallization from ethanol. 
Yield: 0.25 g (0.80 mmol, 31 %, white needles) 
Mp: 121-122 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.80 (s, 3H, COCH3), 3.73 (s, 3H, OCH3), 4.45 
(s, 2H, SCH2), 6.85-6.92 (m, 2H, Ar-H), 7.28-7.44 (m, 4H, Ar-H), 7.61-7.67 (m, 
1H, Ar-H), 7.77-7.84 (m, 1H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 26.0 (+, CH3), 35.3 (-, CH2), 55.0 (+, CH3), 
113.8 (+, 2Ar-C), 114.0 (+, Ar-C), 118.1 (+, Ar-C), 123.2 (+, Ar-C), 124.2 (+, Ar-
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C), 128.3 (Cquart, Ar-C), 130.4 (+, 2Ar-C), 132.7 (Cquart, Ar-C), 143.4 (Cquart, Ar-
C), 154.3 (Cquart, Ar-C), 158.4 (Cquart, Ar-C), 169.5 (Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 312 ([M•+], 20), 270 ([M - CH2CO]+, 12), 121 
([MeOC6H4CH2]+, 100) 
Analysis: C17H16N2O2S (312.4) 
 calculated C: 65.36 H: 5.16 N: 8.97 S: 10.26 
 found C: 65.24 H: 5.38 N: 8.94 S: 10.23 
 
1-(3-Acetyl-1,2-dihydro-2-thioxobenzo[d]imidazol-1-yl)hexan-1-one (5.16) 
To a solution of 1-(2-thioxo-1H-benzo[d]imidazol-1-yl)hexan-1-one (5.6) (0.29 g, 
1.17 mmol), triethylamine (0.19 ml, 1.37 mmol) and absolute THF (10 ml) acetyl 
chloride (0.10 ml, 1.40 mmol) was added. After stirring for 1 h at room tem-
perature, the reaction mixture was concentrated in vacuo. Water (10 ml) was 
added and the aqueous phase was extracted with ethyl acetate (3x10 ml). The 
combined organic layers were washed with a solution of saturated sodium car-
bonate (10 ml), dried over magnesium sulfate and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica 
gel eluting with a 8:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl ace-
tate. 
Yield: 20 mg (0.07 mmol, 6 %, white solid) 
1H-NMR (DMSO-d6): δ [ppm] = 0.88 (t, 3H, 3J = 7.1 Hz, (CH2)4CH3), 1.29-1.40 
(m, 4H, (CH2)2CH3), 1.70-1.80 (m, 2H, COCH2CH2-), 2.98 (s, 3H, COCH3), 3.45 
(t, 2H, 3J = 7.3 Hz, COCH2-), 7.34-7.40 (m, 2H, Ar-H), 7.69-7.74 (m, 1H, Ar-H), 
7.86-7.90 (m, 1H, Ar-H) 
C15H18N2O2S (290.40) 
 
1,3-Diacetyl-1H-benzo[d]imidazol-2(3H)-one (5.18) 
2-Hydroxybenzimidazole (5.17) (0.50 g, 3.73 mmol) was suspended in acetic 
anhydride (15 ml) and heated under reflux for 6 h. Water (20 ml) and ethyl ace-
tate (30 ml) were added and the separated organic phase was extracted with a 
solution of saturated sodium carbonate (3x20 ml). The organic phase was 
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washed with water (20 ml), dried over magnesium sulfate and concentrated un-
der reduced pressure. The crude product was recrystallized from a 1:1 (v/v) 
mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.59 g (2.70 mmol, 73 %, white needles) 
Mp: 145.5-146.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.66 (s, 6H, 2COCH3), 7.27-7.34 (m, 2H, Ar-H), 
8.09-8.16 (m, 2H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 218 ([M•+], 15), 176 ([M - CH2CO]+, 18), 134 
([M - 2CH2CO]+, 100) 
Analysis: C11H10N2O3 (218.21) 
 calculated C: 60.55 H: 4.62 N: 12.84 
 found C: 60.42 H: 4.53 N: 12.98 
 
1,3-Diethyl-1H-benzo[d]imidazol-2(3H)-one (5.19) 
2-Hydroxybenzimidazole (5.17) (0.50 g, 3.73 mmol), dissolved in benzene 
(10 ml), a solution of sodium hydroxide (50%, 5 ml), TEBAC (0.06 g, 0.20 mmol) 
and bromoethane (0.85 ml, 11.39 mmol) were stirred at 60 °C for 4 h. The mix-
ture was cooled down and the separated organic phase was washed with water 
(3x10 ml). After drying the organic phase over magnesium sulfate, the solvent 
was removed under reduced pressure. The pale yellow crude product was puri-
fied by column chromatography on silica gel eluting with a 1:1 (v/v) mixture of 
chloroform and ethyl acetate. 
Yield: 0.40 g (2.10 mmol, 56 %, white solid) 
Mp: 67-68 °C (Lit. 68-69 °C189) 
1H-NMR (CDCl3): δ [ppm] = 1.34 (t, 6H, 3J = 7.3 Hz, 2CH2CH3), 3.95 (q, 4H, 3J 
= 7.3 Hz, 2CH2CH3), 6.97-7.12 (m, 4H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 190 ([M•+], 100), 175 ([M - CH3]+, 87), 162 ([M - 
C2H4]+, 20), 147 ([M - C2H4 - CH3] +, 38) 
Analysis: C11H14N2O (190.24) 
 calculated C: 69.45 H: 7.42 N: 14.73 
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 found C: 69.40 H: 7.07 N: 14.45 
 
1,3-Diethyl-1H-benzo[d]imidazole-2(3H)-thione (5.20) 
N1,N2-Diethylbenzene-1,2-diamine (5.23) (0.15 g, 0.91 mmol) was dissolved in 
absolute THF (10 ml). This solution was treated with TCDI (0.18 g, 1.01 mmol) 
under a nitrogen atmosphere. After stirring at room temperature for 22 h, the 
mixture was concentrated in vacuo. Ethyl acetate (15 ml) and water (15 ml) 
were added to the residue and the organic phase was separated. The aqueous 
phase was extracted three times with ethyl acetate (15 ml). The combined or-
ganic phases were dried over magnesium sulfate and the solvent was removed. 
The crude product was purified by column chromatography on silica gel eluting 
with a 4:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.07 g (0.34 mmol, 37 %, pale yellow oil) 
1H-NMR (DMSO-d6): δ [ppm] = 1.26 (t, 6H, 3J = 7.1 Hz, 2CH2CH3), 4.33 (q, 4H, 
3J = 7.1 Hz, 2CH2CH3), 7.23-7.31 (m, 2H, Ar-H), 7.44-7.53 (m, 2H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 207 ([M•+], 83), 164 ([M – CS + 2H]+, 100), 119 
([C6H5NCH2CH2]+, 53) 
C11H14N2S (206.31) 
 
N1-Ethylbenzene-1,2-diamine (5.22) and N1,N2-diethylbenzene-1,2-diamine 
(5.23) 
A solution of o-phenylendiamine (5.21) (0.50 g, 4.62 mmol) and bromoethane 
(0.68 ml, 9.11 mmol) in DMF (10 ml) was treated with sodium hydride (0.25 g, 
6.25 mmol) in small portions under an inert atmosphere. After stirring for 2 h at 
60 °C, the reaction was quenched with methanol (10 ml) and stirred for further 
30 min. The solution was concentrated under reduced pressure and water 
(20 ml) and ethyl acetate (20 ml) were added. The separated aqueous phase 
was extracted with ethyl acetate (5x20 ml). The combined organic layers were 
dried over magnesium sulfate and the solvent was removed under reduced 
pressure. The mixture was purified by column chromatography on silica gel 
eluting with a 1:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
                                                   Benzimidazole-type hyaluronate lyase inhibitors 
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The first fraction yielded the dialkylated product 5.23 (0.16 g, 0.97 mmol, 21 %, 
red-brown oil) whereas the second fraction provided the monoalkylated com-
pound 5.22 (0.24 g, 1.76 mmol, 38 %, red-brown oil). 
 
N1-Ethylbenzene-1,2-diamine (5.22): 
1H-NMR (DMSO-d6): δ [ppm] = 1.20 (t, 3H, 3J = 7.1 Hz, CH2CH3), 3.02 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 4.46 (br, 3H, NH), 6.36-6.43 (m, 2H, Ar-H), 6.45-6.55 (m, 
2H, Ar-H) 
C8H12N2 (136.19) 
 
N1,N2-Diethylbenzene-1,2-diamine (5.23): 
1H-NMR (DMSO-d6): δ [ppm] = 1.21 (t, 6H, 3J = 7.1 Hz, 2CH2CH3), 3.03 (dq, 
4H, 3J = 7.1 Hz, 3J = 5.0 Hz, NHCH2CH3), 4.41 (t, 2H, 3J = 5.0 Hz, NHCH2), 
6.38-6.45 (m, 2H, Ar-H), 6.48-6.56 (m, 2H, Ar-H) 
C10H16N2 (164.25) 
 
1-Ethyl-1H-benzo[d]imidazole-2(3H)-thione (5.24) 
N1-Ethylbenzene-1,2-diamine (5.22) (0.23 g, 1.69 mmol) was dissolved in ab-
solute THF (10 ml). This solution was treated with TCDI (0.33 g, 1.85 mmol) 
under a nitrogen atmosphere. After stirring at room temperature for 22 h, the 
mixture was concentrated in vacuo. Ethyl acetate (15 ml) and water (15 ml) 
were added to the residue and the organic phase was separated. The aqueous 
phase was extracted three times with ethyl acetate (15 ml). The combined or-
ganic phases were dried over magnesium sulfate and concentrated in vacuo. 
The crude product was purified by column chromatography on silica gel eluting 
with a 1:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.28 g (1.57 mmol, 93 %, white needles) 
Mp: 161.5-162.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.24 (t, 3H, 3J = 7.1 Hz, CH2CH3), 4.27 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 7.17-7.24 (m, 3H, Ar-H), 7.38-7.45 (m, 1H, Ar-H), 12.74 
(br, 1H, NH) 
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MS (PI-EIMS, 70 eV): m/z (%) = 178 ([M•+], 100), 150 ([M - C2H4]+, 91) 
Analysis: C9H10N2S (178.25) 
 calculated C: 60.64 H: 5.65 N: 15.72 
 found C: 60.55 H: 5.68 N: 15.68 
 
1-(3-Ethyl-1,2-dihydro-2-thioxobenzo[d]imidazole-1-yl)ethanone (5.25) 
A solution of 1-ethyl-1H-benzo[d]imidazole-2(3H)-thione (5.24) (0.14 g, 
0.79 mmol), dissolved in absolute THF (5 ml), triethylamine (0.11 ml, 
0.79 mmol) and acetyl chloride (0.07 ml, 0.98 mmol) was stirred at room tem-
perature for 1 h under an inert atmosphere. Afterwards, the reaction mixture 
was concentrated under reduced pressure and water (5 ml) was added. After 
extraction with ethyl acetate (3x10 ml), the combined organic phases were dried 
over magnesium sulfate and concentrated in vacuo. The crude product was pu-
rified by column chromatography on silica gel eluting with a 4:1 (v/v) mixture of 
petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.07 g (0.32 mmol, 40 %, white solid) 
Mp: 81.5-82.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.27 (t, 3H, 3J = 7.1 Hz, CH2CH3), 3.03 (s, 3H, 
COCH3), 4.37 (q, 2H, 3J = 7.1 Hz, CH2CH3), 7.28-7.43 (m, 2H, Ar-H), 7.52-7.57 
(m, 1H, Ar-H), 8.03-8.08 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 220 ([M•+], 42), 178 ([M - CH2CO]+, 97), 150 
([M - C2H4 - CH2CO]+, 100), 43 ([H3C - CO]+, 24) 
Analysis: C11H12N2OS (220.30) 
 calculated C: 59.97 H: 5.49 N: 12.72 
 found C: 59.77 H: 5.53 N: 13.03 
 
Methyl 2-thioxo-3H-benzo[d]imidazole-5-carboxylate (5.27) 
To a solution of methyl 3,4-diaminobenzoate (5.26) (0.20 g, 1.20 mmol), dis-
solved in absolute THF (10 ml), TCDI (0.23 g, 1.29 mmol) was added under 
inert atmosphere. After stirring at room temperature for 4 h, the reaction mixture 
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was concentrated under reduced pressure. The residue was treated with water 
(30 ml) and ethyl acetate (50 ml) and stirred for 10 min. After extraction of the 
isolated aqueous phase with ethyl acetate (3x20 ml), the combined organic 
phases were dried over magnesium sulfate and concentrated in vacuo. The 
crude product was resumed in a small amount of THF and purified by column 
chromatography on silica gel eluting with ethyl acetate. 
Yield: 0.23 g (1.10 mmol, 92 %, beige solid) 
Mp: 285 °C (decomposition) 
1H-NMR (DMSO-d6): δ [ppm] = 3.85 (s, 3H, CO2CH3), 7.23 (dd, 1H, 3J = 8.4 Hz, 
5J = 0.5 Hz, H-7), 7.66 (dd, 1H, 4J = 1.5 Hz, 5J = 0.5 Hz, H-4), 7.78 (dd, 1H, 3J = 
8.4 Hz, 4J = 1.5 Hz, H-6), 12.84 (br, 2H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 208 ([M•+], 100), 177 ([M - OCH3]+, 63), 149 
([M - CH3OCO]+, 21) 
Analysis: C9H8N2O2S (208.24) 
 calculated C: 51.91 H: 3.87 N: 13.45 S: 15.40 
 found C: 51.82 H: 4.03 N: 13.20 S: 15.12 
 
1-(2-Methyl-1H-benzo[d]imidazol-1-yl)propan-1-one (5.29) 
2-Methylbenzimidazole (5.28) (0.40 g, 3.03 mmol) was dissolved in dry THF 
(20 ml) and mixed with triethylamine (0.46 ml, 3.33 mmol). After cooling down to 
0 °C, propionyl chloride (0.29 ml, 3.33 mmol) was added and the mixture was 
allowed to stir for further 30 min. Afterwards, water (20 ml) was added and the 
mixture was extracted with ethyl acetate (3x20 ml). The combined organic 
phases were extracted with a solution of saturated sodium bicarbonate (20 ml), 
dried over magnesium sulfate and concentrated in vacuo. The crude product 
was purified by flash column chromatography on silica gel eluting with a 3:1 
(v/v) mixture of ethyl acetate and petroleum ether (60-80 °C). 
Yield: 0.41 g (2.18 mmol, 72 %, white solid) 
Mp: 74-76 °C 
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1H-NMR (DMSO-d6): δ [ppm] = 1.20 (t, 3H, 3J = 7.1 Hz, CH2CH3), 2.78 (s, 3H, 
CH3), 3.17 (q, 2H, 3J = 7.1 Hz, CH2CH3), 7.28-7.36 (m, 2H, Ar-H), 7.57-7.64 (m, 
1H, Ar-H), 7.95-8.02 (m, 1H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 8.4 (+, CH3), 18.9 (+, CH3), 31.1 (-, CH2), 114.9 
(+, Ar-C), 118.8 (+, Ar-C), 123.8 (+, Ar-C), 123.9 (+, Ar-C), 132.8 (Cquart, Ar-C), 
142.0 (Cquart, Ar-C), 152.5 (Cquart, Ar-C), 173.6 (Cquart, COCH2CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 188 ([M•+], 21), 132 ([M - CH3CHCO]+, 100) 
C11H12N2O (188.23) 
 
5.5.3 Pharmacological methods 
Materials 
Hyaluronan (hyaluronic acid) from Streptococcus zooepidemicus was pur-
chased from Aqua Biochem (Dessau, Germany). Bovine serum albumin (BSA) 
was obtained from Serva (Heidelberg, Germany). The investigated hyaluroni-
dases were enzyme preparations from different sources. Stabilized hyaluronate 
lyase, i.e. 200,000 units†† (0.572 mg from S.agalactiae strain 4755 plus 2.2 mg 
of BSA and 37 mg of Tris-HCl per vial) of lyophilized hyaluronate lyase, was 
kindly provided by id-Pharma (Jena, Germany). Lyophilized hyaluronidase from 
bovine testis (Neopermease®) (200,000 units††; 4 mg plus 25 mg of gelatin per 
vial) was a gift from Sanabo (Vienna, Austria). All other chemicals were of ana-
lytical grade and were received from Merck or Sigma. 
 
Estimation of the aqueous solubility of the test compounds 
see section 4.5.3. 
 
Determination of enzyme inhibition 
The inhibitory effect of benzimidazole derivatives on the activities of hyaluroni-
dases was determined by a turbidimetric assay according to the method of Di 
Ferrante145 described in chapter 3. 
                                            
†† according to the declaration of the supplier 
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10 µl of the test compounds (0.2 µM-2 mM, dissolved in DMSO) were incubated 
at 37 °C in a mixture composed of 120 µl of McIlvaine’s buffer (solution A: 0.2 M 
Na2HPO4, 0.1 M NaCl, solution B: 0.1 M citric acid, 0.1 M NaCl; solution A and 
B were mixed in the appropriate proportions to reach pH 5.0 and pH 7.4), 30 µl 
of BSA solution (0.2 mg/ml in water), 50 µl of water, 30 µl of HA solution 
(2 mg/ml in water) and 30 µl of an enzyme solution (bacterial enzyme was dis-
solved in BSA solution (0.2 mg/ml in water); bovine enzyme dissolved in 1 ml 
H2O and further diluted with BSA solution (0.2 mg/ml in water)). Equiactive con-
centrations of bovine testicular hyaluronidase (54 ng) or of S.agalactiae hyalu-
ronate lyase (2.9 ng) were either incubated for 30 min at pH 5.0 or for 3 h at pH 
7.4 (just used for the bacterial enzyme). Equimolar concentrations of 
S.agalactiae hyaluronate lyase (11.4 ng) or of BTH (8 ng) were either incubated 
at pH 5 for 7.5 min or for 51 h, respectively. The final DMSO concentration was 
3.7% (v/v). After incubation of the assay mixture, the residual high molecular 
weight HA was precipitated by adding 700 µl of a 2.5% (w/v) cetyltrimethylam-
monium bromide (CTAB) solution (2.5 g of CTAB dissolved in 100 ml of 0.5 M 
sodium hydroxide solution, pH 12.5). The stopped enzyme reaction was again 
incubated at 25 °C for 20 min and the turbidity of each sample was visualised at 
600 nm with a Uvikon 930 UV spectrophotometer (Kontron, Eching, Germany). 
 
Quantification of inhibitory activity 
The turbidity of the sample without inhibitor (10 µl of DMSO was used instead) 
was taken as reference for 100% enzyme activity, whereas the turbidity of the 
sample without both enzyme and inhibitor (30 µl of BSA solution and 10 µl of 
DMSO, respectively, was used instead) was taken as reference for 0% enzyme 
activity. 
The activities were plotted against the logarithm of the inhibitor concentration, 
and IC50 ± SEM values were calculated by curve fitting of the experimental data 
with Sigma Plot 8.0 (SPSS Inc., Chicago, IL) and are the means of at least two 
independent experiments performed in duplicate. 
To exclude factors affecting turbidity (interactions of the test compound with the 
substrate, absorption by the test compound etc.) controls containing the afore-
mentioned incubation mixture without enzyme (30 µl of BSA solution was used 
instead) were run in parallel. 
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Chapter 6 
Structure-activity relationships of benzoxa-
zole-2-thiones as inhibitors of bacterial 
hyaluronidase 
6.1 Introduction 
 
In the previous chapter 1,3-diacylated benzimidazole-2-thiones were described 
as the most potent inhibitors of bacterial hyaluronidase hylB4755. However, such 
compounds are very unstable in solution owing to their susceptibility to hydroly-
sis and, furthermore, they possess a poor shelf life. The drawbacks of these 
compounds stimulated us to replace the benzimidazole skeleton by a benzoxa-
zole structure. 
For the design of S. agalactiae hyaluronate lyase (hylB4755) inhibitors, the bind-
ing mode of benzoxazole derivatives was derived from the X-ray structure of the 
related S. pneumoniae hyaluronidase (hylSpn) co-crystallized with an alkyl-2-
phenylindole derivative120, 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl-sul-
famate 5.1 (Fig. 6.1). 
 
 
 
 
 
By superposition of the crystal structure of hylSpn in complex with either com-
pound 5.1 or a hexasaccharide substrate novel benzoxazole-2-thiones bearing 
NH2NO2SO
OSO2NH2
(CH2)9CH3
Fig. 6.1: Structure of 1-decyl-2-(4-sulfamoyloxy-phenyl)-1H-indol-
6-yl-sulfamate 5.1 
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3-substituted N-propanoyl residues were proposed. Therefore, a series of ben-
zoxazole-2-thione derivatives and benzoxazole-2-one derivatives with different 
substituents at the N atom was synthesized. 
Moreover, introducing an additional functional 
group should increase the solubility of such com-
pounds and enable further structural variations. 
Position 5 was chosen for the introduction of a 
functional group (Fig 6.2). This appeared reason-
able considering the structural features of sub-
stance 5.1 with a sulfamate residue at position 6 of 
the indole moiety. All synthesized benzoxazole-2-
thione derivatives were tested for inhibition of hyaluronidases in a turbidimetric 
assay (see chapter 3). 
 
 
6.2 Chemistry 
 
The preparation of the N-acylated benzoxazole-2-thiones 6.5-6.16 was per-
formed by reaction of 2-mercaptobenzoxazole (6.1) with either acid chloride or  
 
N
O
X
R1
R2
X   = O, S
R1 = variable
R2 = H, CO2Me, SO3H
Fig. 6.2: Target compounds 
Scheme 6.1: Synthetic pathway to N-acylated benzoxazole-2-thiones 
N
O
SH
N
O
S
R
O
6.5:   R = CH3
6.6:   R = CH2CH3
6.7:   R = (CH2)4CH3
6.8:   R = (CH2)8CH3
6.9:   R = (CH2)14CH3
6.10: R = CH2Ph
6.11: R = (CH2)2Ph
6.12: R = (CH2)3Ph
6.13: R = CH=CHPh
6.14: R = (CH2)2Cy
6.15: R = CH2OPh
6.16: R = OCH2Ph
RCOOH RCOCl
i
i) SOCl2, DMF(cat.); ii) RCOCl 
or (RCO)2O, THF, Et3N
ii
6.2: R = (CH2)2Ph
6.3: R = (CH2)2Cy
6.4: R = (CH2)3Ph
Reagents:
Cy = cyclohexyl
6.1
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acid anhydride in anhydrous THF using triethylamine as base according to a 
slightly modified protocol of Ueda et al.190. Some acid chlorides were first pre-
pared from the corresponding carboxylic acids with thionyl chloride and one 
drop of DMF as catalyst before reacting with 2-mercaptobenzoxazole (Scheme 
6.1). 
The synthesis of the sulfonylated benzoxazole-2-thione derivative 6.19 was 
tried via N-sulfonylation of o-aminophenol (6.17), yielding 6.18, and cyclisation 
with 1,1’-thiocarbonyldiimidazole (TCDI). However, the ring closing reaction of 
6.18 with TCDI yielded 2-mercaptobenzoxazole (6.1) as main product indicating 
that the sulfonamide bond of the possibly generated product 6.19 was cleaved 
under these reaction conditions. Probably, the reaction time (24 h) for the ring 
closure was too long. However, 6.19 was accessible by N-sulfonylation of 6.1 
(Scheme 6.2) by analogy with the method applied for the N-acylation of ben-
zoxazole-2-thiones. 
 
 
The benzoxazole-2-one derivatives 6.21 and 6.22 were synthesized according 
to a modified procedure described by Ucar et al.191 by an acylation reaction us-
ing acid chloride or acid anhydride and triethylamine in dry THF (Scheme 6.3). 
 
N
H
O
O
N
O
O
R
O
6.21: R = CH3
6.22: R = (CH2)4CH3
RCOCl, (RCO)2O,
THF, Et3N
6.20
N
H
O
S
OH
NH2
OH
N
H
SO2CH3 N
O
S
O
S
O
i
ii
iii
6.18 6.19
6.1
6.17
Reagents: i) MsCl, pyridine;
ii) TCDI, THF; iii) Et3N,
MsCl, THF
Scheme 6.3: Synthesis of N-acylated benzoxazole-2-ones 
Scheme 6.2: Preparation of 6.19 by different pathways 
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For the synthesis of the N-alkylated benzoxazole-2-thione 6.24 a different syn-
thetic strategy was chosen. In compliance with the HSAB concept a direct al-
kylation at the nitrogen atom with alkyl halides should not be favored. Therefore, 
the oxazole ring was build up in the last step as shown in Scheme 6.4. In the 
first step, the N-alkylation of o-aminophenol (6.17) was achieved by using bro-
moethane and sodium hydride in DMF. Afterwards, 2-(ethylamino)phenol (6.23) 
was cyclized with TCDI in anhydrous THF. 
 
 
 
 
 
 
 
 
 
5-Substituted benzoxazole-2-thiones were prepared as illustrated in Scheme 
6.5. In a first step the carboxylic acid of 3-amino-4-hydroxybenzoic acid (6.25) 
was protected by esterification according to a slightly modified method de-
scribed by Brook et al.192. These authors had pointed out a simple procedure for 
OH
NH2
OH
N
H
N
O
S
i ii
6.23 6.246.17
Reagents: i) NaH, BrCH2CH3, DMF; ii) TCDI, THF
Scheme 6.5: Synthetic route to various 5-substituted benzoxazole-2-thione derivatives 
Scheme 6.4: Conversion of o-aminophenol into N-alkylated benzoxazole-2-
thione 6.24 
OH
NH2
OH
NH2
i ii
6.27 6.28
R MeO2C N
O
SH
MeO2C
N
O
S
MeO2C
O
N
O
SH
HO3S
6.25: R = CO2H
6.26: R = SO3H
6.30
6.29
iiiiv
Reagents: i) TMSCl (2.2 eq), MeOH;
ii) TCDI, THF; iii) Ph(CH2)2COCl,
Et3N, THF; iv) NaOH, CS2, H2O
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the esterification of carboxylic acids under mild conditions by using TMSCl both 
as acid catalyst and dehydrating agent. In case of 3-amino-4-hydroxybenzoic 
acid, the methyl ester 6.27 was smoothly formed in presence of an amino 
group. The cyclisation of 6.27 to methyl 2-sulfanylbenzo[d]oxazole-5-carboxy-
late 6.28 was achieved with TCDI in anhydrous THF. Compound 6.29 was 
synthesized by analogy with the procedure for the acylation of benzoxazole-2-
thiones 6.5-6.16 (see Scheme 6.1). Following a procedure described by Matsu-
yama et al.193, 2-sulfanylbenzo[d]oxazole-5-sulfonic acid (6.30) was obtained in 
moderate yields. 
N,N-Dimethylbenzo[d]oxazol-2-amine (6.33) was synthesized according to the 
procedure described by Khalaf et al.194 by refluxing N,N-dimethylbenzylamine 
(6.31) with 2-chlorobenzoxazole (6.32) without solvent at 130 °C for 3 h (see 
Scheme 6.6). 
 
 
 
 
 
Due to the poor stability of 3-acylated benzoxazole-2-thiones, the more stable 
2-methylbenzofurane analogs 6.35 and 6.36, which should mimic the benzoxa-
zole scaffold of 6.5 and 6.11, were synthesized in a Friedel-Crafts reaction as 
depicted in Scheme 6.7. 
For this purpose, 2-methylbenzofurane was transformed in high yields to the 
desired 3-acylated benzofuranes following a procedure described by Carvalho 
et al.195 for acetylation of methyl benzofuran-2-yl-acetate. 
 
 
 
N
N
O
Cl
N
O
N
6.336.326.31
Scheme 6.6: Preparation of compound 6.33 
Scheme 6.7: Synthesis of 3-acylated 2-methyl-benzofuranes 6.35 and 6.36 
O O
R
O
RCOCl, CH2Cl2,
SnCl4
6.34
6.35: R = CH3
6.36: R = (CH2)2Ph
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6.3 Results and discussion 
 
All synthesized compounds were tested in a turbidimetric assay (see chapter 3) 
to determine their inhibitory activities on the bacterial hyaluronidase hylB4755 at 
pH 7.4 and pH 5, the pH optimum of the bacterial hyaluronidase150. In addition, 
the inhibition of the bovine hyaluronidase at pH 5 was investigated to check the 
selectivity of these substances. 
 
6.3.1 Structure-activity relationships of benzoxazole derivatives 
Stimulated by the elucidation of the binding mode of 5.1, the introduction of 
lipophilic N-substituents at benzoxazoles was considered a promising approach 
to obtain potent hyaluronidase inhibitors. The results of the investigations on the 
bacterial enzyme hylB4755 and bovine testicular hyaluronidase are summarized 
in Table 6.1. 
Considering the bovine testicular hyaluronidase, all listed compounds in Table 
6.1 were inactive on the bovine enzyme except for benzoxazoles 6.5 and 6.6, 
which very weakly inhibited the BTH. Hence, in the following only the inhibitory 
influence on the bacterial enzyme hylB4755 is discussed. 
Generally, the compounds were more potent inhibitors of hyaluronate lyase 
hylB4755 at physiological pH (IC50 values in the µM range), however, the marked 
differences in activity at pH 5 are more suitable for structure-activity considera-
tions. One reason for the disagreement of inhibition depending on the pH could 
be the different affinity of the substrate to the enzyme depending on the pH of 
the test system150. At physiological pH, the affinity is lower than at pH optimum 
probably facilitating the displacement of HA. 
The inhibitory effects of benzoxazoles 6.5-6.9 determined on the hyaluronate 
lyase at pH 7.4 were in the lower micromolar range with IC50 values of 42 µM 
(6.5), 48 µM (6.6), 29 µM (6.7), 25 µM (6.8) and 17 µM (6.9) (see Table 6.1 and 
Fig. 6.3). 
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Table 6.1: Inhibitory activities (IC50 values) of benzoxazole derivatives determined on the hyalu-
ronidase from S. agalactiae (hylB4755) at pH 5.0 and pH 7.4 and the bovine testicular hyaluroni-
dase (BTH) at pH 5.0, respectively. 
 
 
 
 
 
Compd. R X hylB4755, IC50 [µM] or %a BTHa 
   pH = 5.0 pH = 7.4 pH = 5.0 
6.5 CH3 S 125 ± 5 42 ± 3 21 % (455) 
6.6 CH2CH3 S 128 ± 5 48 ± 2 19 % (400) 
6.7 (CH2)4CH3 S 51 % (130) 29 ± 1 inactiveb 
6.8 (CH2)8CH3 S 41 % (100) 25 ± 4 inactivec 
6.9 (CH2)14CH3 S 23 % (63) 17 ± 1 inactived 
6.10 CH2Ph S 260 ± 41 69 ± 2 inactivee 
6.11 (CH2)2Ph S 15 ± 1 24 ± 1 inactivef 
6.12 (CH2)3Ph S 47 % (100) 19 ± 1 inactivef 
6.13 CH=CHPh S 9 % (80) 36 % (200) inactivef 
6.14 (CH2)2Cy S 227 ± 122 20 ± 1 inactivee 
6.15 CH2OPh S 213 ± 30 62 ± 2 inactiveg 
6.16 OCH2Ph S inactivef 556 ± 20 inactivef 
6.21 CH3 O inactiveh 1466 ± 76 inactiveh 
6.22 (CH2)4CH3 O inactiveb inactivei inactiveb 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at the concentra-
tion of inhibitor given in parentheses; highest tested concentrations were dependent on the 
solubility of the compounds, b at concentrations ≤ 150 µM, c at concentrations ≤ 125 µM, d at 
concentrations ≤ 80 µM, e at concentrations ≤ 220 µM, f at concentrations ≤ 100 µM, g at con-
centrations ≤ 200 µM, h at concentrations ≤ 2 mM, i at concentrations ≤ 300 µM 
 
Obviously, there is a tendency towards stronger inhibition with increasing alka-
noyl chain length at the nitrogen atom of the benzoxazole moiety. This corre-
lates with the presence and topology of hydrophobic residues in the catalytic 
cleft recently described by Li et al.133. Hydrophobic interactions also play an im-
portant role for the substrate HA since it has been shown to form a 2-fold helical 
N
O
X
O
R1
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structure with an extensive hydrophobic patch of about eight CH units in aque-
ous solution5. 
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Fig. 6.3: Enzymatic activity of hylB4755 at physiological pH in presence of 6.6, 6.7 and 6.9 
 
At the pH optimum of hylB4755, benzoxazoles 6.5 and 6.6 were equipotent (IC50 
values of 125 µM (6.5) and 128 µM (6.6), respectively). For compounds 6.7-6.9 
only a very weak inhibition of hylB4755 at pH 5 was found. This might be associ-
ated with poor solubility of these compounds in the buffer used for the turbidi-
metric assay. The inhibitory activity was also very weak at physiological pH, 
regardless of further elongation of the side chain. 
Among the benzoxazoles, compound 6.11 proved to be the most potent deriva-
tive. 6.11 was about 17 times more active than the lower homolog 6.10 at opti-
mum pH of hylB4755. The calculated IC50 values on hylB4755 at pH 5 were 15 µM 
(6.11) and 260 µM (6.10). The higher homolog 6.12 exhibited an inhibition of 
hylB4755 by about 47 % at a concentration of 100 µM (see Fig. 6.4). The obvious 
difference between the inhibitory effects of 6.10, 6.11 and 6.12, can be possibly 
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explained by the aforementioned hydrophobic patch in the active site of the en-
zyme. 
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Fig. 6.4: Effects of 6.10-6.12 on hyaluronate lyase hylB4755 at pH optimum 
 
On the basis of the IC50 values we concluded that the phenyl ring of 6.11 with a 
spacer of 2 methylene groups is most favorably interacting with the hydrophobic 
patch within the crevice in the active site. This will be discussed in detail in sec-
tion 6.3.2. At physiological pH, the preference for the 3-phenylpropanoyl sub-
stituted benzoxazole 6.11 is only detectable compared to compound 6.10, but 
not for 6.12, which is an equipotent inhibitor (IC50 of 19 µM) as illustrated in Fig. 
6.5. This discrepancy could be explained by the low stability of the benzoxa-
zoles against hydrolysis (see 6.3.3.). Hydrolytic cleavage is more relevant at pH 
7.4 as a longer incubation time is required. To explore the influence of the side 
chain of 6.11, hydrocinnamoic acid was tested for inhibitory potency on hyalu-
ronidases. An inhibition of hylB4755 by 15 % at 2 mM was achieved at pH 5, 
whereas no influence of hydrocinnamoic acid (concentrations ≤ 2 mM) on en-
zyme activity of hylB4755 was detectable at pH 7.4. Thereby, it can be excluded 
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that the high inhibitory potency of 6.11 stems from its degradation products 
formed by hydrolysis (cf. 6.3.3.). 
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Fig. 6.5: Inhibition of hylB4755 by compounds 6.10-6.12 at physiological pH 
 
Replacement of the phenyl in 6.11 by a cyclohexyl ring (6.14) or the introduction 
of a C=C double bond (6.13) resulted in a strong decrease in inhibitory activity 
on hylB4755 at pH optimum compared to 6.11. The C=C double bond in 6.13 re-
duces the flexibility of the side chain which is supposed to bind in a small crev-
ice of the enzyme83. Therefore, this side chain appears to be too rigid. The large 
difference in inhibitory activity (at pH 5) between 6.11 and 6.14 could possibly 
be ascribed to cation-π interactions between inhibitor 6.11 and the enzyme. At 
physiological pH, however, 6.14 was about as active as 6.11 (IC50 values of 20 
µM and 24 µM, respectively) 
Replacing one of the methylene groups of the ethylene spacer in 6.11 by oxy-
gen (6.15, 6.16) resulted in a considerable decrease in inhibitory activity both at 
pH 5 and at pH 7.4. Among the series of benzoxazoles, the thiones were sig-
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nificantly more potent than the corresponding oxo analogs (see, e.g. 6.5 vs. 
6.21). 
To increase the solubility of the benzoxazole-2-thione derivatives and to have 
additional options for structural variations a polar group was introduced in posi-
tion 5. Moreover, this substituent could confer additional affinity by interactions 
with functional groups in the active site of the enzyme. The 5-substituted ben-
zoxazoles 6.28 and 6.30 displayed moderately stronger inhibitory activity on 
hylB4755 at pH 5 compared to 2-mercaptobenzoxazole (6.1) with IC50 values of 
1299 µM (6.28) and 781 µM (6.30). 
 
Table 6.2: Inhibitory activities of 2-mercaptobenzoxazole (6.1) and compounds 6.24-6.26 on 
BTH and on S. agalactiae hyaluronate lyase 
 
 
 
 
 
 
Compd. R1 R2 hylB4755, IC50 [µM] or %a BTHa 
   pH = 5.0 pH = 7.4 pH = 5.0 
6.1 H H 42 % (3800) 2542 ± 125 inactiveb 
6.28 H CO2CH3 1299 ± 223 27 % (2000) inactivec 
6.29 CO(CH2)2Ph CO2CH3 56 % (200) 21 ± 1 inactived 
6.30 H SO3H 781 ± 100 46 % (2000) inactivec 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at concentration of 
inhibitor given in parentheses; b at concentrations ≤ 4.9 mM, c at concentrations ≤ 2 mM, d at 
concentrations ≤ 200 µM. 
 
According to the suggested binding mode of benzoxazoles (see 6.3.2.) addi-
tional hydrogen bonds between the polar substituent in position 5 of the ben-
zoxazole and the amino acids Arg466/Ser463 of hylSpn appear possible. This 
assumption is also in accordance with the structure-activity relationships of 2-
phenylindoles described by Salmen120: polar substituents in position 6 of the in-
dole, for instance a hydroxy group, were found found to enhance the inhibition 
of hylB4755. Surprisingly, the activity-enhancing effect was not confirmed for the 
N
O
R2
R1
S
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benzoxazole-5-sulfonic acid 6.30 when the compound was tested at the 
physiological pH. In this case, the pH-dependent ratio of charged and un-
charged state of the test compound and the amino acids in the active site may 
play a role. By contrast, benzoxazole 6.29 revealed a strong inhibition on 
hylB4755 at physiological pH (IC50 = 21 µM) and an inhibition by about 56 % at a 
concentration of 200 µM at pH 5. Compared to the compound 6.11 (IC50 values: 
15 µM at pH 5, 24 µM at pH 7.4), the striking pH-dependent difference in in-
hibitory effect found for the methoxycarbonyl-substitued analog 6.29 and the 
sulfonic acid 6.30 suggests that ionic interactions as well as H-bonds of the 
functional group with amino acids in the active site could play a role. Unfortu-
nately, the benzoxazole bearing a sulfonic acid group in position 5 and the 3-
phenylpropanoyl side chain was not accessible by acylation of 6.30 to flesh out 
the hypothesis. All compounds listed in Table 6.2 are selective inhibitors of the 
bacterial enzyme since they were all inactive on the bovine testicular hyaluroni-
dase. 
By reason of the labile amide bond of N-acylated benzoxazole-2-thiones (see 
6.3.3.), compound 6.19 and 6.24 were synthesized with the aim to stabilize the 
bond between the nitrogen atom and the substituent without loosing inhibitory 
effect. Unfortunately, on the bacterial enzyme, both at pH 5 and at pH 7.4, a 
distinct decrease in inhibitory potency was found compared to the N-acylated 
substance 6.5 (see Table 6.3). 
Table 6.3: Inhibitory activities of benzoxazole-2-thiones on BTH at pH 5 and hylB4755 at 
optimum and physiological pH 
 
 
 
 
Compound R hylB4755, IC50 [µM] or %a BTHa 
  pH = 5.0 pH = 7.4 pH = 5.0 
6.5 COCH3 125 ± 5 42 ± 3 21 % (455) 
6.19 SO2CH3 inactiveb inactiveb inactiveb 
6.24 CH2CH3 46 % (400) 17 % (1000) inactivec 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at concentration of 
inhibitor given in parentheses; highest tested concentrations were dependent on the solubility of 
the compounds, b at concentrations ≤ 400 µM, c at concentrations ≤ 1 mM. 
 
N
O
R
S
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The decrease in activity may be ascribed to the missing interaction between 
Tyr488, a key residue in the catalytic mechanism of S. agalactiae hyaluronate 
lyase69,66, and the carbonyl oxygen of the acylated benzoxazoles83. 
 
At last, the benzoxazole scaffold was replaced by several analogous heterocyc-
lic systems. The results of the investigation for hyaluronidase inhibition are 
summarized in Table 6.4. 
Table 6.4: Inhibitory activities of various substituted benzoxazoles and related heterocycles on 
the bovine testicular hyaluronidase and S. agalactiae hyaluronate lyase 
 
Compd. Structure hylB4755, IC50 [µM] or %a BTHa 
  pH = 5.0 pH = 7.4 pH = 5.0 
6.1 
N
H
O
S
 
42 % (3800) 2542 ± 125 inactive (4900) 
6.33 
N
O
N
 
20 % (5700) inactive (5700) inactive (5700) 
6.35 
O
O  
43 % (2000) 20 % (2000) inactive (2000) 
6.36 
O
O
Ph
 
inactive (150) inactive (200) inactive (150) 
6.37 
N NH
O
S
 
10 % (2200) inactive (2200) inactive (2200) 
6.38 
N
H
S
S
 
45 % (3700) 1623 ± 56 10 % (3700) 
6.39 N
S
N
NH2
xHCl  
12 % (2000) inactive (2000) inactive (2000) 
a inhibition of enzyme was expressed as IC50 ± SEM in µM or as % inhibition at concentration of 
inhibitor given in parentheses; highest tested concentrations were dependent on the solubility of 
the compounds. 
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With exception of 2-mercaptobenzothiazole 6.38 the tested compounds (6.33-
6.39) were either inactive or displayed only negligible inhibitory activity on BTH 
as well as on hyaluronate lyase hylB4755. Benzothiazole 6.38 may be considered 
a possible alternative to the benzoxazole as a scaffold for the preparation of 
hyaluronidase inhibitors. 
Within the series of the aforementioned benzoxazoles, all compounds showed a 
marked selectivity for the bacterial versus the bovine enzyme. Due to poor 
solubility the compounds could not be investigated at higher concentrations 
than denoted. 
6.3.2 Putative binding mode of the benzoxazoles at hylB4755 
For the design of bacterial hyaluronidase inhibitors, the binding mode of ben-
zoxazole derivatives was derived from X-ray structure of hyaluronate lyase from 
S. pneumoniae (hylSpn) co-crystallized with compound 5.1. Previously, Botzki83 
has shown that structure-activity relationships (SAR) of analogous 2-phenyl-
indoles (see Table 6.5) correlate with the binding mode of compound 5.1 at 
hylSpn83 (see Fig. 6.6). The increase in hylB4755 inhibition with increasing chain 
length of the alkyl substituents at the nitrogen atom of the indole moiety clearly 
indicates that the binding mode of 6.40-6.42 is similar to that found for 5.1. 
Table 6.5: IC50values of 2-phenylindole derivatives (data from Salmen120) 
 
 
 
 
 
Compd. Substitution IC50 [µM] 
       
 R1 R2 R3 R4 pH 5.0 pH 7.4 
5.1 H 6-OSO2NH2 C10H21 OSO2NH2 11 16 
6.40 CH3 5-OH H OH 740 280 
6.41 CH3 5-OH C3H7 OH 220 160 
6.42 CH3 5-OH C7H15 OH 26 12 
N
R1
R4
R3
R2
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Probably, the aliphatic chains of the 3-acylbenzoxazoles occupy the same 
crevice like the decyl substituent of 5.1. The SAR of the benzoxazoles are 
similar to those of the 2-phenylindoles since hylB4755 inhibition increases with 
chain length of R (see Table 6.1). 
It may be concluded that benzoxazole-2-thione derivatives have a binding mode 
similar to that of compound 5.1, i.e. the benzoxazole moiety overlays with the 
indole moiety, and the alkoxy substituents point into the same direction as the 
aliphatic chain of 5.1. Additionally, the amide oxygen might interact with Tyr408. 
These considerations were complemented by comparing the binding mode of 
5.1 and a hexasaccharide unit of the substrate hyaluronic acid with crystallo-
graphic hylSpn data83 allowing the rational prediction of more potent benzoxa-
zoles. As shown in Fig. 6.6, the depicted trisaccharide overlaps with compound 
5.1. 
 
Fig. 6.6: Comparison of binding modes of hylSpn inhibitor 5.1 (carbon atoms orange) 
and a HA hexasaccharide (carbon atoms purple, for clarity only a trisaccharide moiety 
is shown). 
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With respect to substituents at the nitrogen atom of the benzoxazole moiety, 3-
substituted propionic acid derivatives are promising, since a N-acetylglucosa-
mine residue of the HA substrate is in the same location as the methylene 
groups 4 and 5 of the decyl substituent of 5.1 (Fig. 6.6). Moreover, there is a 
hydrophobic patch in this crevice of hylB4755, which is assumed to interact with 
the lipophilic sugar ring of N-acetylglucosamine. Therefore, the substituent at 
the nitrogen atom of the benzoxazole moiety should be a propanoyl residue with 
a lipophilic subsituent at the end. This hypothesis is supported by the 17-fold 
(pH 5) and 3-fold (pH 7.4) higher inhibitory activity of compound 6.11 compared 
to compound 6.10 and the 8-fold (pH 5) and 2-fold (pH 7.4) higher inhibition of 
6.11 compared to compound 6.6. 
 
6.3.3. Stability measurement 
While performing the turbidimetric assay for compound 6.11 fluctuations in the 
determined IC50 values occurred. It turned out that the inhibitor, was not stable 
in the DMSO solutions used in the assay. As we assumed that the amide bond 
is labile against hydrolysis, stability investigations were carried out with the 
strong hylB4755 inhibitor 6.11, the sulfonamide 6.19, and compound 7.16, having 
an indole scaffold instead of the benzoxazole moiety (Fig. 6.7). 
At first, UV spectra of all three compounds and the supposable decomposition 
products, 2-mercaptobenzoxazole (6.1) and 2-methyl-5-nitroindole (7.1), were 
recorded (see Appendix). The stability investigations were performed by HPLC 
analysis with detection at 305 nm corresponding to the absorption maximum of 
6.11. In the chromatograms of 6.11 and 6.19 only one additional peak was de-
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Fig. 6.7: Structures, investigated on their stability against hydrolysis 
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tected at 305 nm. This peak was assigned to the decomposition product 2-mer-
captobenzoxazole. 
For kinetic studies solutions (1 mM) of 6.11, 6.19 and 7.16 were prepared in a 
80:20 (v/v) mixture of DMSO and water. Subsequently, samples were analyzed 
by HPLC at different time intervals. The hydrolysis rate was determined by the 
temporal decrease in absorbance at the characteristic wavelength of 305 nm. 
The extinction area of 2-MBO was normalized on the area of the particular ben-
zoxazole peak by multiplying the area of 2-MBO peak with a factor resulting 
from the division of the molar extinction coefficient of 2-MBO and the particular 
benzoxazole. Then, the extinction areas were summed up and the percentage 
portion of 6.11, 6.19 can be given. As depicted in Fig. 6.8, the decomposition of 
6.11 was plotted against the time. 
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Fig. 6.8: Hydrolysis of compound 6.11 plotted against time 
 
The hydrolysis obeyed a first order kinetic within very close borders. According 
to the kinetic measurement of 6.11, the calculated half-life is 235 minutes with a 
rate constant (first order) of 2.9 ·10-3 min-1. The rate constant was determined 
corresponding to the following equation from the graph illustrated in Fig. 6.9, 
where k is equivalent to the slope of the linear plot. 
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ln c(t) = -k·t + ln c(0) 
c: portion of 6.11 
k: rate constant 
Given that 6.11 is following a first order kinetic, the half-life is independent of the 
starting concentration of 6.11. It was calculated according to the equation: 
t1/2 = ln2 / k 
t1/2 : half-life 
k : rate constant 
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Fig. 6.9: First order kinetics of 6.11 
 
As expected, the hydrolysis of the sulfonamide analog 6.19 was much slower 
than for 6.11. After 475 minutes just 13 % of 6.19 was decomposed. Since the 
decomposition was only tracked as far as 13 %, no decomposition constant 
could be calculated. 
In contrast to the benzoxazoles 6.11 and 6.19 the indole 7.16 showed no sig-
nificant decrease in absorbance over a period of 400 min. This is in good agree-
ment with results reported by Staab196 for N-acetylindole, which was stable in 
aqueous solution at room temperature for a couple of days. 
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6.4 Conclusions 
 
The presented benzoxazole-2-thione derivatives are among the most potent 
inhibitors of bacterial hyaluronidase known so far. All examined compounds are 
highly selective for the hyaluronate lyase of S. agalactiae strain 4755 (hylB4755) 
versus the bovine enzyme. IC50 values in the µM range were determined for 3-
acylated benzoxazole-2-thiones (e.g. 6.5-6.12) at physiological pH, whereas at 
optimum pH 5 the calculated IC50 values of 3-acylated benzoxazole-2-thiones 
reveal slightly decreased inhibitory activity. Within this series of compounds 3-
propanoylbenzoxazole-2-thione (6.11) was the most potent inhibitor of hylB4755 
with an IC50 value of 15 µM at optimum pH. Hence, a carbonyl group in 3-posi-
tion linked to a phenyl group via an ethylene spacer appears to be optimal for 
inhibition of hylB4755. 
With respect to the limited stability of the 3-acylbenzoxazoles in aqueous solu-
tions the obtained inhibition data are more reliable at pH 5 owing to the much 
shorter incubation time necessary at optimum pH. Hence, it has to be taken into 
account that the small amounts of water contained in the solvent DMSO may be 
sufficient to hydrolyze the N-acylated benzoxazoles during storage of stock so-
lution. 
In order to enhance the solubility, substituents were successfully introduced in 
position 5 of the benzoxazole scaffold. The results are promising with respect to 
the design of new structurally related inhibitors. Due to the low stability of 6.11 
against hydrolysis of the amide bond various modifications were attempted. 
However, replacing the amide by a sulfonamide bond or a N-alkyl bond resulted 
in a marked decrease in inhibitory activity on hylB4755, and the exchange of the 
benzoxazole scaffold by other heterocyclic systems such as benzofuranes was 
not tolerated. 
In summary, the structure-activity relationships of the benzoxazole-2-thione de-
rivatives strengthen the structure-based design strategy, which had started from 
the 3D structure of hylSpn. 
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6.5 Experimental section 
 
6.5.1 General conditions 
See section 4.5.1 for general methods. 
HPLC measurement was performed by injecting 30 µl of the corresponding 
sample in mobile phase into a LUNA C18 column (150 x 4.6 mm, 3 µ) at room 
temperature with a flow rate of 0.75 ml/min. The UV absorbance was deter-
mined at 305 nm and the following gradient was used: 
0 min: 30:70 (v/v) mixture of acetonitrile and water 
4 min: 30:70 (v/v) mixture of acetonitrile and water 14 min: 80:20 (v/v) mixture of 
acetonitrile and water 
20 min: 80:20 (v/v) mixture of acetonitrile and water 
22 min: 30:70 (v/v) mixture of acetonitrile and water 
 
6.5.2 Chemistry 
Preparation of acid chlorides 6.2-6.4 
General procedure. Carboxylic acid (1 eq) was treated with thionyl chloride 
(1.5 eq) and one drop of DMF under a nitrogen atmosphere. After stirring for 1 h 
at ambient temperature (development of gas was not observable any more!), 
the mixture was evaporated with a water-jet pump at room temperature to sepa-
rate surplus thionyl chloride. The obtained crude product was used without puri-
fication for further reaction. 
 
3-Phenylpropanoyl chloride (6.2) 
Reaction of 3-phenylpropanoic acid (0.54 g, 3.60 mmol) and thionyl chloride 
(0.39 ml, 5.38 mmol). 
Yield: 0.66 g of oily compound 
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3-Cyclohexylpropanoyl chloride (6.3) 
Reaction of 3-cyclohexylpropanoic acid (0.62 ml, 3.60 mmol) and thionyl chlo-
ride (0.40 ml, 5.51 mmol). 
Yield: 0.80 g of colorless oil 
 
4-Phenylbutanoyl chloride (6.4) 
Reaction of 4-phenylbutanoic acid (0.59 g, 3.59 mmol) and thionyl chloride 
(0.40 ml, 5.51 mmol). 
Yield: 0.87 g of colorless oil 
 
Synthesis of N-acylated benzoxazole-2-thiones 6.5-6.16 and 6.19 
General procedures 
Method A. 2-Mercaptobenzoxazole (6.1) (1 eq) was dissolved in absolute THF 
(5 ml) under an inert atmosphere. Triethylamine (1.1 eq) was added and the 
solution was cooled to 0 °C. The particular acid chloride (1 eq), dissolved in 5 
ml absolute THF, was added dropwise. After stirring for 30 minutes at room 
temperature, the reaction mixture was poured into ice water (35 ml). The pre-
cipitated product was collected, washed with water, dried in vacuo and recrys-
tallized. 
Method B. 2-Mercaptobenzoxazole (6.1) (1 eq) was dissolved in absolute THF 
(5 ml) and mixed with triethylamine (1.1 eq) under a nitrogen atmosphere. Alka-
noic anhydride (1 eq) was added dropwise and the mixture was heated under 
reflux (7 h). After diluting with water (30 ml), the mixture was extracted three 
times with ethyl acetate (10 ml). The combined organic phases were washed 
with a saturated solution of sodium carbonate (10 ml), dried over magnesium 
sulfate and the solvent was removed under reduced pressure. The product was 
purified by column chromatography on a silica gel. 
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1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)ethanone (6.5) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
acetyl chloride (0.24 ml, 3.36 mmol); recrystallization from cyclohexane. 
Yield: 0.46 g (2.38 mmol, 72 %, beige solid) 
Mp: 113-114 °C (Lit. 120-121 °C190) 
1H-NMR (CDCl3): δ [ppm] = 3.06 (s, 3H, COCH3), 7.28-7.38 (m, 3H, Ar-H), 8.07-
8.12 (m, 1H, Ar-H)  
MS (PI-EIMS, 70 eV): m/z (%) = 193 ([M•+], 17), 151 ([M - CH2CO] +, 100) 
Analysis: C9H7NO2S (193.22) 
 calculated C: 55.94 H: 3.65 N: 7.25 S: 16.60 
 found C: 55.89 H: 3.73 N: 7.27  S: 16.64 
 
1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one (6.6) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
propanoyl chloride (0.30 ml, 3.44 mmol); recrystallization from ethanol. 
Yield: 0.30 g (1.45 mmol, 44 %, white needles) 
Mp: 81-82 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.19 (t, 3H, 3J = 7.1 Hz, CH3), 3.44 (q, 2H, 3J = 
7.1 Hz, CH2), 7.37-7.47 (m, 2H, Ar-H), 7.56-7.61 (m, 1H, Ar-H), 8.00-8.05 (m, 
1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 207 ([M•+], 22), 179 ([M - C2H4]+, 14), 151 ([M - 
CH3CHCO] +, 100)  
Analysis: C10H9NO2S (207.25) 
 calculated C: 57.95 H: 4.38 N: 6.76 
 found C: 57.97 H: 4.42 N: 6.77 
 
1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)hexan-1-one (6.7) 
Method B: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
hexanoic anhydride (0.76 ml, 3.30 mmol); purification by chromatography on a 
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silica gel column, elution with chloroform; analytically pure product was obtained 
by recrystallization from methanol. 
Yield: 0.30 g (1.20 mmol, 36 %, white solid) 
Mp: 46-47.5 °C 
1H-NMR (CDCl3): δ [ppm] = 0.94 (t, 3H, 3J = 7.1 Hz, (CH2)4CH3), 1.32-1.48 (m, 
4H, (CH2)2CH3), 1.77-1.88 (m, 2H, COCH2CH2-), 3.51 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 7.27-7.35 (m, 3H, Ar-H), 8.06-8.12 (m, 1H, Ar-H) 
13C-NMR (CDCl3): δ [ppm] = 14.0 (+, CH3), 22.5 (-, CH2), 24.0 (-, CH2), 31.1 (-, 
CH2), 39.2 (-, CH2), 109.7 (+, Ar-C), 116.5 (+, Ar-C), 125.5 (+, Ar-C), 126.1 (+, 
Ar-C), 130.0 (Cquart, Ar-C), 146.6 (Cquart, Ar-C), 174.3 (Cquart, CO), 178.8 (Cquart, 
CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 249 ([M•+], 8), 221 ([M - CO] +, 10), 151 ([M - 
C4H9CHCO] +, 100) 
C13H15NO2S (249.33) 
 
1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)decan-1-one (6.8) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
decanoyl chloride (0.69 ml, 3.35 mmol); stirring for 3 h; recrystallization from 
methanol. 
Yield: 0.51 g (1.67 mmol, 51 %, white solid) 
Mp: 64.5-65 °C 
1H-NMR (CDCl3): δ [ppm] = 0.88 (t, 3H, 3J = 6.9 Hz, (CH2)8CH3), 1.25-1.42 (m, 
12H, (CH2)6CH3), 1.76-1.87 (m, 2H, COCH2CH2-), 3.51 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 7.29-7.36 (m, 3H, Ar-H), 8.05-8.12 (m, 1H, Ar-H) 
13C-NMR (CDCl3): δ [ppm] = 14.1 (+, CH3), 22.7 (-, CH2), 24.3 (-, CH2), 29.0 (-, 
CH2), 29.3 (-, CH2), 29.4 (-, 2CH2), 31.9 (-, CH2), 39.2 (-, CH2), 109.7 (+, Ar-C), 
116.5 (+, Ar-C), 125.5 (+, Ar-C), 126.1 (+, Ar-C), 130.0 (Cquart, Ar-C), 146.6 
(Cquart, Ar-C), 174.3 (Cquart, CO), 178.8 (Cquart, CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 305 ([M•+], 2), 277 ([M - CO] +, 2), 151 ([M - 
C8H17CHCO] +, 100) 
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Analysis: C17H23NO2S (305.44) 
 calculated C: 66.85 H: 7.59 N: 4.59 
 found C: 66.81 H: 7.81 N: 4.39  
 
1-(2-Thioxobenzo[d]oxazol-3(2H)-yl)hexadecan-1-one (6.9) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.51 g, 3.37 mmol) and 
hexadecanoyl chloride (1.00 ml, 3.31 mmol); stirring for 3 h; recrystallization 
from methanol. 
Yield: 0.65 g (1.67 mmol, 50 %, white solid) 
Mp: 81-81.5 °C 
1H-NMR (CDCl3): δ [ppm] = 0.88 (t, 3H, 3J = 6.7 Hz, (CH2)14CH3), 1.23-1.50 (m, 
24H, CH2(CH2)12CH3), 1.76-1.87 (m, 2H, COCH2CH2-), 3.51 (t, 2H, 3J = 7.3 Hz, 
COCH2-), 7.28-7.37 (m, 3H, Ar-H), 8.05-8.11 (m, 1H, Ar-H) 
13C-NMR (CDCl3): δ [ppm] = 14.1 (+, CH3), 22.7 (-, CH2), 24.3 (-, CH2), 28.9 (-, 
CH2), 29.4 (-, 2CH2), 29.5 (-, CH2), 29.6 (-, CH2), 29.7 (-, 5CH2), 31.9 (-, CH2), 
39.2 (-, CH2), 109.6 (+, Ar-C), 116.5 (+, Ar-C), 125.5 (+, Ar-C), 126.0 (+, Ar-C), 
130.0 (Cquart, Ar-C), 146.5 (Cquart, Ar-C), 174.3 (Cquart, CO), 178.8 (Cquart, CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 389 ([M•+], 25), 361 ([M - CO] +, 83), 151 ([M - 
C14H29CHCO] +, 100)  
Analysis: C23H35NO2S (389.60) 
 calculated C: 70.91 H: 9.06 N: 3.60 
 found C: 70.69 H: 9.54 N: 3.33 
 
2-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)ethanone (6.10) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) with 
phenylacetyl chloride (0.44 ml, 3.33 mmol) in 10 ml dry acetone; recrystalliza-
tion from ethanol. 
Yield: 0.28 g (1.04 mmol, 31 %, white solid) 
Mp: 132.5-134 °C 
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1H-NMR (CDCl3): δ [ppm] = 4.91 (s, 2H, CH2), 7.26-7.42 (m, 8H, Ar-H), 8.02-
8.09 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 269 ([M•+], 26), 151 ([M - C6H5CHCO] +, 28), 
118 ([C6H5 - CHCO]+, 85), 91 ([C6H5CH2]+, 100) 
Analysis: C15H11NO2S (269.32) 
 calculated C: 66.89 H: 4.12 N: 5.20 
 found C: 66.84 H: 4.12 N: 5.20 
 
3-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one (6.11) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
3-phenylpropionyl chloride (6.2) (0.66 g , 3.91 mmol); recrystallization from 
ethanol. 
Yield: 0.33 g (1.16 mmol, 35 %, yellow solid) 
Mp: 73-75 °C 
1H-NMR (CDCl3): δ [ppm] = 3.16 (t, 2H, 3J = 7.5 Hz, COCH2CH2Ph), 3.87 (t, 2H, 
3J = 7.5 Hz, COCH2CH2Ph), 7.19-7.25 (m, 1H, Ar-H), 7.27-7.35 (m, 7H, Ar-H), 
8.05-8.10 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 283 ([M•+], 15), 250 ([M - SH]+, 64), 151 ([M - 
C6H5CH2CHCO] +, 100), 105 ([C6H5CH2CH2]+, 69), 91 ([C6H5CH2]+, 78) 
Analysis: C16H13NO2S (283.35) 
 calculated C: 67.82 H: 4.62 N: 4.94 
 found C: 67.67 H: 4.24 N: 4.99  
 
4-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)butan-1-one (6.12) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
4-phenylbutanoyl chloride (6.4) (0.87 g, 4.76 mmol); reaction mixture was ex-
tracted two times with chloroform (15 ml); the combined organic phases were 
dried over magnesium sulfate and the solvent was removed under reduced 
pressure; purification by column chromatography on silica gel, elution with chlo-
roform. 
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Yield: 0.13 g (0.44 mmol, 13 %, brown solid) 
Mp: 145-146.5 °C 
1H-NMR (CDCl3): δ [ppm] = 2.10-2.21 (m, 2H, COCH2CH2CH2Ph), 2.78 (t, 2H, 
3J = 7.8 Hz, COCH2-), 3.54 (t, 2H, 3J = 7.3 Hz, CO(CH2)2CH2Ph), 7.16-7.37 (m, 
8H, Ar-H), 8.04-8.12 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 264 ([M - SH]+, 55), 151 ([M - 
C6H5(CH2)2CHCO] +, 58), 147 ([C6H5CH2CH2CH2CO]+, 65), 91 ([C6H5CH2]+, 
100) 
Analysis: C17H15NO2S (297.38) 
 calculated C: 68.66 H: 5.08 N: 4.71 
 found C: 68.41 H: 5.08 N: 4.70 
 
(E)-3-Phenyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)prop-2-en-1-one (6.13) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
cinnamoyl chloride (0.55 g, 3.30 mmol); recrystallization from ethanol. 
Yield: 0.53 g (1.88 mmol, 57 %, yellow powder) 
Mp: 150.5-151.5 °C (Lit. 148-149 °C197) 
1H-NMR (CDCl3): δ [ppm] = 7.32-7.36 (m, 3H, Ar-H), 7.43-7.48 (m, 3H, Ar-H), 
7.65-7.70 (m, 2H, Ar-H), 7.97-8.02 (m, 1H, Ar-H), 7.98 (d, 1H, 3J = 15.5 Hz, 
=CH), 8.26 (d, 1H, 3J = 15.5 Hz, =CH) 
MS (PI-EIMS, 70 eV): m/z (%) = 281 ([M•+], 16), 253 ([M - CO] +, 3), 151 ([M - 
C6H5CHCHCO] +, 9), 131 ([C6H5CHCHCO] +, 100), 103 ([C6H5 - CH=CH] +, 34), 
77 ([C6H5]+, 18) 
Analysis: C16H11NO2S (281.33) 
 calculated C: 68.31 H: 3.94 N: 4.98 
 found C: 68.32 H: 4.02 N: 4.99 
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3-Cyclohexyl-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)propan-1-one (6.14) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.5 g, 3.31 mmol) and 3-
cyclohexylpropanoyl chloride (6.3) (0.80 g, 4.58 mmol); recrystallization from 
ethanol. 
Yield: 0.54 g (1.87 mmol, 56 %, white solid) 
Mp: 76-77.5 °C 
1H-NMR (CDCl3): δ [ppm] = 0.89-1.44 (m, 5H, 2CH2+CH), 1.62-1.83 (m, 8H, 
4CH2), 3.53 (t, 2H, 3J = 7.7 Hz, COCH2-), 7.27-7.36 (m, 3H, Ar-H), 8.05-8.10 (m, 
1H, Ar-H) 
13C-NMR (CDCl3): δ [ppm] = 26.2 (-, 2CH2), 26.5 (-, CH2), 31.6 (-, CH2), 33.1 (-, 
2CH2), 36.9 (-, CH2), 37.1 (+, CH), 109.6 (+, Ar-C), 116.5 (+, Ar-C), 125.5 (+, Ar-
C), 126.0 (+, Ar-C), 130.0 (Cquart, Ar-C), 146.5 (Cquart, Ar-C), 174.6 (Cquart, CO), 
178.8 (Cquart, CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 289 ([M•+], 5), 151 ([M - C6H11CH2CHCO] +, 
100), 121 (benzoxazole, 56) 
Analysis: C16H19NO2S (289.39) 
 calculated C: 66.40 H: 6.62 N: 4.84 
 found C: 65.86 H: 6.49 N: 5.04  
 
2-Phenoxy-1-(2-thioxobenzo[d]oxazol-3(2H)-yl)ethanone (6.15) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
phenoxyacetyl chloride (0.46 ml, 3.33 mmol); recrystallization from ethanol. 
Yield: 0.32 g (1.12 mmol, 34 %, light-brown solid) 
Mp: 138-139 °C 
1H-NMR (DMSO-d6): δ [ppm] = 5.73 (s, 2H, CH2), 6.96-7.08 (m, 3H, Ar-H), 7.25-
7.50 (m, 4H, Ar-H), 7.61-7.66 (m, 1H, Ar-H), 8.03-8.08 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 285 ([M•+], 36), 192 ([M - OC6H5]+, 46), 164 ([M 
- OC6H5CO]+, 100), 151 ([M - C6H5OCHCO] +, 34), 77 ([C6H5]+, 71) 
Analysis: C15H11NO3S (285.32) 
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 calculated C: 63.14 H: 3.89 N: 4.91 
 found C: 63.07 H: 3.99 N: 4.92  
 
Benzyl 2-thioxobenzo[d]oxazol-3(2H)-carboxylate (6.16) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.50 g, 3.31 mmol) and 
benzyl chloroformate (0.48 ml, 3.36 mmol); different workup: reaction mixture 
was concentrated under reduced pressure and ethyl acetate (15 ml) and water 
(10 ml) were added; the organic phase was dried over magnesium sulfate and 
the solvent was removed under reduced pressure; crystallization from petro-
leum ether (60-80 °C) and subsequent recrystallization from methanol. 
Yield: 0.30 g (1.05 mmol, 32 %, white needles) 
Mp: 86-87 °C (Lit. 89-92 °C198) 
1H-NMR (CDCl3): δ [ppm] = 5.55 (s, 2H, CH2), 7.20-7.47 (m, 6H, Ar-H), 7.50-
7.58 (m, 2H, Ar-H), 7.69-7.75 (m 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 285 ([M•+], 5), 91 ([C6H5CH2]+, 100) 
Analysis: C15H11NO3S (285.32) 
 calculated C: 63.14 H: 3.89 N: 4.91 
 found C: 63.25 H: 3.74 N: 4.83 
 
N-Methanesulfonyl-2-aminophenol (6.18) 
o-Aminophenol (6.17) (1.1 g, 10.08 mmol) was dissolved in pyridine (10 ml) and 
cooled with an ice-bath. Methanesulfonyl chloride (0.85 ml, 10.94 mmol) was 
added and the solution was stirred over night at ambient temperature. The re-
action mixture was poured into an ice-cold solution of hydrochloric acid (10 %, 
70 ml) and extracted with ethyl acetate (3x30 ml). The combined organic 
phases were dried over magnesium sulfate and the solvent was removed under 
reduced pressure. Recrystallization from benzene yielded the desired product. 
Yield: 1.19 g (6.36 mmol, 63 %, pale pink solid) 
Mp: 105-106 °C (Lit. 110-111 °C199) 
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1H-NMR (DMSO-d6): δ [ppm] = 2.93 (s, 3H, SO2CH3), 6.78 (ddd, 1H, 3J = 7.9 
Hz, 3J = 7.3 Hz, 4J = 1.5 Hz, H-5), 6.88 (dd, 1H, 3J = 8.1 Hz, 4J = 1.5 Hz, H-3), 
7.04 (ddd, 1H, 3J = 8.1 Hz, 3J = 7.3 Hz, 4J = 1.7 Hz, H-4), 7.18 (dd, 1H, 3J = 7.9 
Hz, 4J = 1.7 Hz, H-6), 8.69 (br, 1H, NH), 9.84 (br, 1H, OH) 
MS (PI-EIMS, 70 eV): m/z (%) = 187 ([M•+], 31), 108 ([M - SO2CH3] +, 100), 80 
([M - SO2CH3 - CO] +, 46) 
C7H9NO3S (187.20) 
 
3-Methanesulfonylbenzoxazole-2-thione (6.19) 
Method A: Reaction of 2-mercaptobenzoxazole (6.1) (0.51 g, 3.37 mmol) and 
methanesulfonyl chloride (0.27 ml, 3.49 mmol); reaction mixture was extracted 
three times with ethyl acetate (15 ml); the combined organic phases were dried 
over magnesium sulfate and the solvent was removed under reduced pressure; 
purification by column chromatography on silica gel, elution with chloroform. 
Yield: 0.14 g (0.61 mmol, 18 %, light-yellow solid) 
Mp: 131-132 °C (Lit. 136 °C200) 
1H-NMR (CDCl3): δ [ppm] = 3.74 (s, 3H, CH3), 7.28-7.37 (m, 3H, Ar-H), 7.80-
7.86 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 229 ([M•+], 81), 150 ([M - SO2CH3] +, 100), 122 
([M - SO2CH3 - CO] +, 63) 
Analysis: C8H7NO3S2 (229.28) 
 calculated C: 41.91 H: 3.08 N: 6.11 
 found C: 42.07 H: 3.18 N: 6.09  
 
3-Acetylbenzo[d]oxazol-2(3H)-one (6.21) 
Benzoxazol-2-one (6.20) (0.67 g, 4.96 mmol), dissolved in dry THF (10 ml), and 
triethylamine (2.0 ml ,14.43 mmol) were mixed under a nitrogen atmosphere. 
After cooling in an ice bath, acetyl chloride (0.43 ml, 6.03 mmol) was added 
dropwise. The reaction mixture was heated under reflux for 2 h and then poured 
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into ice-cold water (100 ml). After stirring for further 1 h, the precipitate was 
collected, washed with water and recrystallized from ethanol. 
Yield: 0.28 g (1.58 mmol, 32 %, white solid) 
Mp: 90.5-91.5 °C (Lit. 95-96 °C191) 
1H-NMR (DMSO-d6): δ [ppm] = 2.61 (s, 3H, CH3), 7.25-7.35 (m, 2H, Ar-H), 7.39-
7.46 (m, 1H, Ar-H), 7.91-7.99 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 177 ([M•+], 26), 135 ([M - CH2CO]+, 100), 43 
([CH3CO]+, 84) 
Analysis: C9H7NO3 (177.16) 
 calculated C: 61.02 H: 3.98 N: 7.91 
 found C: 60.79 H: 4.34 N: 7.79 
 
3-Hexanoylbenzo[d]oxazol-2(3H)-one (6.22) 
Benzoxazol-2-one (6.20) (0.50 g, 3.70 mmol) was dissolved in dry THF (10 ml) 
under an inert atmosphere and treated with triethylamine (0.63 ml, 4.54 mmol). 
After addition of hexanoic anhydride (1.03 ml, 4.47 mmol), the mixture was 
heated under reflux for 4 h. Then water (15 ml) was added and the mixture was 
extracted three times with ethyl acetate (15 ml). The combined organic layers 
were washed with a saturated solution of sodium carbonate (15 ml), dried over 
magnesium sulfate and concentrated in vacuo. The crude product was purified 
by column chromatography on silica gel eluting with chloroform. 
Yield: 0.60 g (2.57 mmol, 70 %, pale light brown solid) 
Mp: 72.5-73.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.86-0.92 (m, 3H, CH3), 1.29-1.39 (m, 4H, 
(CH2)2CH3), 1.60-1.71 (m, 2H, COCH2CH2-), 3.02 (t, 2H, 3J =7.4 Hz, COCH2-), 
7.24-7.34 (m, 2H, Ar-H), 7.36-7.46 (m, 1H, Ar-H), 7.93-8.02 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 233 ([M•+], 29), 135 ([M - C4H9CHCO] +, 100), 
99 ([C4H9CHCO] +, 60), 71 ([C4H9 - CH2]+, 44) 
Analysis: C13H15NO3 (233.26) 
 calculated C: 66.94 H: 6.48 N: 6.00 
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 found C: 66.80 H: 6.73 N: 5.85  
 
2-(Ethylamino)phenol (6.23) 
To a solution of o-aminophenol (6.17) (0.50 g, 4.58 mmol) and bromoethane 
(0.35 ml, 4.69 mmol), dissolved in DMF (15 ml), sodium hydride (0.12 g, 
5.03 mmol) was added in small portions at 0 °C. After stirring for 3 h, the reac-
tion was quenched with methanol (10 ml). The solvent was removed under re-
duced pressure, and water (20 ml) and ethyl acetate (20 ml) were added. Sub-
sequently, the organic phase was separated and the aqueous phase was ex-
tracted with ethyl acetate (3x20 ml). The combined organic layers were dried 
over magnesium sulfate and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel eluting with a 3:1 (v/v) mixture of petro-
leum ether (60-80 °C) and ethyl acetate. 
Yield: 0.17 g (1.24 mmol, 27 %, brown solid) 
Mp: 105.5 °C (decomposition) (Lit. 110-111 °C201) 
1H-NMR (DMSO-d6): δ [ppm] = 1.16 (t, 3H, 3J = 7.1 Hz, CH3), 3.05 (q, 2H, 3J = 
7.1 Hz, CH2), 4.40 (br, 1H, NH), 6.36-6.49 (m, 2H, Ar-H), 6.60-6.66 (m, 2H, Ar-
H), 9.15 (br, 1H, OH) 
MS (CI-MS, NH3): m/z (%) = 155 ([M+NH4] +, 6), 138 ([M+H] +, 100) 
C8H11NO (137.18) 
 
3-Ethylbenzo[d]oxazole-2(3H)-thione (6.24) 
Compound 6.23 (0.15 g, 1.09 mmol) was dissolved in dry THF (5 ml) under an 
inert atmosphere. Subsequently, TCDI (0.21 g, 1.20 mmol) was added in small 
portions and the mixture was stirred for 3 h at ambient temperature. The reac-
tion mixture was concentrated under reduced pressure and water (15 ml) was 
added. After extraction with ethyl acetate (3x15 ml), the combined organic lay-
ers were dried over magnesium sulfate and reduced in vacuo. The crude prod-
uct was purified by column chromatography on silica gel eluting with a 3:1 (v/v) 
mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.07 g (0.39 mmol, 36 %, beige solid) 
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Mp: 105-107 °C (Lit. 96-98 °C202) 
1H-NMR (DMSO-d6): δ [ppm] = 1.30 (t, 3H, 3J = 7.2 Hz, CH3), 4.25 (q, 2H, 3J = 
7.2 Hz, CH2), 7.30-7.43 (m, 2H, Ar-H), 7.54-7.60 (m, 2H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 179 ([M•+], 100), 151 ([M - C2H4] +, 93) 
C9H9NOS (179.24) 
 
Methyl 3-amino-4-hydroxybenzoate (6.27) 
3-Amino-4-hydroxybenzoic acid (6.25) (0.40 g, 2.61 mmol) was dissolved in dry 
methanol (10 ml) and treated with TMSCl (0.75 ml, 5.94 mmol). The mixture 
was stirred at 55 °C for 2 days. After evaporation of the solvent, the obtained 
residue was purified by column chromatography on silica gel eluting with ethyl 
acetate. 
Yield: 0.25 g (1.50 mmol, 57 %, white solid) 
1H-NMR (DMSO-d6): δ [ppm] = 3.74 (s, 3H, CO2CH3), 4.77 (br, 2H, NH2), 6.70 
(d, 1H, 3J = 8.2 Hz, H-5), 7.09 (dd, 1H, 3J = 8.2 Hz, 4J = 2.2 Hz, H-6), 7.23 (d, 
1H, 4J = 2.2 Hz, H-2), 9.92 (br, 1H, OH) 
MS (PI-EIMS, 70 eV): m/z (%) = 167 ([M•+], 100), 136 ([M - OCH3] +, 99), 108 
([M - CO2CH3] +, 32) 
C8H9NO3 (167.16) 
 
Methyl 2-sulfanylbenzo[d]oxazole-5-carboxylate (6.28) 
Methyl 3-amino-4-hydroxybenzoate (6.27) (0.20 g, 1.20 mmol), dissolved in an-
hydrous THF (10 ml), was mixed with TCDI (0.26 g, 1.46 mmol) under an inert 
atmosphere. The solution was stirred overnight at room temperature. After 
evaporation of the solvent the residue was treated with water (15 ml) and ex-
tracted with ethyl acetate (3x15 ml). The combined organic layers were dried 
over magnesium sulfate and concentrated under reduced pressure. The re-
maining crude product was recrystallized from ethanol. 
Yield: 0.22 g (1.05 mmol, 88 %, brown solid) 
                                      Structure-activity relationships of benzoxazole-2-thiones 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 133 
Mp: 203-205 °C 
1H-NMR (DMSO-d6): δ [ppm] = 3.87 (s, 3H, CO2CH3), 7.62 (d, 1H, 3J = 8.5 Hz, 
H-7), 7.68 (d, 1H, 4J = 1.5 Hz, H-4), 7.88 (dd, 1H, 3J = 8.5 Hz, 4J = 1.5 Hz, H-6), 
14.08 (br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 209 ([M•+], 87), 178 ([M - OCH3] +, 100), 150 
([M - CO2CH3] +, 13) 
C9H7NO3S (209.22) 
 
Methyl 3-(3-phenylpropanoyl)-2,3-dihydro-2-thioxobenzo[d]oxazole-5-car-
boxylate (6.29) 
Methyl 2-sulfanylbenzo[d]oxazole-5-carboxylate (6.28) (0.20 g, 0.96 mmol) was 
dissolved in dry THF (5 ml) and treated with triethylamine (0.15 ml, 1.05 mmol). 
The mixture was cooled in an ice bath and 3-phenylpropanoyl chloride (0.15 ml, 
0.96 mmol) was added dropwise. After stirring for 30 min at 0 °C, the reaction 
mixture was poured into ice water (35 ml). The resulting precipitate was col-
lected, washed with water and dried in vacuo. The remaining crude product was 
recrystallized from ethanol. 
Yield: 0.17 g (0.50 mmol, 52 %, beige solid) 
Mp: 112.5-115.5 °C 
1H-NMR (CDCl3): δ [ppm] = 3.17 (t, 2H, 3J = 7.5 Hz, COCH2CH2Ph), 3.85 (t, 2H, 
3J = 7.5 Hz, COCH2CH2Ph), 3.95 (s, 3H, CO2CH3), 7.22-7.36 (m, 6H, Ar-H), 
8.09 (dd, 1H, 3J = 8.5 Hz, 4J = 1.7 Hz, H-6), 8.74 (dd, 1H, 4J = 1.7 Hz, 5J = 0.6 
Hz, H-4) 
13C-NMR (CDCl3): δ [ppm] = 30.1 (-, CH2), 40.7 (-, CH2), 52.6 (+, CH3), 109.4 
(+, Ar-C), 117.9 (+, Ar-C), 126.5 (+, Ar-C), 127.9 (Cquart, Ar-C), 128.4 (+, Ar-C), 
128.5 (+, 2Ar-C), 128.7 (+, 2Ar-C), 130.1 (Cquart, Ar-C), 139.7 (Cquart, Ar-C), 
149.4 (Cquart, Ar-C), 165.9 (Cquart, CO2Me), 173.0 (Cquart, CO), 178.6 (Cquart, CS) 
MS (PI-EIMS, 70 eV): m/z (%) = 341 ([M•+], 8), 308 ([M - SH] +, 36), 209 ([M - 
C6H5CH2CHCO] +, 87), 178 ([M - C6H5CH2CHCOOCH3] +, 35), 104 
([C6H5cyclopropyl] +, 100), 91 ([C7H7] +, 89) 
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Analysis: C18H15NO4S (341.38) 
 calculated C: 63.33 H: 4.43 N: 4.10 
 found C: 63.27 H: 4.40 N: 3.99 
 
2-Sulfanylbenzo[d]oxazole-5-sulfonic acid (6.30) 
3-Amino-4-hydroxybenzenesulfonic acid hydrate (6.26) (4.0 g, 21.14 mmol), 
sodium hydroxide (1.60 g, 40.0 mmol), carbon disulfide (3.5 ml, 50.9 mmol) and 
water were heated under reflux for 8 h. After cooling the mixture was acidified 
with concentrated hydrochloric acid. The resulting precipitate was removed by 
suction and recrystallized from ethanol. 
Yield: 0.99 g (4.28 mmol, 20 %, white solid) 
Mp: >300 °C 
1H-NMR (DMSO-d6): δ [ppm] = 7.40 (dd, 1H, 4J = 1.6 Hz, 5J = 0.6 Hz, H-4), 7.43 
(dd, 1H, 3J = 8.4 Hz, 5J = 0.6 Hz, H-7), 7.51 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, H-
6), 13.91 (br, 1H, NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 231 ([M•+], 44), 151 ([M - SO3H] +, 82), 76 
([C6H4] +, 100) 
C7H5NO4S2 (231.25) 
 
N,N-Dimethylbenzo[d]oxazol-2-amine (6.33) 
N,N-Dimethylbenzylamine (6.31) (0.78 g, 5.77 mmol) and 2-chlorobenzoxazole 
(6.32) (0.86 g, 5.60 mmol) were heated at 130 °C for 3 h. After cooling the reac-
tion mixture was dissolved in a small amount of chloroform and purified by col-
umn chromatography on silica gel eluting with a 3:1 (v/v) mixture of petroleum 
ether (60-80 °C) and ethyl acetate and then with chloroform. 
Yield: 0.80 g (4.93 mmol, 88 %, white-grey solid) 
Mp: 89-90 °C (Lit. 89-91 °C194) 
1H-NMR (CDCl3): δ [ppm] = 3.30 (s, 6H, N(CH3)2), 7.04-7.11 (m, 1H, Ar-H), 
7.18-7.24 (m, 1H, Ar-H), 7.25-7.31 (m, 1H, Ar-H), 7.44-7.48 (m, 1H, Ar-H) 
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MS (PI-EIMS, 70 eV): m/z (%) = 162 ([M•+], 100), 147 ([M - CH3]+, 79) 
Analysis: C9H10N2O (162.19) 
 calculated C: 66.65 H: 6.21 N: 17.27 
 found C: 66.43 H: 6.45 N: 17.30 
 
Synthesis of 2-methylbenzofuranes 6.35-6.36 
General procedure. To an ice-cold solution of 2-methylbenzofuran (6.34) 
(1 eq), acid chloride (1 eq) and previously dried dichloromethane (5 ml), tin(IV) 
chloride (1 eq) was added dropwise. The solution changed color to dark red and 
purple, respectively. After stirring the reaction mixture at room temperature for 
3.5 h, the mixture was poured into ice water (30 ml) and extracted three times 
with ethyl acetate (15 ml). The combined organic layers were dried over mag-
nesium sulfate, filtrated and the solvent was removed in vacuo. The products 
were purified by column chromatography. 
 
1-(2-Methylbenzofuran-3-yl)ethanone (6.35) 
Reaction of 2-methylbenzofuran (6.34) (0.30 g, 2.27 mmol), acetyl chloride 
(0.16 ml, 2.27 mmol) and tin(IV) chloride (0.28 ml, 2.38 mmol); purification by 
chromatography on a silica gel column, elution with a 1:1 (v/v) mixture of petro-
leum ether (60-80 °C) and ethyl acetate to obtain a yellow oil which gave a yel-
low crystalline solid after cooling in the refrigerator. 
Yield: 0.35 g (2.01 mmol, 89 %, yellow solid) 
Mp: 48-49 °C (Lit. 50-52 °C203) 
1H-NMR (CDCl3): δ [ppm] = 2.65 (s, 3H, COCH3), 2.79 (s, 3H, CH3), 7.27-7.36 
(m, 2H, Ar-H), 7.42-7.48 (m, 1H, Ar-H), 7.91-7.98 (m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 174 ([M•+], 44), 159 ([M - CH3]+, 100), 131 ([M - 
CH3CO] +, 8) 
Analysis: C11H10O2 (174.20) 
 calculated C: 75.84 H: 5.79  
 found C: 75.74 H: 5.85  
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1-(2-Methylbenzofuran-3-yl)-3-phenylpropan-1-one (6.36) 
Reaction of 2-methylbenzofuran (6.34) (0.31 g, 2.34 mmol), hydrocinnamoyl 
chloride (0.35 ml, 2.34 mmol) and tin(IV) chloride (0.28 ml, 2.38 mmol); purifica-
tion by chromatography on a silica gel column, elution with chloroform; recrys-
tallization from methanol yielded analytically pure product. 
Yield: 0.61 g (2.30 mmol, 98 %, white solid) 
Mp: 83-84 °C 
1H-NMR (CDCl3): δ [ppm] = 2.77 (s, 3H, CH3), 3.11 (t, 2H, 3J = 7.8 Hz, COCH2-
), 3.28 (t, 2H, 3J = 7.8 Hz, PhCH2-), 7.19-7.35 (m, 7H, Ar-H), 7.42-7.48 (m, 1H, 
Ar-H), 7.87-7.93 (m, 1H, Ar-H) 
13C-NMR (CDCl3): δ [ppm] = 15.5 (+, CH3), 29.7 (-, CH2), 44.9 (-, CH2), 111.1 
(+, Ar-C), 117.1 (Cquart, Ar-C), 121.4 (+, Ar-C), 124.0 (+, Ar-C), 124.4 (+, Ar-C), 
125.8 (Cquart, Ar-C), 126.2 (+, Ar-C), 128.5 (+, 2Ar-C), 128.6 (+, 2Ar-C), 141.3 
(Cquart, Ar-C), 153.5 (Cquart, Ar-C), 163.0 (Cquart, Ar-C), 195.7 (Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 264 ([M•+], 46), 159 ([M - C6H5CH2CH2]+, 100), 
132 ([M - C6H5CH2CHCO] +, 18) 
Analysis: C18H16O2 (264.32) 
 calculated C: 81.79 H: 6.10 
 found C: 81.84 H: 6.00 
 
6.5.3 Pharmacological methods 
The inhibitory effect of the benzoxazole derivatives on the enzymatic activities 
of hyaluronidases were determined in a turbidimetric assay, developed in our 
laboratory, based on the method of Di Ferrante145 as described in section 5.5.3. 
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Chapter 7 
The indole scaffold as a core structure for 
hyaluronidase inhibitors 
7.1 Introduction 
 
Salmen120 found that 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl-sulfamate 
(5.1) inhibits the bacterial hyaluronidase from Streptococcus agalactiae 
(hylB4755) with an IC50 value of 11 µM at pH optimum, whereas the compound 
was inactive on the bovine testicular hyaluronidase. Subsequently, this 2-
phenylindole derivative was co-crystallized with the related hyaluronate lyase 
from Streptococcus pneumoniae. The elucidation 
of the X-ray structure resulted in new 
suggestions for the development of more potent 
inhibitors. As described in chapter 6 one ap-
proach was the design and synthesis of 3-acyl-
benzoxazoles, which proved to be rather potent 
inhibitors of bacterial hyaluronidases. However, 
the stability of these compounds was unsatisfy-
ing. Therefore, indole derivatives, which are 
structurally similar but more stable under the 
same conditions (cf. 6.3.3), were considered a 
promising alternative. The aim of the investigations described in this chapter 
was to find out whether the structure-activity relationships of the benzoxazoles 
can be transferred to the indole series or not. Hence, N-alkylated and N-acy-
lated indole derivatives (see Fig. 7.1) were prepared. Moreover, as indometha-
N
R1
R2
R3
R4
R1 = H, NO2, NH2, NHR
R2 = H, alkyl, acyl
R3 = H, CH3
R4 = H, acyl
Fig. 7.1: Target compounds 
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cin is a weak inhibitor of hylB4755 (IC50 = 350 µM at pH 5)120, a series of 1,3-
disubstituted 2-methyl-indoles was synthesized (see Fig. 7.1). All synthesized 
indoles were investigated for inhibition of hyaluronidases from bacterial source 
and from bovine testis. 
 
 
7.2 Chemistry 
 
The indole skeleton is an important synthetic building block for the synthesis of 
a variety of natural products and biologically active compounds. A large number 
of preeminent methods for the synthesis of indoles have been well documented. 
But there is still a need for simple methods for the synthesis of highly function-
alized indoles. The Fischer indole reaction is a quite versatile indolization pro-
cedure although it often suffers from low yields. Methods for the preparation of 
selectively substituted indoles were reported by Pindur and Adam204. Recently, 
a general approach for a one-pot synthesis of highly functionalized indoles from 
simple aryl hydrazines and cyclic enol ethers was developed205. This method 
was pointed out in the efficient synthesis of the anti-migraine drug sumitriptan 
and the anti-inflammatory drug indomethacin. Another interesting pathway has 
been described by Dai et al.206 starting from 2-aminophenols including a 
Sonogashira cross-coupling reaction as key step and a subsequent alkoxide-
mediated cyclisation to provide a number of indoles possessing substituents at 
the positions 4, 5, 6 and 7. A similar indole synthesis was reported by Rodri-
guez et al.207. 
As part of this doctoral project N-acylated and N-alkylated indoles with an addi-
tional functionality in position 5 at the indole moiety had to be prepared. In gen-
eral, the regioselective N-acylation of indoles is accompanied by concomitant 
formation of 3-acyl and /or 1,3-diacyl derivatives depending on the associated 
metal cation, the solvent, the other substituents, the temperature and on the 
electrophilic reagent used208. A number of methods for the N-acylation of in-
doles are outlined in a review by Pindur et al.209. A simple acylation of the indole 
nitrogen under neutral conditions was described by Macor et al.210 for the syn-
thesis of indole-1-carboxylates, indole-1-thiocarboxylates and indole-1-carb-
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oxamides: treatment of the indole with CDI and subsequent reaction with the 
corresponding alcohol, thiol or amine yielded the indole-1-carboxylic acid de-
rivatives. Most often the sodium salts of the indoles, prepared in anhydrous 
DMF211, are used as starting material for N-acylation. High yields of N-acylin-
doles were obtained by using the phase transfer catalyst tetrabutylammonium 
hydrogen sulfate and the two-phase system dichloromethane/powdered sodium 
hydroxide212. Another convenient procedure for the synthesis of N-acylated in-
doles was described by Kikugawa213 who used powdered potassium hydroxide 
in dimethoxyethane at room temperature. Moderate yields of acylindoles were 
obtained when carboxylic acids instead of acyl chlorides were used for direct N-
acylation in the presence of boric acid as catalyst at a long reaction time214. 
 
The starting material for both the N-alkylated and N-acylated indole derivatives 
was 2-methyl-5-nitroindole (7.1). As depicted in Scheme 7.1 the N-acylated 2-
methyl-5-nitroindoles 7.12-7.19 were accessible via two synthetic routes. One 
possible pathway is the regioselective acylation of 7.1 with the particular acyl 
chloride after deprotonation with sodium hydride as base in DMF as solvent. 
Some of the acid chlorides (7.10 and 7.11) were prepared from the corre-
sponding carboxylic acids as shown in Scheme 7.1. Another way is the treat-
ment of 7.1 with an activated ester like e.g. a succinimidyl ester. The utilized 
succinimidyl esters 7.5-7.7 were prepared according to a standard method by 
coupling the corresponding carboxylic acids 7.2-7.4 with N-hydroxysuccinimide 
using DCC as coupling reagent and DMF as solvent. After the deprotonation of 
the weakly nucleophilic nitrogen atom of 7.1 with the strong base sodium hy-
dride the succinimidyl esters were added to yield 7.15-7.17. 
The conversion of the nitro group of the N-acylated indoles to an amino group 
required a selective reduction system not affecting the pyrrole moiety of the in-
dole scaffold. Furthermore, the amide bond at the nitrogen atom of the indoles 
should remain unchanged. Numerous methods for the reduction of aromatic 
nitro groups are reported in the literature. However, there are limitations consid-
ering safety, handling and selectivity215. Catalytic hydrogenation216,217 of nitro 
compounds, the most common procedure for the synthesis of aromatic amines, 
is inappropriate for the synthesis of the compounds of interest, as partial reduc-
tion of the indole system may occur under these conditions. Recently, Banik218 
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highlighted reducing systems containing samarium. For instance, an easy, fast 
and highly efficient ultrasound-promoted reduction of aromatic nitro compounds 
was achieved by samarium/ammonium chloride mediated reaction215. 
Scheme 7.1: Pathway to N-acylated indole derivatives 7.8-7.19 
With the aim to find a mild, fast and selective method different reducing systems 
were tried out. In the last years an Indian working group described a facile and 
selective reduction by using magnesium as catalyst and hydrazinium monofor-
mate as hydrogen donor219. Reducible substituents such as alkenes, nitriles, 
carboxylic acids, phenols, halogens, esters, amides should remain unaffected. 
A reaction time of about 5 min at room temperature was reported to result in 
OH
O
O
O
N
O
O
n
n
7.5: n = 1
7.6: n = 2
7.7: n = 3
7.2: n = 1
7.3: n = 2
7.4: n = 3
N
H
O2N
N
O2N
7.12: R = CH2CH3
7.13: R = (CH2)4CH3
7.14: R = (CH2)8CH3
7.15: R = CH2Ph
7.16: R = (CH2)2Ph
7.17: R = (CH2)3Ph
7.18: R = OCH2Ph
7.19: R = CH2OPh
7.1
N
H2N
7.20: R = CH2CH3
7.21: R = (CH2)4CH3
7.22: R = (CH2)8CH3
7.23: R = CH2Ph
7.24: R = (CH2)2Ph
R
O
O
R
i
v
RCOOH
RCOCl
7.8: R = (CH2)4CH3
7.9: R = (CH2)8CH3
7.10: R = (CH2)4CH3
7.11: R = (CH2)8CH3
ii iv
iii
Reagents: i) DCC, N-hydroxysuccinimide, DMF; ii) NaH, DMF; iii) SOCl2, 
DMF(cat.); iv) RCOCl, NaH, DMF, 0 °C; v) SnCl2·2 H2O, EtOAc
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high yields. Unfortunately, when this method was applied to the reduction of 7.1, 
no conversion to 5-amino-2-methyl-1H-indole 7.25 was detected after 10 
minutes or after longer reaction times. The use of ammonium formate instead of 
hydrazinium formate as hydrogen donor was unsuccessful, too. The attempt to 
reduce the aromatic nitro group of 7.1 by transfer hydrogenation with Pd-C (10 
%) and formic acid according to a protocol described by Entwistle et al.220 re-
sulted in a black slurry. According to the literature the reduction of nitroarenes 
using the system of Ram and Ehrenkaufer221, containing anhydrous ammonium 
formate as a hydrogen transfer agent and Pd-C (10%) in methanol at room 
temperature, should occur without affecting functional groups such as carbox-
ylic acids, esters, ethers, nitriles, guanidino and amide groups. However, the 
application of this method to the reduction of 7.12 resulted in 7.26, i. e. the in-
dole scaffold was partially hydrogenated (see Scheme 7.2). 
At last, two methods afforded the selective reduction of 7.1. The first was the 
use of nickel boride/hydrazine hydrate which was successfully applied by Lloyd 
and Nichols222 for the synthesis of 4-(benzyloxy)indole and α-alkyltryptamines. 
The catalyst is of nonpyrophoric nature and is easy to prepare. The reduction of 
nitroindole 7.1 gave compound 7.25 in 71 % yield. However, under the same 
conditions this method failed to reduce the N-acylated 2-methyl-5-nitroindoles 
7.12-7.19, since the acyl residue was cleaved off. Nose and Kudo223,224 de-
scribed nickel boride in methanol/THF or in basic or acidic medium as an effec-
tive system for the conversion of aromatic nitro compounds containing reducible 
groups such as olefins, aldehydes, ketones, nitriles, amides, carboxylic acids 
N
H
O2N
N
H
H2N
N
H2N
7.1 7.25
7.26
ii
i
N
O2N
O
7.12
O
Reagents: i) Method A:
Ni(OAc)2·4H2O, NaBH4,
N2H4·H2O, 2-propanol;
Method B: SnCl2·2 H2O,
EtOAc; ii) HCO2NH4,
10% Pd/C, MeOH
Scheme 7.2: Reduction of nitro compounds 7.1 and 7.12 
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and esters. But keeping the reaction conditions exactly as reported by Nose and 
Kudo the desired product was not formed. Presumably, the catalyst was inacti-
vated. This could be explained by the difficult preparation of the catalyst and its 
susceptibility against air. As an alternative the reduction of the nitro groups with 
stannous chloride in non acidic and non aqueous medium was tried out by 
analogy with the method reported by Bellamy and Ou225. Ethyl acetate or alco-
hols were used as solvents, and sensitive groups like aldehyde, ketone, ester, 
cyano, halogen and O-benzyl remained unaffected. According to this protocol 
all N-acylated compounds 7.20-7.24 were accessible in moderate to good 
yields. 
 
Scheme 7.3: Synthetic route to N-alkylated indole derivatives 
For the synthesis of N-alkylindols with a hydrophilic group in position 5 a similar 
strategy was selected as that applied for the N-acylated indoles (see Scheme 
7.3). 2-Methyl-5-nitroindole (7.1) was converted into the corresponding alkylated 
compounds 7.27-7.33 via a nucleophilic substitution reaction using the particu-
lar iodoalkane and sodium hydride as base. Compound 7.33 was obtained by 
refluxing 7.1 with ethyl 5-bromopentanoate in the presence of potassium car-
bonate in acetonitrile for 48 h. In contrast to our results Gray et al.226 described 
a procedure for the regioselective alkylation of ethyl indole-2-carboxylate at po-
sition 3. The reduction of 7.27-7.33 to the corresponding amines was performed 
either with the nickel boride/hydrazine hydrate system or with stannous chloride 
N
H
O2N
N
O2N
7.27: R = CH2CH3
7.28: R = (CH2)5CH3
7.29: R = (CH2)7CH3
7.30: R = (CH2)9CH3
7.31: R = (CH2)3Ph
7.32: R = CH2(p-biphenylyl)
7.33: R = (CH2)4COOEt
7.1
R
N
H2N
R7.34: R = (CH2)2CH3
7.35: R = (CH2)5CH3
7.36: R = (CH2)7CH3
7.37: R = (CH2)9CH3
7.38: R = (CH2)3Ph
7.39: R = CH2(p-biphenylyl)
7.40: R = (CH2)4COOEt
i
ii
Reagents:i) NaH, DMF, 0 °C;
ii) Method A: Ni(OAc)2·4H2O,
NaBH4, N2H4·H2O, 2-propanol;
Method B: SnCl2·2 H2O, EtOAc
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in ethyl acetate as explained above for the reduction of the N-acylated sub-
stances. Compared to the 1-acylindoles the 1-alkylindoles are much more sta-
ble against hydrogenolytic cleavage, and in contrast to the former the N-alky-
lated 2-methyl-5-nitroindoles 7.27-7.33 could be successfully reduced to the 
corresponding aminoindoles by nickel boride/hydrazine hydrate. 
The iodo compounds 7.44-7.46 used for the N-alkylation of 7.1 were not com-
mercially available and were prepared by the Finkelstein reaction (Scheme 7.4). 
 
Scheme 7.4: Finkelstein reaction 
Several derivatives of the amine 7.37 were synthesized as shown in Scheme 
7.5. Sulfonamides 7.47 and 7.48 were prepared by a standard method using 
pyridine as solvent and either methanesulfonyl chloride or N,N-dimethylsulfa-
moyl chloride as reagent. Urea 7.49 was obtained in excellent yields by treat-
ment of 7.37 with ethyl isocyanate in acetonitrile as solvent. 
Scheme 7.5: Conversion of 7.37 into sulfonamide derivatives 7.47 and 7.48 and  
urea derivative 7.49 
The 1,3-disubstituted 5-amino-2-methylindole derivatives 7.54-7.56 were ob-
tained in a two-step reaction sequence as illustrated in Scheme 7.6. In the first 
step, the indole derivatives 7.27, 7.28 and 7.33 were acylated in position 3 of 
the indole skeleton in a Friedel-Crafts like reaction using the corresponding acid 
chloride and tin(IV) chloride by analogy with a procedure described by Carvalho 
et al.195 for acylation of benzofuranes. Subsequently, the obtained 1,3-disubsti-
tuted compounds 7.50-7.53 were treated with stannous chloride according to 
R-X        +         NaI                                     R-I          +         NaX
7.44: R = (CH2)9CH3
7.45: R = (CH2)3Ph
7.46: R = CH2(p-biphenylyl)
7.41: R = (CH2)9CH3,  X = Br
7.42: R = (CH2)3Ph,    X = Cl
7.43: R = CH2(p-biphenylyl),  X = Cl
acetone,
heat
N
H2N
(CH2)9CH3
N
H
N
(CH2)9CH3
R
7.47: R = SO2CH3
7.48: R = SO2N(CH3)2
7.49: R = CONHC2H5
7.37
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the aforementioned procedure described by Bellamy and Ou225 resulting in 
7.54-7.56. 
 
Scheme 7.6: Synthetic pathway for the preparation of 1,3-disubstituted indole derivatives 
 
As depicted in Scheme 7.7, a 3-phenylpropanoyl side chain was introduced at 
the indole-N of 7.57-7.59 by a nucleophilic substitution reaction utilizing TEBAC 
as phase transfer catalyst according to a protocol described by Illi212. 
 
Scheme 7.7: N-acylation of indoles 7.57-7.59 using phase transfer conditions 
For the introduction of a sulfonic acid group in position 5 of the indole scaffold a 
Fischer indole reaction protocol227 was carried out as illustrated in Scheme 7.8. 
In the first step, the hydrazone 7.64 was prepared from 4-hydrazinobenzene-
N
O2N
R1
N
O2N
R1
7.27: R1 = (CH2)2CH3
7.28: R1 = (CH2)5CH3
7.33: R1 = (CH2)4COOEt
R2
O
N
H2N
R1
R2
O
i
ii
7.50: R1 = (CH2)2CH3,
7.51: R1 = (CH2)4COOEt,
7.52: R1 = (CH2)4COOEt,
7.53: R1 = (CH2)5CH3,
R2 = (CH2)2Ph
R2 = m-ClC6H4
R2 = CH2CH3
R2 = CH2CH3
7.54: R1 = (CH2)4COOEt,
7.55: R1 = (CH2)4COOEt,
7.56: R1 = (CH2)5CH3,
R2 = m-ClC6H4
R2 = CH2CH3
R2 = CH2CH3
Reagents: i) SnCl4, R2COCl,
DCM; ii) SnCl2·2 H2O, EtOAc
N
H
N
O
R1
R2
R1
R2
7.57: R1 = H, R2 = H
7.58: R1 = COCH3, R2 = H
7.59: R1 = H, R2 = COOH
7.60: R1 = H, R2 = H
7.61: R1 = COCH3, R2 = H
7.62: R1 = H, R2 = COOH
i
Reagents: i) 3-phenylpro-
panoyl chloride, TEBAC,
NaOH, DCM
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sulfonic acid 7.63 and acetone. In contrast to the direct transformation of 7.64 
into 7.65 described in the patent, the hydrazone had to be isolated and the fol-
lowing diaza-cope rearrangement succeeded by treatment with concentrated 
sulfuric acid as promoter under reflux for several hours. The acylation of 7.65 by 
acid chlorides or activated esters such as succinimidyl esters in DMF failed, 
presumably, due to insufficient solubility of the starting material. 
 
Scheme 7.8: Preparation of 2-methyl-1H-indole-5-sulfonic acid (7.65) according to a Fischer 
indole synthesis 
 
 
7.3 Results and discussion 
 
To investigate the synthesized indoles for hyaluronidase inhibition a turbidimet-
ric assay was carried out using either the bacterial hyaluronate lyase from S. 
agalactiae at pH 5 and pH 7.4, respectively, or bovine testicular hyaluronidase 
at pH 5. The Morgan-Elson assay is not suitable as the indole derivatives and 
Ehrlich’s reagent give colored compounds which are detectable at 590 nm, the 
wavelength used for the quantification of the red-colored product of the Morgan-
Elson reaction. 
At highest concentrations tested the synthesized 5-nitroindoles, which are 
poorly soluble in aqueous buffer, had only negligible inhibitory effects on both 
hyaluronidases (data not shown). All other investigated indoles except for 7.25 
and 7.65 were inactive on the bovine testicular hyaluronidase but proved to be 
HO3S
N
H
NH2
HO3S
N
H
N
N
H
HO3S
i
ii7.63 7.64
7.65
Reagents: i) acetone, glacial acid,
110 °C; ii) conc. H2SO4, 130 °C
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weak to moderate inhibitors of hylB4755 indicating selectivity for the bacterial en-
zyme (results see Tables 7.1-7.5). 
 
7.3.1 N-acylated 5-amino-2-methylindole derivatives 
In accordance with the results from the X-ray structure of 5.1 co-crystallized 
with the bacterial hyaluronidase from S. pneumoniae long alkyl chains were in-
troduced at the nitrogen atom of the indole scaffold in order to increase the in-
hibitory activity (see Table 7.1). Assuming similar binding modes of benzoxa-
zoles and indole 5.1 arylalkanoyl residues such as the 3-phenylpropanoyl group 
were suggested as activity-enhancing substituents. 
 
Table 7.1: Inhibitory activities of N-acylated indoles determined on the hyaluronidase from S. 
agalactiae at pH 5 and pH 7.4 and on the bovine testicular hyaluronidase at pH 5 
 
 
 
 
 
 
Compound R hylB4755, % inhibitiona BTHa 
  pH = 5.0 pH = 7.4 pH = 5.0 
7.20 CH2CH3 20 % (2000) 12 % (2000) inactive (2000) 
7.21 (CH2)4CH3 42 % (600) 42 % (600) inactive (600) 
7.22 (CH2)8CH3 12 % (100) 8 % (100) inactive 100) 
7.23 (CH2)2Ph 3 % (200) 4 % (200) inactive (200) 
7.24 (CH2)3Ph 10 % (200) 9 % (200) inactive (200) 
a inhibition of enzyme expressed as percent inhibition at inhibitor concentration (µM) given in 
parentheses; highest tested concentrations were dependent on the solubility of the compounds. 
 
As this structural modification led to the most potent benzoxazole-type hyalu-
ronidase inhibitors (see chapter 6) the optimized 3-phenylpropanoyl side chain 
was attached to the indole-N as well. Compounds 7.20-7.22 each induced 
about the same percentage inhibition of hylB4755 at pH 5 and pH 7.4, respec-
N
H2N
O
R
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tively. Due to different solubilities 7.20-7.22 were tested at different concentra-
tions. Therefore, the comparability of the data presented in Tab 7.1 is restricted 
in terms of structure-activity considerations. The very weak inhibitory activity of 
compound 7.23 demonstrates that the optimized side chain of the strong ben-
zoxazole-type inhibitor 6.11 is not suitable for the 5-amino-2-methyl-indole 
scaffold suggesting different binding modes of indoles and benzoxazoles and 
lower affinity of the indole compared to the benzoxazole-2-thione scaffold. Nev-
ertheless, due to the aforementioned unfavorable physicochemical properties of 
the acylindoles, these results should not be over interpreted. 
7.3.2 N-alkylated 5-amino-2-methylindole derivatives 
The hyaluronidase inhibitory activities of the N-alkylindoles 7.35-7.37 are sum-
marized in Table 7.2. 
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Fig. 7.2: Enzymatic activity of hyaluronate lyase of S. agalactiae in the presence of compounds 
7.35-7.37 at pH 5 
At pH optimum, IC50 values in the micromolar range were determined for the 
inhibition of the hyaluronate lyase from S. agalactiae strain 4755: 334 µM 
(7.35), 285 µM (7.36) and 47 µM (7.37) (see Fig. 7.2). Compared to the 1-
unsubstituted parent compound 7.25 the inhibitory activity of the alkylindoles 
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7.34-7.37 was considerably higher, and there was a remarkable increase in 
potency with elongation of the alkyl chain. This result is in good agreement with 
the structure-activity relationships discussed in the previous chapters and 
underlines the contribution of hydrophobic interactions to ligand binding in the 
active site of the enzyme. However, at physiological pH there was no clear 
increase in activity depending on the chain length of the substituent, in fact the 
hexyl group proved to be the optimum. 
 
Table 7.2:Inhibitory activities of N-alkylated indole derivatives on hyaluronate lyase from S. 
agalactiae at pH 5 and pH 7.4 and on bovine testicular hyaluronidase at pH 5 
 
 
 
 
 
Compd. R hylB4755, IC50 [µM] or % inhibitiona BTHa 
  pH = 5.0 pH = 7.4 pH = 5.0 
7.25 H 17 % (5000) 27 % (5000) 25 % (5000) 
7.34 (CH2)2CH3 15 % (2000) 32 % (2000) inactiveb 
7.35 (CH2)5CH3 334 ± 6 376 ± 24 inactivec 
7.36 (CH2)7CH3 285 ± 12 21 % (200) inactived 
7.37 (CH2)9CH3 47 ± 2 7 % (160) inactivee 
7.38 (CH2)3Ph 31 % (420) 13 % (420) inactivef 
7.39 CH2-p-biphenylyl 13 % (200) inactiveg inactiveg 
7.40 (CH2)4COOEt 25 % (1600) 51 % (1600) inactiveh 
a inhibition of enzyme expressed as IC50 ± SEM in µM or as percent inhibition at inhibitor con-
centration (µM) given in parentheses; highest tested concentrations were dependent on the 
solubility of the compounds, b at concentrations ≤ 2 mM, c at concentrations ≤ 150 µM, d at con-
centrations ≤ 350 µM, e at concentrations ≤ 160 µM, f at concentrations ≤ 420 µM, g at concen-
trations ≤ 200 µM, h at concentrations ≤ 1.6 mM. 
 
A phenyl group as in compound 7.38 slightly increased the inhibitory potency 
(7.38 vs. 7.34) whereas a p-biphenylylmethyl group (7.39) was not tolerated. An 
ester group (7.40) led to improved solubility but the inhibitory activity of com-
pound 7.40 on hylB4755 was considerably reduced (25 % inhibition at a concen-
N
H2N
R
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tration of 1.6 mM). Obviously, the ester group is not tolerated due to its elec-
tronic properties, whereas methylene groups are favorable. Therefore, it is con-
ceivable that homologisation of the alkyl alkanoate moiety could compensate or 
even over-compensate the decrease in activity caused by the ester function. 
However, this approach could not be further elaborated within this doctoral 
project. 
Compound 7.37, the strongest inhibitor within the N-alkylindole series, was 
taken for further structural modifications. In consideration of the structure-activ-
ity relationships of 5.1120 interactions of a polar substituent in position 5 of the 
indole moiety with amino acids in the active site of hylB4755 are conceivable. 
Salmen proposed two possible binding modes for the sulfamoyl substituent in 
position 5 of the indole 5.1: hydrogen bonds between sulfamoyl group, water 
molecules and either Arg466/Ser463 or Asn349/Asp352 of hylSpn. 
Table 7.3: Inhibitory potency of 5-amino-1-decyl-2-methyl-1H-indole (7.37) and its derivatives 
7.47-7.49 determined on the hyaluronidase from S. agalactiae at pH 5 and pH 7.4 and on the 
bovine testicular hyaluronidase at pH 5 
 
 
 
 
 
Compd. R hylB4755, IC50 [µM] or % inhibitiona BTHa 
  pH = 5.0 pH = 7.4 pH = 5.0 
7.37 H 47 ± 2 7 % (160) inactiveb 
7.47 SO2CH3 16 % (50) 12 % (200) inactivec 
7.48 SO2N(CH3)2 6 % (100) 6 % (200) inactived 
7.49 CONHC2H5 inactivec 8 % (200) inactived 
a inhibition of enzyme expressed as IC50 ± SEM in µM or as percent inhibition at inhibitor con-
centration (µM) given in parentheses; highest tested concentrations were dependent on the 
solubility of the compounds, b at concentrations ≤ 160 µM, c at concentrations ≤ 50 µM, d at con-
centrations ≤ 100 µM. 
Hence, the amino group in 7.37 was derivatized in order to increase the N-H 
acidity (see Table 7.3). As summarized in Table 7.3, neither an urea nor a sul-
famoyl group did enhance the inhibitory effect on the bacterial enzyme at pH 5. 
N
(CH2)9CH3
H
N
R
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H-bonds as well as ionic interactions might play an important role in this part of 
enzyme-ligand interaction. 
 
7.3.3 1,3-disubstituted 5-amino-2-methylindole derivatives 
Starting from the inhibition data for indomethacin (IC50 values of 350 µM at pH 5 
and of 1.1 mM at pH 7.4 for inhibition of hylB4755) determined by Salmen120, a 
series of 1,3-disubstituted 2-methylindole derivatives with an additional amino 
function in position 5 were investigated for inhibition of hylB4755 at pH 5 and pH 
7.4 (see Table 7.4). Compounds 7.55 and 7.56 showed a moderate percentage 
inhibition of hyaluronate lyase of S. agalactiae strain 4755 at both physiological 
pH and optimum pH. The poorly soluble 7.54 revealed only a low percentage 
inhibition at the highest tested concentration. 
 
Table 7.4: Inhibitory activities of 1,3-disubstituted 5-amino-2-methyl-1H-indole derivatives 7.54-
7.56 determined on the hyaluronidase from S. agalactiae at pH 5 and pH 7.4 and on the bovine 
testicular hyaluronidase at pH 5 
 
 
 
 
 
 
Compd. R1 R2 hylB4755, % inhibitiona BTHa 
   pH = 5.0 pH = 7.4 pH = 5.0 
7.54 (CH2)4COOEt m-ClC6H4 20 % (100) 8 % (100) inactiveb 
7.55 (CH2)4COOEt CH2CH3 52 % (1600) 59 % (1600) inactivec 
7.56 (CH2)5CH3 CH2CH3 60 % (400) 31 % (400) inactived 
a inhibition of enzyme expressed as percent inhibition at inhibitor concentration (µM) given in 
parentheses; highest tested concentrations were dependent on the solubility of the compounds, 
b at concentrations ≤ 100 µM, c at concentrations ≤ 1.6 mM, d at concentrations ≤ 400 µM. 
 
The 3-propanoylindoles 7.55 and 7.56 were about equipotent with the 3-unsub-
stituted analogs 7.40 and 7.35, respectively. Thus, the propanoyl substituent in 
N
H2N
R1
O
R2
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position 3 does neither result in an increase nor in a decrease in inhibitory ac-
tivity. 
 
7.3.4 1-Phenylpropanoylindole derivatives 
According to the hypothesis that the phenylpropanoyl-substituted benzoxazole-
2-thiones (discussed in chapter 6) and the corresponding indoles have a similar 
binding mode comparable inhibitory activities on the bacterial hyaluronidase 
were expected. However, compounds 7.60 and 7.61, tested at highest possible 
concentrations, were inactive on hylB4755. Presumably, due to poor solubility at 
pH 5 compound 7.62 could not be tested at concentrations higher than 200 µM. 
Under these conditions only a low percentage inhibition of 20 % was deter-
mined, whereas at physiological pH 7.62 displayed a moderate inhibitory effect 
on hylB4755 with an IC50 value of 906 µM. 
 
Table 7.5: Inhibitory activities of indoles determined on the bacterial hyaluronidase from S. 
agalactiae at pH 5 and pH 7.4 and on the bovine hyaluronidase from testis at pH 5 
 
 
 
 
 
 
No. R1 R2 R3 R4 hylB4755, IC50 [µM] or %a BTHa 
     pH = 5.0 pH = 7.4 pH = 5.0 
7.60 H CO(CH2)2Ph H H inactiveb inactiveb inactiveb 
7.61 H CO(CH2)2Ph H COCH3 inactiveb inactiveb inactiveb 
7.62 COOH CO(CH2)2Ph H H 12 % (200) 906 ± 18 inactivec 
7.65 SO3H H CH3 H 2310 ± 66 28 % (7000) 2352 ± 107 
a inhibition of enzyme expressed as IC50 ± SEM in µM or as percent inhibition at inhibitor con-
centration (µM) given in parentheses; highest tested concentrations were dependent on the 
solubility of the compounds, b at concentrations ≤ 100 µM, c at concentrations ≤ 200 µM. 
 
N
R1
R2
R4 R
3
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Obviously, an acidic functional group like a carboxylic acid in position 5 of the 
indole structure is favorable to increase both the solubility and the inhibitory ac-
tivity. The sulfonic acid 7.65 induced an inhibition of hylB4755, too, but the level 
of activity was rather low. As compound 7.65 is lacking the N-substituent, it is 
conceivable that an increase in activity can be achieved by lipophilic substitu-
ents in 1-position. For the sulfonic acid 7.65 the IC50 values for inhibition of 
hylB4755 and BTH were in the same range (about 2.3 mM). 
 
 
7.4 Summary 
 
The indoles presented in this study showed a preference for the bacterial hyalu-
ronidase of S. agalactiae strain 4755 (hylB4755). Among the examined indole de-
rivatives the N-alkylated 5-amino-2-methylindole derivatives 7.35-7.37 displayed 
the strongest inhibitory potency (in the micromolar range) against hylB4755 at 
optimum pH. Modifications of the amino group in position 5 of the potent inhibi-
tor 7.37 (IC50 value of 47 µM at pH 5) resulted in a strong decrease in inhibitory 
activity. The N-acylated indoles revealed only very weak inhibitory effects indi-
cating a missing interaction of the carbonyl oxygen with Tyr488 in the active site 
of hylB4755. Within the series of 1,3-disubstituted 5-amino-2-methylindole de-
rivatives, compounds bearing a hexyl group at the nitrogen atom and a 3-pro-
panoyl substituent are about as potent as indomethacin and compound 7.35. 
Different substituents such as nitro, amino, urea, sulfonamide, carboxylic acid 
and sulfonic acid groups were introduced in position 5 of the indole scaffold. 
Only the amino group and the acidic groups confer additional affinity resulting in 
increased inhibitory potency against the bacterial enzyme. This suggests that 
ionic interactions as well as hydrogen bonds may play a role in the interactions 
between the 5-substituent and the enzyme. In summary, compared to benzoxa-
zole-2-thione the indole structure is less promising as a scaffold for the devel-
opment of hyaluronidase inhibitors. 
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7.5 Experimental section 
 
7.5.1 General conditions 
For general methods see section 4.5.1. 
 
7.5.2 Chemistry 
Synthesis of succinimidyl esters 7.5-7.7 
General procedure. N-Hydroxysuccinimide (1 eq) was dissolved in DMF (10-
20 ml). After cooling in an ice-bath, DCC (1.1 eq) and the corresponding carb-
oxylic acid (1 eq) was added. Then, the reaction mixture was stirred for further 2 
h at 0 °C and, subsequently, stirring was continued overnight at room tempera-
ture. The resulting precipitate was filtered off using a sintered glass crucible and 
the filtrate was treated with a solution of sodium bicarbonate (5 %, 20 ml). After 
extraction with ethyl acetate (3x30 ml), the combined organic phases were 
washed with water (20 ml) and dried over magnesium sulfate. The solvent was 
removed under reduced pressure and the crude product was purified by column 
chromatography on silica gel eluting with ethyl acetate.  
 
1-(2-Phenylethanoyl)pyrrolidine-2,5-dione (7.5) 
Reaction of N-hydroxysuccinimide (0.58 g, 5.04 mmol), DCC (1.13 g, 
5.48 mmol) and 2-phenylacetic acid (7.2) (0.68 g, 4.99 mmol). 
Yield: 0.68 g (2.91 mmol, 58 %, white solid) 
Mp: 109.5-112.5 °C (Lit. 113-117 °C228) 
1H-NMR (DMSO-d6): δ [ppm] = 2.81 (s, 4H, CH2), 4.11 (s, 2H, PhCH2CO-), 
7.28-7.41 (m, 5H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 233 ([M•+], 5), 119 ([C6H5CH2CO] +, 17), 91 
([C7H7] +, 100) 
C12H11NO4 (233.22) 
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1-(3-Phenylpropanoyl)pyrrolidine-2,5-dione (7.6) 
Reaction of N-hydroxysuccinimide (0.58 g, 5.04 mmol), DCC (1.15 g, 
5.57 mmol) and 3-phenylpropanoic acid (7.3) (0.76 g, 5.06 mmol). 
Yield: 0.84 g (3.40 mmol, 67 %, white solid) 
Mp: 115.5-117.5 °C (Lit. 111-113 °C229) 
1H-NMR (DMSO-d6): δ [ppm] = 2.81 (s, 4H, CH2), 2.91-3.05 (m, 4H, Ph(CH2)2-), 
7.18-7.33 (m, 5H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 247 ([M•+], 1), 149 ([C6H5(CH2)2CO2] +, 10), 
133 ([C6H5(CH2)2CO] +, 33), 105 ([C8H9] +, 100), 91 ([C7H7] +, 69) 
C13H13NO4 (247.25) 
 
1-(4-Phenylbutanoyl)pyrrolidine-2,5-dione (7.7) 
Reaction of N-hydroxysuccinimide (0.58 g, 5.04 mmol), DCC (1.14 g, 
5.53 mmol) and 4-phenylbutanoic acid (7.4) (0.82 g, 4.99 mmol). 
Yield: 0.88 g (3.37 mmol, 67 %, white solid) 
Mp: 55.5-57 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.86-1.98 (m, 2H, PhCH2CH2CH2-), 2.63-2.71 
(m, 4H, PhCH2CH2CH2-), 2.82 (s, 4H, CH2), 7.17-7.34 (m, 5H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 261 ([M•+], 6), 163 ([C6H5(CH2)3CO2] +, 20), 
147 ([C6H5(CH2)3CO] +, 100), 104 ([C6H5CHCH2] +, 27), 91 ([C7H7] +, 82) 
C14H15NO4 (261.27) 
 
Preparation of acid chlorides 7.10 and 7.11 
General procedure. Carboxylic acid (1 eq) was treated with thionyl chloride 
(1.5 eq) and one drop of DMF under a nitrogen atmosphere. After stirring for 1 h 
at ambient temperature until the liberation of gas had ceased the mixture was 
evaporated with a water-jet pump at room temperature to separate surplus thio-
nyl chloride. The obtained crude product was used for further reaction without 
purification. 
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Hexanoyl chloride (7.10) 
Reaction of hexanoic acid (7.8) (0.23 ml, 1.87 mmol) and thionyl chloride 
(0.20 ml, 2.76 mmol). 
Yield: colorless liquid 
Decanoyl chloride (7.11) 
Reaction of decanoic acid (7.9) (0.32 g, 1.86 mmol) and thionyl chloride 
(0.20 ml, 2.76 mmol). 
Yield: colorless liquid 
 
Synthesis of the N-acylated 2-methyl-5-nitro-1H-indoles 7.12-7.19 
General procedures 
Method A. 2-Methyl-5-nitro-1H-indole (7.1) (1 eq) was dissolved in DMF (10 ml) 
and cooled down to 0 °C under a nitrogen atmosphere. Sodium hydride (1.5 eq) 
was added and the reaction mixture was allowed to stir for about 20 min until 
gas generation ceased. After dropwise addition of the pertinent acid chloride (1 
eq), the mixture was stirred for further 30 min at 0 °C. The reaction was 
quenched with a solution of hydrochloric acid (1 N, 20 ml). After extraction with 
ethyl acetate (3x30 ml) the combined organic phases were washed with a solu-
tion of saturated sodium bicarbonate (20 ml) and dried over magnesium sulfate. 
The solvent was removed under reduced pressure. 
Method B. 2-Methyl-5-nitro-1H-indole (7.1) (1 eq) was dissolved in DMF (10 ml) 
and cooled down to 0 °C under a nitrogen atmosphere. Sodium hydride (1.5 eq) 
was added and the reaction mixture was allowed to stir for about 30 min until 
gas generation ceased. After dropwise addition of the pertinent succinimidyl 
ester (1 eq) the mixture was stirred for further 2 h at room temperature. The re-
action was quenched with a solution of hydrochloric acid (1 N, 20  ml). After ex-
traction with ethyl acetate (3x 30 ml) the combined organic phases were 
washed with a solution of saturated sodium bicarbonate (20 ml), dried over 
magnesium sulfate and the solvent was removed under reduced pressure. 
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2-Methyl-5-nitro-1-propanoyl-1H-indole (7.12) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (105 mg, 2.62 mmol) and propanoyl chloride (0.15 ml, 1.72 mmol); 
purification by flash column chromatography on silica gel, elution with a 3:1 (v/v) 
mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.34 g (1.46 mmol, 86 %, yellow solid) 
Mp: 121 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.20 (t, 3H, 3J = 7.1 Hz, CH2CH3), 2.68 (d, 3H, 
4J = 1.1 Hz, CH3), 3.12 (q, 2H, 3J = 7.1 Hz, COCH2CH3), 6.73 (dq, 1H, 4J = 1.1 
Hz, 5J = 0.8 Hz, H-3), 8.09 (dd, 1H, 3J = 9.2 Hz, 4J = 2.5 Hz, H-6), 8.30 (ddd, 
1H, 3J = 9.2 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 8.43 (dd, 1H, 4J = 2.5 Hz, 5J = 
0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 8.7 (+, COCH2CH3), 17.1 (+, CH3), 31.3 (-, 
COCH2CH3), 109.1 (+, indole), 115.4 (+, indole), 115.8 (+, indole), 118.2 (+, 
indole), 129.1 (Cquart, indole), 139.3 (Cquart, indole), 140.6 (Cquart, indole), 142.8 
(Cquart, indole), 174.8 (Cquart, COCH2CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 232 ([M•+], 29), 176 ([M - CH3CHCO] +, 100), 
146 ([M - CH3CHCO - NO] +, 10), 130 ([M - CH3CHCO - NO2] +, 34), 57 ([C4H9] +, 
40)  
IR [cm-1]: 3143 (C-H) aromatic, 3093 (C-H) aromatic, 2992 (C-H) aliphatic, 
2947 (C-H) aliphatic, 2928 (C-H) aliphatic, 1719 (C=O), 1337 (C-NO2) 
Analysis: C12H12N2O3 (232.24) 
 calculated C: 62.06 H: 5.21 N: 12.06  
 found C: 62.10 H: 4.89 N: 12.01   
 
1-Hexanoyl-2-methyl-5-nitro-1H-indole (7.13) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (102 mg, 2.55 mmol) and hexanoyl chloride (7.10); purification by 
flash column chromatography on silica gel, elution with a 3:1 (v/v) mixture of 
petroleum ether (60-80 °C) and ethyl acetate. 
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Yield: 0.14 g (0.51 mmol, 30 %, yellow solid) 
Mp: 76-77.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.89 (t, 3H, 3J = 7.1 Hz, CO(CH2)4CH3), 1.31-
1.41 (m, 4H, CO(CH2)2(CH2)2CH3), 1.66-1.77 (m, 2H, COCH2CH2-), 2.67 (d, 3H, 
4J = 1.1 Hz, CH3), 3.09 (t, 2H, 3J = 7.2 Hz, COCH2CH2-), 6.72 (dq, 1H, 4J = 1.1 
Hz, 5J = 0.7 Hz, H-3), 8.09 (dd, 1H, 3J = 9.2 Hz, 4J = 2.4 Hz, H-6), 8.26 (ddd, 
1H, 3J = 9.2 Hz, 5J = 0.7 Hz, 5J = 0.5 Hz, H-7), 8.43 (dd, 1H, 4J = 2.4 Hz, 5J = 
0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 13.8 (+, CO(CH2)4CH3), 17.0 (+, CH3), 21.9 (-, 
CH2), 23.8 (-, CH2), 30.5 (-, CH2), 37.7 (-, CH2), 109.1 (+, indole), 115.4 (+, in-
dole), 115.7 (+, indole), 118.2 (+, indole), 129.1 (Cquart, indole), 139.2 (Cquart, 
indole), 140.5 (Cquart, indole), 142.8 (Cquart, indole), 174.1 (Cquart, CO(CH2)4CH3) 
MS (CI-MS, NH3): m/z (%) = 292 ([M + NH4] +, 100), 275 ([M + H] +, 4), 245 ([M 
+ H - NO2] +, 19) 
Analysis: C15H18N2O3 (274.32) 
 calculated C: 65.68 H: 6.61 N: 10.21 
 found C: 65.54 H: 6.43 N: 10.03 
 
1-Decanoyl-2-methyl-5-nitro-1H-indole (7.14) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (103 mg, 2.58 mmol) and decanoyl chloride (7.11); purification by 
flash column chromatography on silica gel, elution with a 3:1 (v/v) mixture of 
petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.22 g (0.67 mmol, 39 %, pale yellow solid) 
Mp: 75-77.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.85 (t, 3H, 3J = 6.7 Hz, CO(CH2)8CH3), 1.21-
1.30 (m, 12H, CO(CH2)2(CH2)6CH3), 1.65-1.76 (m, 2H, COCH2CH2-), 2.67 (d, 
3H, 4J = 1.1 Hz, CH3), 3.10 (t, 2H, 3J = 7.2 Hz, COCH2CH2-), 6.73 (dq, 1H, 4J = 
1.1 Hz, 5J = 0.7 Hz, H-3), 8.10 (dd, 1H, 3J = 9.2 Hz, 4J = 2.5 Hz, H-6), 8.27 (ddd, 
1H, 3J = 9.2 Hz, 5J = 0.7 Hz, 5J = 0.5 Hz, H-7), 8.45 (dd, 1H, 4J = 2.5 Hz, 5J = 
0.5 Hz, H-4) 
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13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CO(CH2)8CH3), 17.0 (+, CH3), 22.0 (-, 
CH2), 24.2 (-, CH2), 28.2 (-, CH2), 28.5 (-, CH2), 28.8 (-, 2CH2), 31.2 (-, CH2), 
37.8 (-, CH2), 109.1 (+, indole), 115.4 (+, indole), 115.7 (+, indole), 118.2 (+, 
indole), 129.1 (Cquart, indole), 139.2 (Cquart, indole), 140.5 (Cquart, indole), 142.8 
(Cquart, indole), 174.1 (Cquart, CO(CH2)8CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 330 ([M•+], 7), 176 ([M - C8H17 - CHCO] +, 100), 
130 ([M - NO2 - C8H17 - CHCO] +, 9) 
Analysis: C19H26N2O3 (330.42) 
 calculated C: 69.06 H: 7.93 N: 8.48 
 found C: 68.97 H: 8.14 N: 8.16 
 
2-Methyl-5-nitro-1-(2-phenylethanoyl)-1H-indole (7.15) 
Method B: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (102 mg, 2.55 mmol) and 1-(2-phenylethanoyl)pyrrolidine-2,5-
dione (7.5) (0.40 g, 1.71 mmol); purification by flash column chromatography on 
silica gel, elution with a 4:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl 
acetate. 
Yield: 0.11 g (0.37 mmol, 22 %, yellow solid) 
1H-NMR (DMSO-d6): δ [ppm] = 2.74 (d, 3H, 4J = 1.0 Hz, CH3), 4.52 (s, 2H, 
COCH2Ph), 6.77 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 7.23-7.39 (m, 5H, Ar-
H), 8.10 (dd, 1H, 3J = 9.2 Hz, 4J = 2.5 Hz, H-6), 8.31 (ddd, 1H, 3J = 9.2 Hz, 5J = 
0.8 Hz, 5J = 0.5 Hz, H-7), 8.46 (dd, 1H, 4J = 2.5 Hz, 5J = 0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 17.1 (+, CH3), 44.1 (-, COCH2Ph), 109.4 (+, 
indole), 115.4 (+, indole), 115.9 (+, indole), 118.3 (+, indole), 126.7 (+, Ar-C), 
128.1 (+, 2Ar-C), 129.1 (Cquart, indole), 129.9 (+, 2Ar-C), 134.1 (Cquart, Ar-C), 
139.5 (Cquart, indole), 140.6 (Cquart, indole), 142.9 (Cquart, indole), 172.5 (Cquart, 
COCH2Ph) 
MS (PI-EIMS, 70 eV): m/z (%) = 294 ([M•+], 13), 176 ([M - C6H5 - CHCO] +, 54), 
118 ([C6H5 - CHCO] +, 41), 91 ([C7H7] +, 100)  
C17H14N2O3 (294.30) 
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2-Methyl-5-nitro-1-(3-phenylpropanoyl)-1H-indole (7.16) 
Method B: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.25 g, 1.42 mmol), 
sodium hydride (86 mg, 2.15 mmol) and 1-(3-phenylpropanoyl)pyrrolidine-2,5-
dione (7.6) (0.35 g, 1.42 mmol); purification by flash column chromatography on 
silica gel, elution with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl 
acetate. 
Yield: 0.25 g (0.81 mmol, 57 %, yellow solid) 
Mp: 130.5-131.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.65 (d, 3H, 4J = 1.1 Hz, CH3), 3.05 (t, 2H, J = 
7.4 Hz, COCH2CH2Ph), 3.46 (t, 2H, J = 7.4 Hz, COCH2CH2Ph), 6.73 (dq, 1H, 4J 
= 1.1 Hz, 5J = 0.8 Hz, H-3), 7.15-7.34 (m, 5H, Ph-H), 8.10 (dd, 1H, 3J = 9.2 Hz, 
4J = 2.4 Hz, H-6), 8.26 (ddd, 1H, 3J = 9.2 Hz, 5J = 0.8 Hz, 5J = 0.4 Hz, H-7), 8.44 
(dd, 1H, 4J = 2.4 Hz, 5J = 0.4 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 17.0 (+, CH3), 30.0 (-, CH2), 39.2 (-, CH2), 
109.2 (+, indole), 115.4 (+, indole), 115.7 (+, indole), 118.3 (+, indole), 126.0 (+, 
Ar-C), 128.2 (+, 2Ar-C), 128.4 (+, 2Ar-C), 129.1 (Cquart, indole), 139.2 (Cquart, 
indole), 140.3 (Cquart, Ar-C), 140.5 (Cquart, indole), 142.9 (Cquart, indole), 173.4 
(Cquart, COCH2CH2Ph) 
MS (PI-EIMS, 70 eV): m/z (%) = 308 ([M•+], 17), 176 ([M - C6H5CH2 - CHCO] +, 
100), 130 ([M - NO2 - C6H5CH2 - CHCO] +, 16), 105 ([C8H9] +, 55), 91 ([C7H7] +, 
79)  
Analysis: C18H16N2O3 (308.33) 
 calculated C: 70.12 H: 5.23 N: 9.09 
 found C: 70.25 H: 5.34 N: 8.96 
 
2-Methyl-5-nitro-1-(4-phenylbutanoyl)-1H-indole (7.17) 
Method B: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (102 mg, 2.55 mmol) and 1-(4-phenylbutanoyl)pyrrolidine-2,5-
dione (7.7) (0.45 g, 1.72 mmol); purification by flash column chromatography on 
silica gel, elution with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl 
acetate. 
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Yield: 0.32 g (0.99 mmol, 58 %, yellow solid) 
1H-NMR (DMSO-d6): δ [ppm] = 1.95-2.08 (m, 2H, COCH2CH2CH2Ph), 2.63 (d, 
3H, 4J = 1.1 Hz, CH3), 2.71 (t, 2H, J = 7.8 Hz, COCH2CH2CH2Ph), 3.12 (t, 2H, J 
= 7.2 Hz, COCH2CH2CH2Ph), 6.72 (dq, 1H, 4J = 1.1 Hz, 5J = 0.8 Hz, H-3), 7.13-
7.32 (m, 5H, Ph-H), 8.09 (dd, 1H, 3J = 9.2 Hz, 4J = 2.4 Hz, H-6), 8.24 (ddd, 1H, 
3J = 9.2 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 8.44 (dd, 1H, 4J = 2.4 Hz, 5J = 0.5 
Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 17.0 (+, CH3), 26.1 (-, CH2), 34.2 (-, CH2), 37.3 
(-, CH2), 109.2 (+, indole), 115.4 (+, indole), 115.7 (+, indole), 118.2 (+, indole), 
125.8 (+, Ar-C), 128.2 (+, 2Ar-C), 128.3 (+, 2Ar-C), 129.1 (Cquart, indole), 139.2 
(Cquart, indole), 140.5 (Cquart, indole), 141.5 (Cquart, Ar-C), 142.9 (Cquart, indole), 
173.8 (Cquart, COCH2-) 
MS (PI-EIMS, 70 eV): m/z (%) = 322 ([M•+], 20), 176 ([M - C6H5CH2CH2 - 
CHCO] +, 100), 91 ([C7H7] +, 56) 
C19H18N2O3 (322.36) 
 
Benzyl 2-methyl-5-nitro-1H-indole-1-carboxylate (7.18) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.31 g, 1.76 mmol), 
sodium hydride (115 mg, 2.88 mmol) and benzyl chloroformate (0.25 ml, 
1.78 mmol); purification by recrystallization from methanol. 
Yield: 0.49 g (1.58 mmol, 90 %, orange-brown solid) 
Mp: 121.5-122.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.56 (d, 3H, 4J = 1.1 Hz, CH3), 5.50 (s, 2H, 
OCH2Ph), 6.71 (dq, 1H, 4J = 1.1 Hz, 5J = 0.8 Hz, H-3), 7.39-7.48 (m, 3H, Ar-H), 
7.54-7.58 (m, 2H, Ar-H), 8.09 (dd, 1H, 3J = 9.2 Hz, 4J = 2.4 Hz, H-6), 8.19 (ddd, 
1H, 3J = 9.2 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 8.43 (dd, 1H, 4J = 2.4 Hz, 5J = 
0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 16.4 (+, CH3), 69.0 (-, CH2), 108.6 (+, indole), 
115.3 (+, indole), 115.6 (+, indole), 118.3 (+, indole), 128.6 (+, 5Ar-C), 129.1 
(Cquart, indole), 134.8 (Cquart, Ar-C), 139.1 (Cquart, indole), 141.0 (Cquart, indole), 
143.1 (Cquart, indole), 150.6 (Cquart, COOCH2Ph) 
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MS (PI-EIMS, 70 eV): m/z (%) = 310 ([M•+], 14), 266 ([M - CO2] +, 6), 176 ([M - 
C6H5CH - CO2] +, 6), 130 ([M - NO2 - C6H5CH - CO2] +, 4), 91 ([C7H7] +, 100)  
Analysis: C17H14N2O4 (310.30) 
 calculated C: 65.80 H: 4.55 N: 9.03 
 found C: 65.88 H: 4.59 N: 8.96 
 
2-Methyl-5-nitro-1-(2-phenoxyethanoyl)-1H-indole (7.19) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), so-
dium hydride (102 mg, 2.55 mmol) and phenoxyacetyl chloride (0.24 ml, 
1.74 mmol); purification by column chromatography on silica gel, elution with a 
3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate and afterwards 
by column chromatography on silica gel eluting with chloroform. 
Yield: 0.18 g (0.58 mmol, 34 %, yellow solid) 
Mp: 99.5-100.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.73 (d, 3H, 4J = 1.0 Hz, CH3), 5.53 (s, 2H, 
COCH2OPh), 6.78 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 6.95-7.07 (m, 3H, Ar-
H), 7.26-7.33 (m, 2H, Ar-H), 8.12 (dd, 1H, 3J = 9.2 Hz, 4J = 2.5 Hz, H-6), 8.32 
(ddd, 1H, 3J = 9.2 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 8.47 (dd, 1H, 4J = 2.5 Hz, 
5J = 0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 16.4 (+, CH3), 67.9 (-, CH2), 109.7 (+, indole), 
114.6 (+, 2Ar-C), 115.4 (+, indole), 116.0 (+, indole), 118.6 (+, indole), 121.1 (+, 
Ar-C), 129.4 (+, 2Ar-C), 129.5 (Cquart, indole), 139.5 (Cquart, Ar-C), 140.3 (Cquart, 
indole), 143.2 (Cquart, indole), 157.5 (Cquart, indole), 169.8 (Cquart, COCH2OPh) 
MS (PI-EIMS, 70 eV): m/z (%) = 310 ([M•+], 39), 189 ([M - C6H5OCH2 - CH2] +, 
100), 143 ([M - NO2 - C6H5OCH2 - CH2] +, 22), 107 ([C6H5 - NO] +, 37), 77 ([C6H5] 
+, 26)  
Analysis: C17H14N2O4 (310.30) 
 calculated C: 65.80 H: 4.55 N: 9.03  
 found C: 65.81 H: 4.62 N: 8.95   
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Synthesis of N-alkylated 2-methyl-5-nitro-1H-indoles 7.27-7.33 
General procedure. Sodium hydride (1.5 eq) was dissolved in DMF (7-10 ml) 
and cooled with an ice bath under an inert atmosphere. A solution of 2-methyl-
5-nitro-1H-indole (7.1) (1 eq), dissolved in DMF (7-10 ml), was slowly added. 
After completion of the gas development (about 20 min) the pertinent iodoal-
kane (1 eq), dissolved in DMF (5 ml), was added with a dropping funnel. The 
reaction mixture was stirred for further 2 h at 0 °C. Then the solution was diluted 
with water (50 ml) and extracted three times with ethyl acetate (30 ml). The 
combined organic layers were dried over magnesium sulfate and concentrated 
in vacuo. 
 
2-Methyl-5-nitro-1-propyl-1H-indole (7.27) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), sodium hydride 
(110 mg, 2.75 mmol) and propyl iodide (0.17 ml, 1.74 mmol); purification by 
flash column chromatography on silica gel, elution with a 3:1 (v/v) mixture of 
petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.32 g (1.47 mmol, 86 %, yellow solid) 
Mp: 46.5-47.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.87 (t, 3H, 3J = 7.4 Hz, NC2H4CH3), 1.63-1.76 
(m, 2H, NCH2CH2CH3), 2.45 (d, 3H, 4J = 1.0 Hz, CH3), 4.16 (t, 2H, 3J = 7.3 Hz, 
NCH2-), 6.51 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 7.62 (ddd, 1H, 3J = 9.1 Hz, 
5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 7.95 (dd, 1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.43 
(d, 1H, 4J = 2.3 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 10.9 (+, (CH2)2CH3), 12.4 (+, CH3), 22.9 (-, 
CH2), 44.3 (-, CH2), 102.1 (+, indole), 109.8 (+, indole), 115.4 (+, indole), 115.9 
(+, indole), 126.6 (Cquart, indole), 139.4 (Cquart, indole), 140.4 (Cquart, indole), 
140.9 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 218 ([M•+], 55), 189 ([M - C2H5] +, 100), 143 ([M 
- C2H5 - NO2] +, 39) 
IR [cm-1]: 2969 (C-H) aliphatic, 2873 (C-H) aliphatic, 1317 (C-NO2) 
Analysis: C12H14N2O2 (218.26) 
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 calculated C: 66.04 H: 6.47 N: 12.84 
 found C: 66.05 H: 6.51 N: 12.60 
 
1-Hexyl-2-methyl-5-nitro-1H-indole (7.28) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.3 g, 1.70 mmol), sodium hydride 
(110 mg, 2.75 mmol) and hexyl iodide (0.26 ml, 1.75 mmol); purification by flash 
column chromatography on silica gel, elution with a 3:1 (v/v) mixture of petro-
leum ether (60-80 °C) and ethyl acetate. 
Yield: 0.41 g (1.57 mmol, 92 %, yellow solid) 
Mp: 63-64.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.83 (t, 3H, 3J = 7.0 Hz, N(CH2)5CH3), 1.20-1.32 
(m, 6H, N(CH2)2(CH2)3CH3), 1.59-1.71 (m, 2H, NCH2CH2-), 2.45 (d, 3H, 4J = 1.0 
Hz, CH3), 4.18 (t, 2H, 3J = 7.4 Hz, NCH2-), 6.51 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 
Hz, H-3), 7.60 (ddd, 1H, 3J = 9.1 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 7.95 (dd, 
1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.43 (d, 1H, 4J = 2.3 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.4 (+, CH3), 13.7 (+, (CH2)5CH3), 21.9 (-, 
CH2), 25.8 (-, CH2), 29.5 (-, CH2), 30.8 (-, CH2), 42.9 (-, CH2), 102.1 (+, indole), 
109.7 (+, indole), 115.4 (+, indole), 116.0 (+, indole), 126.6 (Cquart, indole), 139.3 
(Cquart, indole), 140.4 (Cquart, indole), 140.8 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 260 ([M•+], 45), 245 ([M - CH3] +, 13), 189 ([M - 
C5H11] +, 100), 143 ([M - C5H11 - NO2] +, 32) 
Analysis: C15H20N2O2 (260.34) 
 calculated C: 69.20 H: 7.74 N: 10.76 
 found C: 69.29 H: 7.91 N: 10.45 
 
2-Methyl-5-nitro-1-octyl-1H-indole (7.29) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.2 g, 1.14 mmol), sodium hydride 
(70 mg, 1.75 mmol) and octyl iodide (0.21 ml, 1.15 mmol); purification by flash 
column chromatography on silica gel, elution with a 3:1 (v/v) mixture of petro-
leum ether (60-80 °C) and ethyl acetate. 
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Yield: 0.29 g (1.01 mmol, 89 %, yellow solid) 
Mp: 62-63 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.83 (t, 3H, 3J = 6.9 Hz, N(CH2)7CH3), 1.15-1.30 
(m, 10H, N(CH2)2(CH2)5CH3), 1.59-1.71 (m, 2H, NCH2CH2-), 2.45 (d, 3H, 4J = 
1.0 Hz, CH3), 4.18 (t, 2H, 3J = 7.4 Hz, NCH2-), 6.51 (dq, 1H, 4J = 1.0 Hz, 5J = 
0.8 Hz, H-3), 7.59 (ddd, 1H, 3J = 9.1 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7), 7.95 (dd, 
1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.43 (d, 1H, 4J = 2.3 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.4 (+, CH3), 13.8 (+, (CH2)7CH3), 21.9 (-, 
CH2), 26.1 (-, CH2), 28.5 (-, 2CH2), 29.5 (-, CH2), 31.1 (-, CH2), 42.9 (-, CH2), 
102.1 (+, indole), 109.7 (+, indole), 115.4 (+, indole), 116.0 (+, indole), 126.6 
(Cquart, indole), 139.3 (Cquart, indole), 140.4 (Cquart, indole), 140.8 (Cquart, indole) 
MS (CI-MS, NH3): m/z (%) = 306 ([M + NH4] +, 75), 289 ([M + H] +, 100), 259 ([M 
+ H - NO] +, 12) 
Analysis: C17H24N2O2 (288.38) 
 calculated C: 70.80 H: 8.39 N: 9.71 
 found C: 70.93 H: 8.72 N: 9.39 
 
1-Decyl-2-methyl-5-nitro-1H-indole (7.30) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.50 g, 2.84 mmol), sodium hy-
dride (0.17 g, 4.26 mmol) and decyl iodide (7.44) (0.66 ml, 3.12 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 3:1 (v/v) mix-
ture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.88 g (2.78 mmol, 98 %, yellow solid) 
Mp: 54-55 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.83 (t, 3H, 3J = 6.8 Hz, N(CH2)9CH3), 1.15-1.30 
(m, 14H, N(CH2)2(CH2)7CH3), 1.59-1.72 (m, 2H, NCH2CH2-), 2.45 (d, 3H, 4J = 
1.0 Hz, CH3), 4.18 (t, 2H, 3J = 7.4 Hz, NCH2-), 6.51 (dq, 1H, 4J = 1.0 Hz, 5J = 
0.8 Hz, H-3), 7.59 (ddd, 1H, 3J = 9.1 Hz, 5J = 0.8, 5J = 0.5 Hz, H-7), 7.95 (dd, 
1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.42 (d, 1H, 4J = 2.3 Hz, H-4) 
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13C-NMR (DMSO-d6): δ [ppm] = 12.4 (+, CH3), 13.8 (+, (CH2)9CH3), 22.0 (-, 
CH2), 26.1 (-, CH2), 28.5 (-, 2CH2), 28.8 (-, 2CH2), 29.5(-, CH2), 31.1 (-, CH2), 
42.9 (-, CH2), 102.1 (+, indole), 109.7 (+, indole), 115.4 (+, indole), 116.0 (+, 
indole), 126.7 (Cquart, indole), 139.3 (Cquart, indole), 140.4 (Cquart, indole), 140.8 
(Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 316 ([M•+], 89), 301 ([M - CH3] +, 49), 287 ([M - 
C2H5] +, 5), 273 ([M - C3H7] +, 5), 259 ([M - C4H9] +, 5), 245 ([M - C5H11] +, 5), 231 
([M - C6H13] +, 10), 217 ([M - C7H15] +, 15), 203 ([M - C8H17] +, 15), 189 ([M - 
C9H19] +, 100), 143 ([M - C9H19 - NO2] +, 40) 
Analysis: C19H28N2O2 (316.44) 
 calculated C: 72.12 H: 8.92 N: 8.85 
 found C: 72.03 H: 8.72 N: 8.74 
 
2-Methyl-5-nitro-1-(3-phenylpropyl)-1H-indole (7.31) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.19 g, 1.08 mmol), sodium hy-
dride (70 mg, 1.75 mmol) and 1-iodo-3-phenylpropane (7.45) (0.34 g, 
1.38 mmol); purification by flash column chromatography on silica gel, elution 
with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.11 g (0.37 mmol, 35 %, yellow solid) 
Mp: 101-101.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.92-2.05 (m, 2H, NCH2CH2CH2Ph), 2.42 (d, 
3H, 4J = 1.0 Hz, CH3), 2.64 (t, 2H, 3J = 7.9 Hz, NCH2CH2CH2Ph), 4.22 (t, 2H, 3J 
= 7.6 Hz, NCH2-), 6.52 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 7.15-7.32 (m, 5H, 
Ar-H), 7.56 (ddd, 1H, 3J = 9.1 Hz, 5J = 0.8, 5J = 0.5 Hz, H-7), 7.95 (dd, 1H, 3J = 
9.1 Hz, 4J = 2.3 Hz, H-6), 8.43 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 31.1 (-, CH2), 32.1 (-, CH2), 42.6 
(-, CH2), 102.1 (+, indole), 109.6 (+, indole), 115.5 (+, indole), 116.0 (+, indole), 
125.9 (+, Ar-C), 126.7 (Cquart, indole), 128.1 (+, 2Ar-C), 128.3 (+, 2Ar-C), 139.3 
(Cquart, indole), 140.4 (Cquart, Ar-C), 140.8 (Cquart, indole), 140.9 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 294 ([M•+], 100), 189 ([M - C6H5C2H4] +, 77), 
143 ([M - C6H5C2H4 - NO2] +, 33), 91 ([C7H7] +, 48) 
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Analysis: C18H18N2O2 (294.35) 
 calculated C: 73.45 H: 6.16 N: 9.52 
 found C: 73.36 H: 6.28 N: 9.49 
 
2-Methyl-5-nitro-1-(4-phenylbenzyl)-1H-indole (7.32) 
Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.20 g, 1.14 mmol), sodium hy-
dride (70 mg, 1.75 mmol) and 4-phenylbenzyl iodide (7.46) (0.40 g, 1.36 mmol); 
purification by flash column chromatography on silica gel, elution with a 3:1 (v/v) 
mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.39 g (1.14 mmol, 99 %, yellow solid) 
Mp: 122-124.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.43 (d, 3H, 4J = 1.0 Hz, CH3), 5.58 (s, 2H, 
CH2), 6.64 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 7.06-7.09 (m, 2H, Ar-H), 
7.29-7.46 (m, 3H, Ar-H), 7.58-7.63 (m, 4H, Ar-H), 7.64 (ddd, 1H, 3J = 9.0 Hz, 5J 
= 0.8, 5J = 0.5 Hz, H-7), 7.97 (dd, 1H, 3J = 9.0 Hz, 4J = 2.3 Hz, H-6), 8.50 (d, 
1H, 4J = 2.3 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.5 (+, CH3), 45.8 (-, CH2), 102.6 (+, indole), 
110.0 (+, indole), 115.9 (+, indole), 116.1 (+, indole), 126.5 (+, 2Ar-C), 126.6 (+, 
2Ar-C), 126.9 (Cquart, indole), 127.0 (+, 2Ar-C), 127.4 (+, Ar-C), 128.8 (+, 2Ar-C), 
136.6 (Cquart, Ar-C) 139.2 (Cquart, Ar-C), 139.5 (Cquart, Ar-C), 139.8 (Cquart, in-
dole), 140.7 (Cquart, indole), 141.1 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 342 ([M•+], 29), 312 ([M - NO] +, 6), 167 ([C6H5 - 
C6H4 - CH2] +, 100) 
Analysis: C22H18N2O2 (342.39) 
 calculated C: 77.17 H: 5.30 N: 8.18 
 found C: 77.58 H: 5.67 N: 7.63 
 
Ethyl 5-(2-methyl-5-nitro-1H-indole-1-yl)pentanoate (7.33) 
2-Methyl-5-nitro-1H-indole (7.1) (1.50 g, 8.51 mmol), ethyl 5-bromopentanoate 
(1.88 ml, 11.88 mmol) and potassium carbonate (2.57 g, 18.59 mmol) were 
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mixed with acetonitrile (25 ml) under a nitrogen atmosphere and heated under 
reflux for 48 h. Water (25 ml) was poured into the mixture and it was extracted 
with ether (3x30 ml). The combined organic phases were washed with water 
(3x15 ml), dried over magnesium sulfate and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel eluting with a 
95:5 (v/v) mixture of chloroform and methanol. 
Yield: 2.38 g (7.82 mmol, 92 %, yellow solid) 
Mp: 56-57.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.14 (t, 3H, 3J = 7.1 Hz, CO2CH2CH3), 1.46-1.60 
(m, 2H, N(CH2)2CH2-), 1.61-1.74 (m, 2H, NCH2CH2-), 2.32 (t, 2H, 3J = 7.2 Hz, 
N(CH2)3CH2-), 2.45 (d, 3H, 4J = 1.0 Hz, CH3), 4.02 (q, 2H, 3J = 7.1 Hz, CO2CH2-
), 4.21 (t, 2H, 3J = 7.2 Hz, NCH2-), 6.51 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 
7.61 (ddd, 1H, 3J = 9.1 Hz, 5J = 0.8 Hz, 5J = 0.4 Hz, H-7), 7.95 (dd, 1H, 3J = 9.1 
Hz, 4J = 2.3 Hz, H-6), 8.43 (d, 1H, 4J = 2.3 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 14.0 (+, CH3), 21.6 (-, CH2), 28.9 
(-, CH2), 32.9 (-, CH2), 42.5 (-, CH2), 59.6 (-, CH2), 102.2 (+, indole), 109.7 (+, 
indole), 115.4 (+, indole), 116.0 (+, indole), 126.7 (Cquart, indole), 139.4 (Cquart, 
indole), 140.4 (Cquart, indole), 140.8 (Cquart, indole), 172.5 (Cquart, CO2Et) 
MS (PI-EIMS, 70 eV): m/z (%) = 304 ([M•+], 78), 289 ([M - CH3] +, 11), 259 ([M - 
OC2H5] +, 23), 217 ([M - CH2CO2Et] +, 22), 189 ([M - (CH2)3CO2Et] +, 100), 143 
([M - (CH2)3CO2Et - NO2] +, 38) 
Analysis: C16H20N2O4 (304.34) 
 calculated C: 63.14 H: 6.62 N: 9.20 
 found C: 63.30 H: 6.97 N: 8.91 
 
Reduction of the N-alkylated or N-acylated 2-methyl-5-nitro-1H-indole de-
rivatives (7.20-7.26 and 7.34-7.40) 
Method A. Preparation of the catalyst Ni2B: 
The catalyst was prepared just prior to use by dropwise addition of sodium 
borohydride (10 eq, 1.0 M solution in 0.1 M aqueous sodium hydroxide) to a 
stirred 0.1 M solution of nickel(II) acetate tetrahydrate (5 eq). After gas evolution 
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had completely ceased the aqueous solution was decanted, the black granular 
nickel boride was resuspended in distilled water, then again decanted. After 
several quick washings with water the catalyst was washed twice with ethanol 
and used like this for the reduction. 
Reduction: 
The freshly prepared catalyst, which was obtained as aforementioned from 5 eq 
of nickel(II) acetate tetrahydrate, was suspended in isopropyl alcohol (10 ml) 
and the pertinent 5-nitro-1H-indole derivative (1 eq), dissolved or suspended in 
isopropyl alcohol (7-10 ml), was added to form a 0.1 M solution. The reaction 
mixture was heated to reflux and a solution of hydrazine hydrate (10 eq) in iso-
propyl alcohol (5 ml) was added dropwise. After addition, reflux was continued 
for further 30 min. The mixture was allowed to cool down to room temperature 
before it was filtered through a pad of Celite. Afterwards, the filtrate was con-
centrated in vacuo, the residue was resumed in ethyl acetate (30 ml) and ex-
tracted three times with acetic acid (10%, 20 ml). The combined aqueous ex-
tracts were basified with concentrated ammonia solution (25%) and extracted 
three times with ethyl acetate (20 ml). The combined organic phases were dried 
over magnesium sulfate and the solvent was removed under reduced pressure. 
Method B. A mixture of the 5-nitro-1H-indole derivative (1 eq), dissolved in 
ethyl acetate (5 ml), and tin(II) chloride dihydrate (5 eq) was heated at 70 °C 
under a nitrogen atmosphere and stirred over night. After cooling, the mixture 
was diluted with ice-cold water (10 ml) and the pH is made slightly basic (pH = 
8) by an aqueous solution of sodium bicarbonate (5%). After stirring for 1 h the 
aqueous phase was extracted three times with ethyl acetate (20 ml). The com-
bined organic layers were washed with brine (15 ml), dried over magnesium 
sulfate and concentrated under reduced pressure. 
 
1-(5-Amino-2-methyl-1H-indol-1-yl)propan-1-one (7.20) 
Method B: Reaction of 2-methyl-5-nitro-1-propanoyl-1H-indole (7.12) (0.33 g, 
1.42 mmol) and tin(II) chloride dihydrate (1.60 g, 7.09 mmol); purification by 
flash column chromatography on silica gel, elution with a 50:50:1 (v/v) mixture 
of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
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Yield: 0.25 g (1.24 mmol, 87 %, red-brown solid) 
Mp: 74.5-76 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.15 (t, 3H, 3J = 7.2 Hz, CH2CH3), 2.55 (d, 3H, 
4J = 1.1 Hz, CH3), 2.97 (q, 2H, 3J = 7.2 Hz, COCH2CH3), 4.84 (br, 2H, NH2), 
6.24 (dq, 1H, 4J = 1.1 Hz, 5J = 0.8 Hz, H-3), 6.50 (dd, 1H, 3J = 8.8 Hz, 4J = 2.3 
Hz, H-6), 6.58 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4), 7.77 (ddd, 1H, 3J = 8.8 
Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 8.9 (+, COCH2CH3), 17.4 (+, CH3), 30.7 (-, 
CH2), 103.1 (+, indole), 109.0 (+, indole), 111.4 (+, indole), 116.0 (+, indole), 
128.6 (Cquart, indole), 130.3 (Cquart, indole), 136.6 (Cquart, indole), 144.4 (Cquart, 
indole), 173.4 (Cquart, COCH2CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 202 ([M•+], 40), 146 ([M - CH3 - CHCO] +, 100) 
IR [cm-1]: 3453 (N-H), 3355 (N-H), 2979 (C-H) aliphatic, 2921 (C-H) aliphatic, 
1691 (C=O) 
Analysis: C12H14N2O · 0.1 H2O (204.05) 
 calculated C: 70.64 H: 7.01 N: 13.73 
 found C: 70.50 H: 6.88 N: 13.49 
 
1-(5-Amino-2-methyl-1H-indol-1-yl)hexan-1-one (7.21) 
Method B: Reaction of 1-hexanoyl-2-methyl-5-nitro-1H-indole (7.13) (0.11 g, 
0.40 mmol) and tin(II) chloride dihydrate (0.45 g, 2.00 mmol); purification by 
flash column chromatography on silica gel, elution with a 50:50:1 (v/v) mixture 
of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.09 g (0.37 mmol, 92 %, brown solid) 
Mp: 85-87 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.89 (t, 3H, 3J = 6.9 Hz, CO(CH2)4CH3), 1.29-
1.38 (m, 4H, CO(CH2)2(CH2)2CH3), 1.62-1.73 (m, 2H, COCH2CH2-), 2.54 (d, 3H, 
4J = 1.1 Hz, CH3), 2.94 (t, 2H, 3J = 7.2 Hz, NCOCH2-), 4.84 (br, 2H, NH2), 6.24 
(dq, 1H, 4J = 1.1 Hz, 5J = 0.8 Hz, H-3), 6.50 (dd, 1H, 3J = 8.8 Hz, 4J = 2.3 Hz, H-
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6), 6.58 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4), 7.74 (ddd, 1H, 3J = 8.8 Hz, 5J = 
0.8 Hz, 5J = 0.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 13.8 (+ ,CO(CH2)4CH3), 17.4 (+, CH3), 22.0 (-, 
CH2), 24.0 (-, CH2), 30.6 (-, CH2), 37.3 (-, CH2), 103.1 (+, indole), 108.9 (+, in-
dole), 111.5 (+, indole), 115.9 (+, indole), 128.6 (Cquart, indole), 130.2 (Cquart, 
indole), 136.6 (Cquart, indole), 144.4 (Cquart, indole), 172.7 (Cquart, CO(CH2)4CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 244 ([M•+], 20), 146 ([M - C4H9CHCO] +, 100) 
C15H20N2O (244.33) 
 
1-(5-Amino-2-methyl-1H-indol-1-yl)decan-1-one (7.22) 
Method B: Reaction of 1-decanoyl-2-methyl-5-nitro-1H-indole (7.14) (0.13 g, 
0.39 mmol) and tin(II) chloride dihydrate (0.45 g, 1.99 mmol); purification by 
flash column chromatography on silica gel, elution with a 50:50:1 (v/v) mixture 
of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.10 g (0.33 mmol, 85 %, brown solid) 
Mp: 86-88 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.86 (t, 3H, 3J = 6.7 Hz, CO(CH2)8CH3), 1.20-
1.36 (m, 12H, CO(CH2)2(CH2)6CH3), 1.60-1.71 (m, 2H, COCH2CH2-), 2.54 (d, 
3H, 4J = 1.0 Hz, CH3), 2.94 (t, 2H, 3J = 7.1 Hz, NCOCH2-), 4.86 (br, 2H, NH2), 
6.24 (dq, 1H, 4J = 1.0 Hz, 5J = 0.8 Hz, H-3), 6.49 (dd, 1H, 3J = 8.8 Hz, 4J = 2.3 
Hz, H-6), 6.58 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4), 7.73 (ddd, 1H, 3J = 8.8 
Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 13.9 (+, CO(CH2)8CH3), 17.4 (+, CH3), 22.0 (-, 
CH2), 24.3 (-, CH2), 28.4 (-, CH2), 28.6 (-, CH2), 28.8 (-, CH2), 28.9 (-, CH2), 31.2 
(-, CH2), 37.3 (-, CH2), 103.1 (+, indole), 108.9 (+, indole), 111.5 (+, indole), 
115.9 (+, indole), 128.6 (Cquart, indole), 130.2 (Cquart, indole), 136.6 (Cquart, in-
dole), 144.3 (Cquart, indole), 172.7 (Cquart, CO(CH2)8CH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 300 ([M•+], 17), 146 ([M - C8H17CHCO] +, 100) 
C19H28N2O (300.44) 
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1-(5-Amino-2-methyl-1H-indol-1-yl)-3-phenylpropan-1-one (7.23) 
Method B: Reaction of 2-methyl-5-nitro-1-(3-phenylpropanoyl)-1H-indole (7.16) 
(0.16 g, 0.52 mmol) and tin(II) chloride dihydrate (0.59 g, 2.61 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.14 g (0.50 mmol, 97 %, brown solid) 
Mp: 68-70 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.52 (d, 3H, 4J = 1.1 Hz, CH3), 3.01 (t, 2H, 3J = 
7.4 Hz, COCH2CH2Ph), 3.30 (t, 2H, 3J = 7.4 Hz, COCH2CH2Ph), 4.82 (br, 2H, 
NH2), 6.25 (dq, 1H, 4J = 1.1 Hz, 5J = 0.8 Hz, H-3), 6.49 (dd, 1H, 3J = 8.8 Hz, 4J = 
2.3 Hz, H-6), 6.58 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4), 7.15-7.34 (m, 5H, Ar-
H), 7.74 (ddd, 1H, 3J = 8.8 Hz, 5J = 0.8 Hz, 5J = 0.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 17.3 (+, CH3), 30.1 (-, CH2), 38.9 (-, CH2), 
103.2 (+, indole), 109.0 (+, indole), 111.5 (+, indole), 115.9 (+, indole), 125.9 (+, 
Ar-C), 128.2 (+, 2Ar-C), 128.4 (+, 2Ar-C), 128.6 (Cquart, indole), 130.3 (Cquart, 
indole), 136.5 (Cquart, indole), 140.9 (Cquart, Ar-C), 144.5 (Cquart, indole), 171.9 
(Cquart, CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 278 ([M•+], 43), 146 ([M - C6H5CH2 - CHCO] +, 
100), 91 ([C7H7] +, 14)  
C18H18N2O (278.35) 
 
1-(5-Amino-2-methyl-1H-indol-1-yl)-4-phenylbutan-1-one (7.24) 
Method B: Reaction of 2-methyl-5-nitro-1-(4-phenylbutanoyl)-1H-indole (7.17) 
(0.24 g, 0.74 mmol) and tin(II) chloride dihydrate (0.84 g, 3.72 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.15 g (0.51 mmol, 69 %,brown oil) 
1H-NMR (DMSO-d6): δ [ppm] = 1.93-2.04 (m, 2H, COCH2CH2CH2Ph), 2.51 (d, 
3H, 4J = 1.0 Hz, CH3), 2.70 (t, 2H, 3J = 7.8 Hz, COCH2CH2CH2Ph), 2.97 (t, 2H, 
3J = 7.2 Hz, COCH2CH2CH2Ph), 4.83 (br, 2H, NH2), 6.24 (dq, 1H, 4J = 1.0 Hz, 
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5J = 0.8 Hz, H-3), 6.49 (dd, 1H, 3J = 8.8 Hz, 4J = 2.3 Hz, H-6), 6.58 (dd, 1H, 4J = 
2.3 Hz, 5J = 0.5 Hz, H-4), 7.12-7.33 (m, 5H, Ar-H), 7.70 (ddd, 1H, 3J = 8.8 Hz, 5J 
= 0.8 Hz, 5J = 0.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 17.3 (+, CH3), 26.2 (-, CH2), 34.3 (-, CH2), 36.8 
(-, CH2), 103.2 (+, indole), 109.0 (+, indole), 111.5 (+, indole), 115.9 (+, indole), 
125.7 (+, Ar-C), 128.2 (+, 4Ar-C), 128.5 (Cquart, indole), 130.3 (Cquart, indole), 
136.6 (Cquart, indole), 141.7 (Cquart, Ar-C), 144.4 (Cquart, indole), 172.4 (Cquart, 
CO) 
MS (PI-EIMS, 70 eV): m/z (%) = 292 ([M•+], 31), 146 ([M - C6H5(CH2)2-CHCO] +, 
100), 91 ([C7H7] +, 19) 
C19H20N2O (292.38) 
 
5-Amino-2-methyl-1H-indole (7.25) 
Method A: Reaction of 2-methyl-5-nitro-1H-indole (7.1) (0.29 g, 1.65 mmol), 
sodium borohydride (0.64 g, 16.92 mmol), nickel(II) acetate tetrahydrate 
(2.12 g, 8.52 mmol) and hydrazine hydrate (0.83 ml, 17.08 mmol); purification 
by flash column chromatography on silica gel, elution with a 100:1 (v/v) mixture 
of ethyl acetate and triethylamine. 
Yield: 0.17 g (1.16 mmol, 71 %, hazel solid) 
Mp: 147.5-148.5 °C (Lit. 158-159 °C230) 
1H-NMR (DMSO-d6): δ [ppm] = 2.28 (d, 3H, 4J = 0.9 Hz, CH3), 4.39 (br, 2H, 
NH2), 5.80-5.82 (m, 1H, H-3), 6.36 (dd, 1H, 3J = 8.4 Hz, 4J = 2.1 Hz, H-6), 6.55 
(ddd, 1H, 4J = 2.1 Hz, 5J = 0.7 Hz, 5J = 0.6 Hz, H-4), 6.93 (ddd, 1H, 3J = 8.4 Hz, 
5J = 0.8 Hz, 5J = 0.6 Hz, H-7), 10.36 (br, 1H, indole NH) 
MS (PI-EIMS, 70 eV): m/z (%) = 146 ([M•+], 100) 
C9H10N2 (146.19) 
 
1-(5-Amino-2-methylindolin-1-yl)propan-1-one (7.26) 
2-Methyl-5-nitro-1-propanoyl-1H-indole (7.12) (146 mg, 0.63 mmol) was dis-
solved in methanol (10 ml) and THF (2 ml) under an inert atmosphere. After 
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treatment with palladium (10% Pd) on charcoal, a 0.5 M methanolic solution of 
ammonium formate (6.5 ml) was added and the reaction was allowed to stir for 
1 h at room temperature. Afterwards, the reaction mixture was filtrated through 
a pad of celite and washed with ethyl acetate. The filtrate was concentrated un-
der reduced pressure and the remaining residue was treated with water (10 ml). 
After extraction with ethyl acetate (3x15 ml) the combined organic phases were 
dried over magnesium sulfate and concentrated in vacuo. The crude product 
was purified by column chromatography on silica gel eluting with ethyl acetate. 
The solid was obtained as hydrochloride. 
Yield: 0.10 g (0.49 mmol, 78 %, beige solid) 
Mp: > 200 °C decomposition 
1H-NMR (MeOD): δ [ppm] = 1.21 (t, 3H, 3J = 7.4 Hz, COCH2CH3), 1.28 (d, 2H, 
3J = 6.4 Hz, CHCH3), 2.48-2.82 (m, 3H, COCH2CH3, CH(CHCH3)), 3.46 (dd, 1H, 
2J = 17.0 Hz, 3J = 8.2 Hz, CH(CHCH3)), 4.66-4.80 (m, 1H, CHCH3), 7.20 (dd, 
1H, 3J = 8.5 Hz, 4J = 1.6 Hz, H-6), 7.28 (s, 1H, H-4), 8.17 (d, 1H, 3J = 8.5 Hz, H-
7) 
MS (PI-EIMS, 70 eV): m/z (%) = 204 ([M•+], 87), 148 ([M - CH3CHCO] +, 80), 
133 ([M - CH3CHCO - CH3] +, 100) 
C12H16N2O (204.27) 
 
5-Amino-2-methyl-1-propyl-1H-indole (7.34) 
Method A: Reaction of 2-methyl-5-nitro-1-propyl-1H-indole (7.27) (0.20 g, 
0.92 mmol), sodium borohydride (0.35 g, 9.25 mmol), nickel(II) acetate tetrahy-
drate (1.14 g, 4.58 mmol) and hydrazine hydrate (0.45 ml, 9.26 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.17 g (0.90 mmol, 99 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 7.4 Hz, N(CH2)2CH3), 1.56-1.69 
(m, 2H, NCH2CH2CH3), 2.31 (d, 3H, 4J = 0.9 Hz, CH3), 3.93 (t, 2H, 3J = 7.3 Hz, 
NCH2-), 4.45 (br, 2H, NH2), 5.89 (dq, 1H, 4J = 0.9 Hz, 5J = 0.8 Hz, H-3), 6.42 
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(dd, 1H, 3J = 8.5 Hz, 4J = 2.2 Hz, H-6), 6.58 (dd, 1H, 4J = 2.1 Hz, 5J = 0.6 Hz, H-
4), 7.04 (ddd, 1H, 3J = 8.5 Hz, 5J = 0.8 Hz, 5J = 0.6 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 11.1 (+, (CH2)2CH3), 12.3 (+, CH3), 23.0 (-, 
CH2), 43.7 (-, CH2), 98.0 (+, indole), 102.9 (+, indole), 109.3 (+, indole), 110.2 
(+, indole), 128.3 (Cquart, indole), 130.3 (Cquart, indole), 135.7 (Cquart, indole), 
140.8 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 188 ([M•+], 58), 159 ([M - C2H5] +, 100), 145 ([M 
- C3H7] +, 8) 
IR [cm-1]: 3413 (N-H), 3340 (N-H), 3017 (C-H) aromatic, 2962 (C-H) aliphatic, 
2931 (C-H) aliphatic, 2873 (C-H) aliphatic 
Analysis: C12H16N2 · 0.1 H2O (190.07) 
 calculated C: 75.83 H: 8.58 N: 14.74 
 found C: 75.62 H: 8.19 N: 14.43 
 
5-Amino-1-hexyl -2-methyl-1H-indole (7.35) 
Method A: Reaction of 1-hexyl-2-methyl-5-nitro-1H-indole (7.28) (0.20 g, 
0.77 mmol), sodium borohydride (0.29 g, 7.67 mmol), nickel(II) acetate tetrahy-
drate (0.96 g, 3.86 mmol) and hydrazine hydrate (0.37 ml, 7.61 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.09 g (0.39 mmol, 51 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J =6.8 Hz, N(CH2)5CH3), 1.20-1.30 
(m, 6H, N(CH2)2(CH2)3CH3), 1.51-1.65 (m, 2H, NCH2CH2-), 2.30 (d, 3H, 4J = 0.9 
Hz, CH3), 3.95 (t, 2H, 3J = 7.3 Hz, NCH2-), 4.43 (br, 2H, NH2), 5.88 (dq, 1H, 4J = 
0.9 Hz, 5J = 0.8 Hz, H-3), 6.42 (dd, 1H, 3J = 8.5 Hz, 4J = 2.1 Hz, H-6), 6.56 (dd, 
1H, 4J = 2.1 Hz, 5J = 0.6 Hz, H-4), 7.02 (ddd, 1H, 3J = 8.5 Hz, 5J = 0.8 Hz, 5J = 
0.6 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.8 (+, (CH2)5CH3), 22.0 (-, 
CH2), 25.9 (-, CH2), 29.7 (-, CH2), 30.9 (-, 2CH2), 42.2 (-, CH2), 98.0 (+, indole), 
102.9 (+, indole), 109.2 (+, indole), 110.2 (+, indole), 128.3 (Cquart, indole), 130.2 
(Cquart, indole), 135.6 (Cquart, indole), 140.9 (Cquart, indole) 
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MS (PI-EIMS, 70 eV): m/z (%) = 230 ([M•+], 83), 159 ([M - C5H11] +, 100), 145 
([M - C6H13] +, 8) 
C15H22N2 (230.35) 
 
5-Amino-2-methyl-1-octyl-1H-indole (7.36) 
Method B: Reaction of 2-methyl-5-nitro-1-octyl-1H-indole (7.29) (0.14 g, 
0.49 mmol) and tin(II) chloride dihydrate (0.55 g, 2.44 mmol); purification by 
flash column chromatography on silica gel, elution with a 50:50:1 (v/v) mixture 
of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.07 g (0.27 mmol, 56 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 6.7 Hz, N(CH2)7CH3), 1.18-1.31 
(m, 10H, N(CH2)2(CH2)5CH3), 1.54-1.65 (m, 2H, NCH2CH2-), 2.30 (d, 3H, 4J = 
0.9 Hz, CH3), 3.94 (t, 2H, 3J = 7.3 Hz, NCH2-), 4.52 (br, 2H, NH2), 5.88 (dq, 1H, 
4J = 0.9 Hz, 5J = 0.6 Hz, H-3), 6.42 (dd, 1H, 3J = 8.5 Hz, 4J = 2.2 Hz, H-6), 6.57 
(dd, 1H, 4J = 2.2 Hz, 5J = 0.6 Hz, H-4), 7.02 (ddd, 1H, 3J = 8.5 Hz, 5J = 0.6 Hz, 
5J = 0.8 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.8 (+, (CH2)7CH3), 22.0 (-, 
CH2), 26.2 (-, CH2), 28.6 (-, 2CH2), 29.7(-, CH2), 31.1 (-, CH2), 42.2 (-, CH2), 
98.0 (+, indole), 102.9 (+, indole), 109.2 (+, indole), 110.2 (+, indole), 128.3 
(Cquart, indole), 130.2 (Cquart, indole), 135.6 (Cquart, indole), 140.9 (Cquart, indole) 
MS (CI-MS, NH3): m/z (%) = 259 ([M + H] +, 100) 
C17H26N2 (258.40) 
 
5-Amino-1-decyl-2-methyl-1H-indole (7.37) 
Method B: Reaction of 1-decyl-2-methyl-5-nitro-1H-indole (7.30) (0.88 g, 
2.78 mmol) and tin(II) chloride dihydrate (3.14 g, 13.90 mmol); purification by 
flash column chromatography on silica gel, elution with a 50:50:1 (v/v) mixture 
of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.49 g (1.71 mmol, 62 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 0.85 (t, 3H, 3J =6.8 Hz, N(CH2)9CH3), 1.18-1.31 
(m, 14H, N(CH2)2(CH2)7CH3), 1.51-1.65 (m, 2H, NCH2CH2-), 2.30 (d, 3H, 4J = 
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0.9 Hz, CH3), 3.94 (t, 2H, 3J = 7.3 Hz, NCH2-), 4.44 (br, 2H, NH2), 5.88 (dq, 1H, 
4J = 0.9 Hz, 5J = 0.8 Hz, H-3), 6.42 (dd, 1H, 3J = 8.5 Hz, 4J = 2.1 Hz, H-6), 6.56 
(dd, 1H, 4J = 2.1 Hz, 5J = 0.6 Hz, H-4), 7.01 (ddd, 1H, 3J = 8.5 Hz, 5J = 0.8 Hz, 
5J =0.6 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.9 (+, (CH2)9CH3), 22.0 (-, 
CH2), 26.2 (-, CH2), 28.6 (-, CH2), 28.7 (-, CH2), 28.8 (-, CH2), 28.9 (-, CH2), 29.7 
(-, CH2), 31.2 (-, CH2), 42.2 (-, CH2), 98.0 (+, indole), 102.8 (+, indole), 109.2 (+, 
indole), 110.2 (+, indole), 128.3 (Cquart, indole), 130.2 (Cquart, indole), 135.6 
(Cquart, indole), 140.9 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 286 ([M•+], 100), 159 ([M - C9H19] +, 73) 
Analysis: C19H30N2 · 0.1 H2O (288.25) 
 calculated C: 79.17 H: 10.55 N: 9.72 
 found C: 79.15 H: 10.74 N: 9.38 
 
5-Amino-2-methyl-1-(3-phenylpropyl)-1H-indole (7.38) 
Method B: Reaction of 2-methyl-5-nitro-1-(3-phenylpropyl)-1H-indole (7.31) 
(0.05 g, 0.17 mmol) and tin(II) chloride dihydrate (0.19 g, 0.84 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 22 mg (0.08 mmol, 49 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 1.83-1.96 (m, 2H, NCH2CH2CH2Ph), 2.27 (d, 
3H, 4J = 0.9 Hz, CH3), 2.60 (t, 2H, 3J = 7.8 Hz, NCH2CH2CH2Ph), 3.99 (t, 2H, 3J 
= 7.5 Hz, NCH2CH2CH2Ph), 4.48 (br, 2H, NH2), 5.89 (dq, 1H, 4J = 0.9 Hz, 5J = 
0.8 Hz, H-3), 6.41 (dd, 1H, 3J = 8.6 Hz, 4J = 2.2 Hz, H-6), 6.57 (dd, 1H, 4J = 2.2 
Hz, 5J = 0.6 Hz, H-4), 6.97 (ddd, 1H, 3J = 8.6 Hz, 5J = 0.8 Hz, 5J = 0.6 Hz, H-7), 
7.10-7.32 (m, 5H, Ar-H) 
13C-NMR (DMSO-d6): δ [ppm] = 12.2 (+, CH3), 31.3 (-, CH2), 32.2 (-, CH2), 41.9 
(-, CH2), 98.1 (+, indole), 102.9 (+, indole), 109.1 (+, indole), 110.2 (+, indole), 
125.8 (+, Ar-C), 128.1 (+, 2Ar-C), 128.2 (+, 2Ar-C), 128.3 (Cquart, indole), 130.2 
(Cquart, indole), 135.7 (Cquart, indole), 141.0 (Cquart, indole), 141.3 (Cquart, Ar-C) 
MS (CI-MS, NH3): m/z (%) = 265 ([M + H] +, 100) 
C18H20N2 (264.36) 
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5-Amino-2-methyl-1-(4-phenylbenzyl)-1H-indole (7.39) 
Method B: Reaction of 2-methyl-5-nitro-1-(4-phenylbenzyl)-1H-indole (7.32) 
(0.10 g, 0.29 mmol) and tin(II) chloride dihydrate (0.33 g, 1.46 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.06 g (0.19 mmol, 66 %, brown liquid) 
1H-NMR (DMSO-d6): δ [ppm] = 2.31 (d, 3H, 4J = 0.9 Hz, CH3), 4.50 (br, 2H, 
NH2), 5.31 (s, 2H, NCH2-), 6.01 (dq, 1H, 4J = 0.9 Hz, H-3), 6.41 (dd, 1H, 3J = 8.5 
Hz, 4J = 2.3 Hz, H-6), 6.62 (dd, 1H, 4J = 2.2 Hz, 5J = 0.6 Hz, H-4), 7.01-7.06 (m, 
3H, Ph-H), 7.29-7.37 (m, 1H, Ph-H), 7.40-7.46 (m, 2H, Ph-H), 7.54-7.62 (m, 3H, 
Ph-H), 7.56 (d, 1H, 3J = 8.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 12.4 (+, CH3), 45.2 (-, CH2), 98.7 (+, indole), 
102.9 (+, indole), 109.6 (+, indole), 110.5 (+, indole), 126.5 (+, 2Ph-C), 126.6 (+, 
2Ph-C), 126.7 (+, 2Ph-C), 127.3 (+, Ph-C), 128.5 (Cquart, indole), 128.8 (+, 2Ph-
C), 130.6 (Cquart, indole), 136.0 (Cquart, indole), 138.0 (Cquart, Ph-C), 138.8 (Cquart, 
Ph-C), 139.7 (Cquart, Ph-C), 141.4 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 312 ([M•+], 73), 167 ([C6H5 - C6H4 - CH2] +, 100) 
C22H20N2 (312.41) 
 
Ethyl 5-(5-amino-2-methyl-1H-indol-1-yl)pentanoate (7.40) 
Method B: Reaction of ethyl 5-(2-methyl-5-nitro-1H-indole-1-yl)pentanoate 
(7.33) (0.20 g, 0.66 mmol) and tin(II) chloride dihydrate (0.74 g, 3.28 mmol); 
purification by flash column chromatography on silica gel, elution with a 50:50:1 
(v/v) mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.10 g (0.36 mmol, 55 %, dark red oil) 
1H-NMR (DMSO-d6): δ [ppm] = 1.15 (t, 3H, 3J = 7.1 Hz, CO2CH2CH3), 1.45-1.67 
(m, 4H, NCH2(CH2)2-), 2.30 (t, 2H, 3J = 7.2 Hz, N(CH2)3CH2-), 2.30 (d, 3H, 4J = 
0.9 Hz, CH3), 3.97 (t, 2H, 3J = 7.2 Hz, NCH2-), 4.02 (q, 2H, 3J = 7.1 Hz, 
CO2CH2-), 4.39 (br, 2H, NH2), 5.89 (dq, 1H, 4J = 0.9 Hz, 5J = 0.8 Hz, H-3), 6.42 
(dd, 1H, 3J = 8.6 Hz, 4J = 2.1 Hz, H-6), 6.56 (dd, 1H, 4J = 2.1 Hz, 5J = 0.6 Hz, H-
4), 7.03 (ddd, 1H, 3J = 8.6 Hz, 5J = 0.8 Hz, 5J = 0.6 Hz, H-7) 
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13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 14.0 (+, CH3), 21.8 (-, CH2), 29.1 
(-, CH2), 33.0 (-, CH2), 41.9 (-, CH2), 59.6 (-, CH2), 98.1 (+, indole), 102.8 (+, 
indole), 109.2 (+, indole), 110.2 (+, indole), 128.3 (Cquart, indole), 130.2 (Cquart, 
indole), 135.6 (Cquart, indole), 141.0 (Cquart, indole), 172.6 (Cquart, CO2Et) 
MS (CI-MS, NH3): m/z (%) = 275 ([M + H] +, 100) 
C16H22N2O2 (274.36) 
 
Preparation of the iodides 7.44-7.46 by Finkelstein reaction 
General procedure. Sodium iodide (1.3 eq) was suspended with dry acetone 
(10 ml) and heated under reflux. After complete dissolution of sodium iodide the 
alkyl halide (1 eq) was slowly added. Subsequently, the reaction mixture was 
refluxed for further 4 h. Afterwards the cooled mixture was mixed with diethyl 
ether (20 ml) and filtrated, and the filtrate was concentrated in vacuo. The resi-
due was dissolved in diethyl ether (25 ml) and washed successively with a solu-
tion of sodium hydroxide (2%, 2x15 ml), water (15 ml) and a saturated solution 
of sodium chloride (15 ml). The organic phase was dried over magnesium sul-
fate and the solvent was removed under reduced pressure. The obtained crude 
product was used for further reactions without purification. 
1-Iododecane (7.44) 
Reaction of 1-bromodecane (7.41) (2.08 ml, 10.00 mmol) and sodium iodide 
(1.95 g, 13.01 mmol). 
Yield: 2.54 g, colorless liquid 
1H-NMR (DMSO-d6): δ [ppm] = 0.86 (t, 3H, 3J = 6.7 Hz, CH3), 1.20-1.38 (m, 
14H, CH3(CH2)7-), 1.69-1.79 (m, 2H, ICH2CH2-), 3.27 (t, 2H, 3J = 6.9 Hz, ICH2-) 
MS (PI-EIMS, 70 eV): m/z (%) = 268 ([M•+], 3), 155 ([C2H4I] +, 5), 141 ([M - I] +, 
10), 99 ([C7H15] +, 10), 85 ([C6H13] +, 57), 71 ([C5H11] +, 58), 57 ([C4H9] +, 100), 43 
([C3H7] +, 97) 
C10H21I (268.18) 
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1-Iodo-3-phenylpropane (7.45) 
Reaction of 1-chloro-3-phenylpropane (7.42) (0.72 ml, 5.02 mmol) and sodium 
iodide (0.98 g, 6.54 mmol). 
Yield: 0.98 g, light brown liquid 
1H-NMR (DMSO-d6): δ [ppm] = 1.96-2.06 (m, 2H, PhCH2CH2CH2I), 2.75 (t, 2H, 
3J = 7.7 Hz, PhCH2CH2CH2I), 3.61 (t, 2H, 3J = 6.5 Hz, PhCH2CH2CH2I), 7.16-
7.33 (m, 5H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 246 ([M•+], 20), 119 ([M - I] +, 9), 117 ([M - I] +, 
6), 91 ([C7H7] +, 100) 
C9H11I (246.09) 
 
4-Phenylbenzyliodide (7.46) 
Reaction of 4-phenylbenzyl chloride (7.43) (0.40 g, 1.97 mmol) and sodium io-
dide (0.39 g, 2.60 mmol). 
Yield: 0.53 g, beige solid 
1H-NMR (DMSO-d6): δ [ppm] = 4.70 (s, 2H, CH2), 7.34-7.78 (m, 9H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 294 ([M•+], 1), 167 ([M - I] +, 100), 165 ([M - I] +, 
19) 
C13H11I (294.13) 
 
Synthesis of sulfonamide derivatives of 5-amino-1-decyl-2-methyl-1H-in-
dole 7.37 (7.47-7.48) 
General procedure. 5-Amino-1-decyl-2-methyl-1H-indole (7.37) (1 eq) was dis-
solved in pyridine (5 ml) under an inert atmosphere. The pertinent sulfonyl chlo-
ride or sulfamoyl chloride, respectively, (1.1 eq) was added dropwise and the 
mixture was allowed to stir for further 2 h at room temperature. Afterwards, ethyl 
acetate (20 ml) was added and the mixture was extracted three times with a 
solution of hydrochloric acid (3 M, 20 ml). The organic phase was washed with 
water (20 ml), dried over magnesium sulfate and concentrated in vacuo. 
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N-(1-Decyl-2-methyl-1H-indol-5-yl)methanesulfonamide (7.47) 
Reaction of 5-amino-1-decyl-2-methyl-1H-indole (7.37) (0.08 g, 0.28 mmol) and 
methanesulfonyl chloride (0.024 ml, 0.31 mmol); purification by flash column 
chromatography on silica gel, elution with a 2:1 (v/v) mixture of petroleum ether 
(60-80 °C) and ethyl acetate. 
Yield: 0.06 g (0.16 mmol, 59 %, red-pink oil) 
1H-NMR (DMSO-d6): δ [ppm] = 0.85 (t, 3H, 3J = 6.7 Hz, N(CH2)9CH3), 1.20-1.29 
(m, 14H, N(CH2)2(CH2)7CH3), 1.57-1.68 (m, 2H, NCH2CH2-), 2.38 (d, 3H, 4J = 
0.9 Hz, CH3), 2.84 (s, 3H, SO2CH3), 4.06 (t, 2H, 3J = 7.5 Hz, NCH2-), 6.17 (dq, 
1H, 4J = 0.9 Hz, 5J = 0.7 Hz, H-3), 6.94 (dd, 1H, 3J = 8.7 Hz, 4J = 2.1 Hz, H-6), 
7.27 (dd, 1H, 4J = 2.1 Hz, 5J = 0.4 Hz, H-4), 7.33 (d, 1H, 3J = 8.7 Hz, H-7), 9.21 
(s, 1H, NH) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.9 (+, CH3), 14.0 (+, CH3), 
22.0 (-, CH2), 26.2 (-, CH2), 28.6 (-, 2CH2), 28.8 (-, CH2), 28.9 (-, CH2), 29.7 (-, 
CH2), 31.2 (-, CH2), 42.4 (-, CH2), 99.3 (+, indole), 109.5 (+, indole), 113.1 (+, 
indole), 116.1 (+, indole), 127.6 (Cquart, indole), 129.5 (Cquart, indole), 134.1 
(Cquart, indole), 137.5 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 364 ([M•+], 22), 285 ([M - SO2CH3] +, 100) 
C20H32N2O2S (364.55) 
 
N’-(1-Decyl-2-methyl-1H-indol-5-yl)-N,N-dimethylsulfamide (7.48) 
Reaction of 5-amino-1-decyl-2-methyl-1H-indole (7.37) (0.08 g, 0.28 mmol) and 
N,N-dimethylsulfamoyl chloride (0.033 ml, 0.31 mmol); purification by flash col-
umn chromatography on silica gel, elution with a 2:1 (v/v) mixture of petroleum 
ether (60-80 °C) and ethyl acetate. 
Yield: 0.05 g (0.13 mmol, 45 %, brown oil) 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 6.6 Hz, N(CH2)9CH3), 1.20-1.29 
(m, 14H, N(CH2)2(CH2)7CH3), 1.56-1.67 (m, 2H, NCH2CH2-), 2.37 (d, 3H, 4J = 
0.9 Hz, CH3), 2.63 (s, 6H, N(CH3)2), 4.04 (t, 2H, 3J = 7.2 Hz, NCH2-), 6.14 (dq, 
1H, 4J = 0.9 Hz, 5J = 0.5 Hz, H-3), 6.96 (dd, 1H, 3J = 8.6 Hz, 4J = 2.2 Hz, H-6), 
7.27 (d, 1H, 4J = 2.2 Hz, H-4), 7.28 (d, 1H, 3J = 8.6 Hz, H-7), 9.42 (s, 1H, NH) 
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13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.9 (+, CH3), 22.0 (-, CH2), 26.2 
(-, CH2), 28.5 (-, CH2), 28.6 (-, CH2), 28.8 (-, CH2), 28.9 (-, CH2), 29.7 (-, CH2), 
31.2 (-, CH2), 37.8 (+, N(CH3)2), 42.4 (-, CH2), 99.3 (+, indole), 109.3 (+, indole), 
112.3 (+, indole), 115.5 (+, indole), 127.4 (Cquart, indole), 129.7 (Cquart, indole), 
133.8 (Cquart, indole), 137.3 (Cquart, indole) 
MS (PI-EIMS, 70 eV): m/z (%) = 393 ([M•+], 22), 285 ([M - SO2N(CH3)2] +, 100) 
C21H35N3O2S (393.59) 
 
N-Ethyl-N’-(1-decyl-2-methyl-1H-indol-5-yl)urea (7.49) 
5-Amino-1-decyl-2-methyl-1H-indole (7.37) (0.08 g, 0.28 mmol) was dissolved 
in acetonitrile (5 ml) under a nitrogen atmosphere. Ethyl isocyanate (0.025 ml, 
0.31 mmol) was added dropwise and the reaction mixture was stirred for 1 h at 
room temperature. The reaction was quenched with water (5 ml) and the mix-
ture was extracted two times with ethyl acetate (10 ml). The combined organic 
phases were dried over magnesium sulfate and the solvent was removed under 
reduced pressure. The crude product was purified by flash column chromatog-
raphy on silica gel eluting with ethyl acetate. 
Yield: 0.10 g (0.28 mmol, 99 %, beige solid) 
Mp: 116-117.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 6.8 Hz, N(CH2)9CH3), 1.04 (t, 
3H, 3J = 7.2 Hz, NHCH2CH3), 1.20-1.29 (m, 14H, N(CH2)2(CH2)7CH3), 1.55-1.65 
(m, 2H, NCH2CH2-), 2.35 (d, 3H, 4J = 0.9 Hz, CH3), 3.10 (dq, 2H, 3J = 7.2 Hz, 3J 
= 5.7 Hz, NHCH2CH3), 4.02 (t, 2H, 3J = 7.1 Hz, NCH2-), 5.91 (t, 1H, 3J = 5.7 Hz, 
NHCH2), 6.06 (dq, 1H, 4J = 0.9 Hz, 5J = 0.7 Hz, H-3), 6.94 (dd, 1H, 3J = 8.8 Hz, 
4J = 1.9 Hz, H-6), 7.19 (d, 1H, 3J = 8.8 Hz, H-7), 7.46 (d, 1H, 4J = 1.9 Hz, H-4), 
8.05 (s, 1H, NH) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 13.9 (+, CH3), 15.5 (+, CH3), 
22.0 (-, CH2), 26.2 (-, CH2), 28.6 (-, CH2), 28.7 (-, CH2), 28.8 (-, CH2), 28.9 (-, 
CH2), 29.7 (-, CH2), 31.2 (-, CH2), 33.9 (-, NHCH2CH3), 42.3 (-, CH2), 99.0 (+, 
indole), 108.7 (+, indole), 108.9 (+, indole), 113.1 (+, indole), 127.4 (Cquart, in-
dole), 132.3 (Cquart, 2 indole-C), 136.5 (Cquart, indole), 155.6 (Cquart, -NHCONH-) 
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MS (PI-EIMS, 70 eV): m/z (%) = 357 ([M•+], 100), 286 ([M - CH3CH2NCO] +, 80), 
230 ([M - C9H19] +, 7), 159 ([M - C9H19 - CH3CH2NCO] +, 57) 
Analysis: C22H35N3O · 0.1 H2O (359.13) 
 calculated C: 73.58 H: 9.87 N: 11.70 
 found C: 73.42 H: 10.09 N: 11.46 
 
Synthesis of the 3-acylated 1H-indoles 7.50-7.53 
General procedure. The particular N-substituted 2-methyl-5-nitro-1H-indole 
(1 eq) was dissolved in dry dichloromethane (5-10 ml) and cooled in an ice-
bath. The corresponding acid chloride (1 eq) and tin(IV) chloride (1 eq) was 
added consecutively. Then, the ice-bath was removed and the solution was 
stirred for 4 h at ambient temperature. Ice-cold water (20 ml) was poured into 
the reaction mixture. After extraction with ethyl acetate (3x15 ml), the organic 
layers were combined, washed with a solution of sodium hydroxide (0.1 N, 
15 ml), dried over magnesium sulfate and evaporated under reduced pressure. 
 
1-(2-Methyl-5-nitro-1-propyl-1H-indol-3-yl)-3-phenylpropan-1-one (7.50) 
Reaction of 2-methyl-5-nitro-1-propyl-1H-indole (7.27) (0.13 g, 0.60 mmol), 3-
phenylpropanoyl chloride (0.09 ml, 0.60 mmol) and tin(IV) chloride (0.07 ml, 
0.60 mmol); purification by flash column chromatography on silica gel, elution 
with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.11 g (0.31 mmol, 53 %, yellow solid) 
Mp: 106-108 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.89 (t, 3H, 3J = 7.4 Hz, N(CH2)2CH3), 1.64-1.77 
(m, 2H, NCH2CH2CH3), 2.78 (s, 3H, CH3), 3.00 (t, 2H, 3J = 7.4 Hz, 
COCH2CH2Ph), 3.33 (t, 2H, 3J = 7.4 Hz, COCH2CH2Ph), 4.29 (t, 2H, 3J = 7.3 
Hz, NCH2-), 7.15-7.21 (m, 1H, Ph-H), 7.26-7.35 (m, 4H, Ph-H), 7.81 (dd, 1H, 3J 
= 9.1 Hz, 4J = 0.4 Hz, H-7), 8.09 (dd, 1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.96 (d, 
1H, 4J = 2.3 Hz, H-4) 
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13C-NMR (DMSO-d6): δ [ppm] = 10.8 (+, CH3), 12.9 (+, CH3), 22.5 (-, CH2), 29.4 
(-, CH2), 43.6 (-, CH2), 44.4 (-, CH2), 111.0 (+, indole), 114.6 (Cquart, indole-C3), 
117.0 (+, indole), 117.2 (+, indole), 125.1 (Cquart, indole), 125.7 (+, Ph-C), 128.2 
(+, 2Ph-C), 128.4 (+, 2Ph-C), 138.8 (Cquart, indole), 141.5 (Cquart, indole), 142.4 
(Cquart, indole), 147. 8 (Cquart, Ph-C), 194.7 (Cquart, CO(CH2)2-) 
MS (PI-EIMS, 70 eV): m/z (%) = 350 ([M•+], 49), 245 ([M - C6H5CH2CH2] +, 100), 
218 ([M - C6H5CH2CHCO] +, 55) 
Analysis: C21H22N2O3 (350.41) 
 calculated C: 71.98 H: 6.33 N: 7.99 
 found C: 71.60 H: 6.25 N: 7.79 
 
Ethyl 5-(3-m-chlorobenzoyl-2-methyl-5-nitro-1H-indol-1-yl)pentanoate 
(7.51) 
Reaction of Ethyl 5-(2-methyl-5-nitro-1H-indole-1-yl)pentanoate (7.33) (0.30 g, 
0.99 mmol), m-chlorobenzoyl chloride (0.13 ml, 1.01 mmol) and tin(IV) chloride 
(0.12 ml, 1.02 mmol); purification by flash column chromatography on silica gel, 
successive elution with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and 
ethyl acetate and then with dichloromethane. 
Yield: 0.18 g (0.41 mmol, 41 %, yellow solid) 
1H-NMR (DMSO-d6): δ [ppm] = 1.14 (t, 3H, 3J = 7.1 Hz, CO2CH2CH3), 1.52-1.66 
(m, 2H, N(CH2)2(CH2)-), 1.68-1.80 (m, 2H, NCH2CH2-), 2.35 (t, 2H, 3J = 7.3 Hz, 
N(CH2)3CH2-), 2.46 (s, 3H, CH3), 4.03 (q, 2H, 3J = 7.1 Hz, CO2CH2-), 4.34 (t, 
2H, 3J = 7.3 Hz, NCH2-), 7.53-7.64 (m, 2H, Ph-H), 7.67-7.76 (m, 2H, Ph-H), 
7.86 (dd, 1H, 3J = 9.1 Hz, 5J = 0.5 Hz, H-7), 8.10 (dd, 1H, 3J = 9.1 Hz, 4J = 2.3 
Hz, H-6), 8.29 (dd, 1H, 4J = 2.3 Hz, 5J = 0.5 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 12.7 (+, CH3), 14.0 (+, CH3), 21.5 (-, CH2), 28.3 
(-, CH2), 32.8 (-, CH2), 43.0 (-, CH2), 59.7 (-, CH2), 111.1 (+, indole), 113.6 
(Cquart, indole-C3), 116.2 (+, indole), 117.4 (+, indole), 125.8 (Cquart, indole-C3a), 
127.1 (+, Ph-C), 127.9 (+, Ph-C), 130.5 (+, Ph-C), 131.6 (+, Ph-C), 133.4 (Cquart, 
Ph-C), 138.9 (Cquart, Ph-C), 142.2 (Cquart, indole), 142.3 (Cquart, indole), 148.4 
(Cquart, indole), 172.5 (Cquart, CO2Et), 189.5 (Cquart, COPh(3-Cl)) 
Chapter 7 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 184 
MS (PI-EIMS, 70 eV): m/z (%) = 442 ([M•+], 30), 397 ([M - OC2H5] +, 28), 355 
([M - CH2CO2C2H5] +, 16), 327 ([M - (CH2)3CO2Et] +, 35), 313 ([M - (CH2)4CO2Et] 
+, 71), 139 ([ClC6H4CO] +, 100) 
C23H23ClN2O5 (442.89) 
 
Ethyl 5-(2-methyl-5-nitro-3-propanoyl-1H-indol-1-yl)pentanoate (7.52) 
Reaction of Ethyl 5-(2-methyl-5-nitro-1H-indole-1-yl)pentanoate (7.33) (0.30 g, 
0.99 mmol), propionyl chloride (0.09 ml, 1.03 mmol) and tin(IV) chloride 
(0.12 ml, 1.02 mmol); purification by flash column chromatography on silica gel, 
elution with a 1:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.29 g (0.80 mmol, 82 %, yellow solid) 
Mp: 83-84 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.13 (t, 3H, 3J = 7.2 Hz, COCH2CH3), 1.14 (t, 
3H, 3J = 7.1 Hz, CO2CH2CH3), 1.51-1.62 (m, 2H, N(CH2)2(CH2)-), 1.64-1.75 (m, 
2H, NCH2CH2-), 2.34 (t, 2H, 3J = 7.2 Hz, N(CH2)3CH2-), 2.79 (s, 3H, CH3), 3.02 
(q, 2H, 3J = 7.2 Hz, COCH2CH3), 4.02 (q, 2H, 3J = 7.1 Hz, CO2CH2-), 4.34 (t, 
2H, 3J = 7.2 Hz, NCH2-), 7.81 (dd, 1H, 3J = 9.1 Hz, 5J = 0.4 Hz, H-7), 8.10 (dd, 
1H, 3J = 9.1 Hz, 4J = 2.4 Hz, H-6), 8.97 (dd, 1H, 4J = 2.4 Hz, 5J = 0.4 Hz, H-4) 
13C-NMR (DMSO-d6): δ [ppm] = 8.0 (+, CH3), 12.8 (+, CH3), 14.0 (+, CH3), 21.5 
(-, CH2), 28.5 (-, CH2), 32.8 (-, CH2), 35. 3 (-, CH2), 42.6 (-, CH2), 59.7 (-, CH2), 
110.9 (+, indole), 114.6 (Cquart, indole-C3), 117.1 (+, 2 indole-CH), 125.2 (Cquart, 
indole), 138.7 (Cquart, indole), 142.4 (Cquart, indole), 147.5 (Cquart, indole), 172.5 
(Cquart, CO2Et), 196.1 (Cquart, COEt) 
MS (PI-EIMS, 70 eV): m/z (%) = 360 ([M•+], 31), 331 ([M - C2H5] +, 100), 315 ([M 
- OC2H5] +, 11) 
Analysis: C19H24N2O5 (360.40) 
 calculated C: 63.32 H: 6.71 N: 7.77 
 found C: 63.58 H: 7.02 N: 7.52 
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1-(1-Hexyl-2-methyl-5-nitro-1H-indol-3-yl)propan-1-one (7.53) 
Reaction of 1-hexyl-2-methyl-5-nitro-1H-indole (7.28) (0.14 g, 0.54 mmol), 
propionyl chloride (0.05 ml, 0.57 mmol) and tin(IV) chloride (0.07 ml, 
0.60 mmol); purification by flash column chromatography on silica gel, elution 
with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.16 g (0.51 mmol, 94 %, pale yellow solid) 
Mp: 112.5-113 °C 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 7.1 Hz, N(CH2)5CH3), 1.13 (t, 
3H, 3J = 7.2 Hz, COCH2CH3), 1.21-1.36 (m, 6H, N(CH2)2(CH2)3CH3), 1.60-1.72 
(m, 2H, NCH2CH2-), 2.79 (s, 3H, CH3), 3.01 (q, 2H, 3J = 7.1 Hz, COCH2-), 4.31 
(t, 2H, 3J = 7.5 Hz, NCH2-), 7.79 (dd, 1H, 3J = 9.1 Hz, 5J = 0.4 Hz, H-7), 8.09 
(dd, 1H, 3J = 9.1 Hz, 4J = 2.3 Hz, H-6), 8.97 (dd, 1H, 4J = 2.3 Hz, 5J = 0.4 Hz, H-
4) 
13C-NMR (DMSO-d6): δ [ppm] = 8.0 (+, CH3), 12.8 (+, CH3), 13.8 (+, CH3), 21.9 
(-, CH2), 25.7 (-, CH2), 29.2 (-, CH2), 30.8 (-, CH2), 35.2 (-, CH2), 43.0 (-, CH2), 
110.9 (+, indole), 114.6 (Cquart, indole-C3), 117.1 (+, 2 indole-CH), 125.2 (Cquart, 
indole), 138.7 (Cquart, indole), 142.3 (Cquart, indole), 147.5 (Cquart, indole), 196.1 
(Cquart, COEt) 
MS (PI-EIMS, 70 eV): m/z (%) = 316 ([M•+], 19), 301 ([M - CH3] +, 8), 287 ([M - 
C2H5] +, 100) 
C18H24N2O3 (316.39) 
 
Reduction of the 3-acylated 1H-indoles 7.54-7.56 
General procedure. A mixture of the N-substituted 3-acylated-2-methyl-5-nitro-
1H-indole derivative (1 eq), dissolved in ethyl acetate (5-7 ml), and tin(II) chlo-
ride dihydrate (5 eq) was heated at 70 °C and stirred under a nitrogen atmos-
phere overnight. After cooling, the mixture was diluted with ice-cold water (10-
20 ml) and the pH is made slightly basic (pH = 8) by an aqueous solution of so-
dium bicarbonate (5 %). After stirring for 1 h the aqueous phase was extracted 
three times with ethyl acetate (20 ml). The combined organic layers were 
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washed with brine (15 ml), dried over magnesium sulfate and concentrated un-
der reduced pressure. 
 
Ethyl 5-(5-amino-2-methyl-3-m-chlorobenzoyl-1H-indol-1-yl)pentanoate 
(7.54) 
Reaction of ethyl 5-(3-m-chlorobenzoyl-2-methyl-5-nitro-1H-indol-1-
yl)pentanoate (7.51) (0.11 g, 0.25 mmol) and tin(II) chloride dihydrate (0.28 g, 
1.24 mmol); purification by flash column chromatography on silica gel, elution 
with a 50:50:1 (v/v) mixture of petroleum ether (60-80 °C), ethyl acetate and 
triethylamine. 
Yield: 0.08 g (0.19 mmol, 78 %, red-brown oil) 
1H-NMR (DMSO-d6): δ [ppm] = 1.15 (t, 3H, 3J = 7.1 Hz, CO2CH2CH3), 1.50-1.77 
(m, 4H, NCH2(CH2)2-), 2.33 (s, 3H, CH3), 2.34 (t, 2H, 3J = 7.2 Hz, N(CH2)3CH2-), 
4.03 (q, 2H, 3J = 7.1 Hz, CO2CH2-), 4.12 (t, 2H, 3J = 7.2 Hz, NCH2-), 4.74 (br, 
2H, NH2), 6.53 (dd, 1H, 3J = 8.5 Hz, 4J = 2.2 Hz, H-6), 6.58 (d, 1H, 4J = 2.2 Hz, 
H-4), 7.23 (d, 1H, 3J = 8.5 Hz, H-7), 7.49-7.53 (m, 2H, Ph-H), 7.55-7.58 (m, 1H, 
Ph-H), 7.61-7.67 (m, 1H, Ph-H) 
13C-NMR (DMSO-d6): δ [ppm] = 12.3 (+, CH3), 14.0 (+, CH3), 21.7 (-, CH2), 28.4 
(-, CH2), 32.9 (-, CH2), 42.2 (-, CH2), 59.6 (-, CH2), 103.5 (+, indole), 110.4 (+, 
indole), 111.3 (Cquart, indole-C3), 111.5 (+, indole), 126.8 (+, Ph-C), 127.6 (+, 
Ph-C), 127.6 (Cquart, indole), 129.0 (Cquart, indole), 130.3 (+, Ph-C), 130.3 (Cquart, 
Ph-C), 130.6 (+, Ph-C), 133.1 (Cquart, Ph-C), 143.7 (Cquart, indole), 143.8 (Cquart, 
indole), 172.6 (Cquart, CO2Et), 189.4 (Cquart, COPh(3-Cl)) 
MS (CI-MS, NH3): m/z (%) = 413 ([M + H] +, 100) 
C23H25ClN2O3 (412.91) 
 
Ethyl 5-(5-amino-2-methyl-3-propanoyl-1H-indol-1-yl)pentanoate (7.55) 
Reaction of ethyl 5-(2-methyl-5-nitro-3-propanoyl-1H-indol-1-yl)pentanoate 
(7.52) (0.21 g, 0.58 mmol) and tin(II) chloride dihydrate (0.66 g, 2.93 mmol); 
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purification by flash column chromatography on silica gel, elution with a 100:1 
(v/v) mixture of ethyl acetate and triethylamine. 
Yield: 0.16 g (0.48 mmol, 83 %, light brown solid) 
Mp: 88-91 °C 
1H-NMR (DMSO-d6): δ [ppm] = 1.10 (t, 3H, 3J = 7.2 Hz, COCH2CH3), 1.14 (t, 
3H, 3J = 7.1 Hz, CO2CH2CH3), 1.47-1.69 (m, 4H, NCH2(CH2)2-), 2.32 (t, 2H, 3J = 
7.1 Hz, N(CH2)3CH2-), 2.65 (s, 3H, CH3), 2.85 (q, 2H, 3J = 7.2 Hz, COCH2CH3), 
4.03 (q, 2H, 3J = 7.1 Hz, CO2CH2CH3), 4.10 (t, 2H, 3J = 7.3 Hz, NCH2-), 4.86 
(br, 2H, NH2), 6.54 (dd, 1H, 3J = 8.5 Hz, 4J = 1.9 Hz, H-6), 7.15 (d, 1H, 4J = 1.9 
Hz, H-4), 7.21 (d, 1H, 3J = 8.5 Hz, H-7) 
13C-NMR (DMSO-d6): δ [ppm] = 8.4 (+, CH3), 12.4 (+, CH3), 14.0 (+, CH3), 21.6 
(-, CH2), 28.5 (-, CH2), 32.9 (-, CH2), 35.2 (-, CH2), 41.8 (-, CH2), 59.6 (-, CH2), 
104.3 (+, indole), 110.4 (+, indole), 111.0 (+, indole), 112.1 (Cquart, indole-C3), 
126.7 (Cquart, indole), 129.0 (Cquart, indole), 143.1 (Cquart, indole), 143.6 (Cquart, 
indole), 172.6 (Cquart, CO2Et), 195.6 (Cquart, COEt) 
MS (PI-EIMS, 70 eV): m/z (%) = 330 ([M•+], 74), 301 ([M - C2H5] +, 100) 
C19H26N2O3 (330.42) 
 
1-(5-Amino-1-hexyl-2-methyl-1H-indol-3-yl)propan-1-one (7.56) 
Reaction of 1-(1-hexyl-2-methyl-5-nitro-1H-indol-3-yl)propan-1-one (7.53) 
(0.13 g, 0.41 mmol) and tin(II) chloride dihydrate (0.47 g, 2.08 mmol); purifica-
tion by flash column chromatography on silica gel, elution with a 50:50:1 (v/v) 
mixture of petroleum ether (60-80 °C), ethyl acetate and triethylamine. 
Yield: 0.09 g (0.31 mmol, 76 %, red-brown oil) 
1H-NMR (DMSO-d6): δ [ppm] = 0.84 (t, 3H, 3J = 7.0 Hz, N(CH2)5CH3), 1.10 (t, 
3H, 3J = 7.3 Hz, COCH2CH3), 1.21-1.33 (m, 6H, N(CH2)2(CH2)3CH3), 1.54-1.67 
(m, 2H, NCH2CH2-), 2.65 (s, 3H, CH3), 2.84 (q, 2H, 3J = 7.3 Hz, COCH2CH3), 
4.08 (t, 2H, 3J = 7.4 Hz, NCH2-), 4.87 (br, 2H, NH2), 6.54 (dd, 1H, 3J = 8.6 Hz, 4J 
= 2.0 Hz, H-6), 7.16 (d, 1H, 4J = 2.0 Hz, H-4), 7.19 (d, 1H, 3J = 8.6 Hz, H-7) 
Chapter 7 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 188 
13C-NMR (DMSO-d6): δ [ppm] = 8.4 (+, CH3), 12.4 (+, CH3), 13.8 (+, CH3), 21.9 
(-, CH2), 25.8 (-, CH2), 29.2 (-, CH2), 30.8 (-, CH2), 35.2 (-, CH2), 42.1 (-, CH2), 
104.3 (+, indole), 110.4 (+, indole), 111.0 (+, indole), 112.0 (Cquart, indole-C3), 
126.7 (Cquart, indole), 129.0 (Cquart, indole), 143.1 (Cquart, indole), 143.5 (Cquart, 
indole), 195.6 (Cquart, COEt) 
MS (PI-EIMS, 70 eV): m/z (%) = 286 ([M•+], 49), 257 ([M - C2H5] +, 100) 
C18H26N2O (286.41) 
 
Method for the N-acylation of the 1H-indole derivatives 7.60-7.62 
The corresponding 1H-indole derivative (1 eq) and TEBAC (0.1 eq) was dis-
solved in dry dichloromethane (5-15 ml) (if necessary small amounts of THF 
were added to dissolve the remaining starting material). After addition of sodium 
hydroxide (2.5 eq) and 3-phenylpropanoyl chloride (1.5 eq), dissolved in 10 ml 
anhydrous dichloromethane, the mixture was allowed to stir for 30 min at room 
temperature. Subsequently, the reaction mixture was filtrated and washed with 
dichloromethane (25 ml). The filtrate was concentrated and purified by column 
chromatography on silica gel. 
 
1-(1H-Indol-1-yl)-3-phenylpropan-1-one (7.60) 
Reaction of 1H-indole (7.57) (0.50 g, 4.27 mmol), TEBAC (126 mg, 0.43 mmol), 
sodium hydroxide (0.40 g, 10.00 mmol) and 3-phenylpropanoyl chloride 
(0.95 ml, 6.39 mmol); purification by column chromatography on silica gel, elu-
tion with a 1:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.50 g (2.01 mmol, 47 %, white solid) 
Mp: 76-77.5 °C (Lit. 78.5-79.5 °C214) 
1H-NMR (DMSO-d6): δ [ppm] = 3.03 (t, 2H, 3J = 7.6 Hz, CH2CH2Ph), 3.40 (t, 2H, 
3J = 7.6 Hz, CH2CH2Ph), 6.73 (dd, 1H, 3J = 3.8 Hz, 5J = 0.8 Hz, H-3), 7.16-7.36 
(m, 7H, Ar-H), 7.59-7.63 (m, 1H, Ar-H), 7.95 (d, 1H, 3J = 3.8 Hz, H-2), 8.34-8.39 
(m, 1H, Ar-H) 
MS (PI-EIMS, 70 eV): m/z (%) = 249 ([M•+], 31), 117 ([M - C6H5CH2 - CHCO] +, 
100) 
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C17H15NO (249.31) 
 
1-(3-Acetyl-1H-indol-yl)-3-phenylpropan-1-one (7.61) 
Reaction of 3-acetyl-1H-indole (7.58) (0.50 g, 3.14 mmol), TEBAC (93 mg, 
0.31 mmol), sodium hydroxide (0.32 g, 7.85 mmol) and 3-phenylpropanoyl chlo-
ride (0.70 ml, 4.71 mmol); purification by column chromatography on silica gel, 
elution with a 3:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl acetate. 
Yield: 0.71 g (2.44 mmol, 77 %, white solid) 
Mp: 115-115.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.55 (s, 3H, CH3), 3.06 (t, 2H, 3J = 7.8 Hz, 
CH2CH2Ph), 3.54 (t, 2H, 3J = 7.8 Hz, CH2CH2Ph), 7.18-7.44 (m, 7H, Ar-H), 
8.21-8.25 (m, 1H, Ar-H), 8.37-8.41 (m, 1H, Ar-H), 8.85 (s, 1H, H-2) 
13C-NMR (DMSO-d6): δ [ppm] = 27.6 (+, CH3), 29.5 (-, CH2), 36.2 (-, CH2), 
115.8 (+, Ar-C), 120.0 (Cquart, C-3), 121.6 (+, Ar-C), 124.6 (+, Ar-C), 125.6 (+, 
Ar-C), 126.0 (+, Ar-C), 126.7 (Cquart, Ar-C), 128.2 (+, 2Ar-C), 128.5 (+, 2Ar-
C),134.3 (+, Ar-C), 135.4 (Cquart, Ar-C), 140.4 (Cquart, Ar-C), 172.1 (Cquart, 
CO(CH2)2Ph), 194.1 (Cquart, COCH3) 
MS (PI-EIMS, 70 eV): m/z (%) = 291 ([M•+], 51), 159 ([M - C6H5CH2 - CHCO] +, 
94), 144 ([M - C6H5CH2 – CHCO - CH3] +, 100), 91 ([C6H5CH2] +, 45) 
Analysis: C19H17NO2 (291.34) 
 calculated C: 78.33 H: 5.88 N: 4.81 
 found C: 78.13 H: 5.79 N: 4.59 
 
1-(3-Phenylpropanoyl)-1H-indole-5-carboxylic acid (7.62) 
Reaction of 1H-indole-5-carboxylic acid (7.59) (0.15 g, 0.93 mmol), TEBAC 
(28 mg, 0.09 mmol), sodium hydroxide (0.11 g, 2.79 mmol) and 3-phenylpro-
panoyl chloride (0.21 ml, 1.41 mmol); purification by column chromatography on 
silica gel, elution with a 2:1 (v/v) mixture of petroleum ether (60-80 °C) and ethyl 
acetate; analytical pure product was obtained by recrystallization from metha-
nol. 
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Yield: 0.16 g (0.55 mmol, 59 %, pink solid) 
Mp: 188.5-189.5 °C 
1H-NMR (DMSO-d6): δ [ppm] = 3.04 (t, 2H, 3J = 7.6 Hz, COCH2CH2Ph), 3.43 (t, 
2H, 3J = 7.6 Hz, COCH2CH2Ph), 6.85 (dd, 1H, 3J = 3.8 Hz, 5J = 0.8 Hz, H-3), 
7.16.7.37 (m, 5H, Ar-H), 7.92 (dd, 1H, 3J = 8.7 Hz, 4J = 1.7 Hz, H-6), 8.06 (d, 
1H, 3J = 3.8 Hz, H-2), 8.24 (dd, 1H, 4J = 1.7 Hz, 5J = 0.7 Hz, H-4), 8.42 (ddd, 
1H, 3J = 8.7 Hz, 5J = 0.8 Hz, 5J = 0.7 Hz, H-7), 12.83 (br, 1H, COOH) 
13C-NMR (DMSO-d6): δ [ppm] = 29.6 (-, CH2), 36.2 (-, CH2), 108.5 (+, Ar-C), 
115.5 (+, Ar-C), 122.6 (+, Ar-C), 125.6 (+, Ar-C), 126.0 (+, Ar-C), 127.9 (+, Ar-
C), 128.2 (+, 2Ar-C), 128.4 (+, 2Ar-C), 130.0 (Cquart, Ar-C), 134.43 (Cquart, Ar-C), 
137.2 (Cquart, Ar-C), 140.4 (Cquart, Ar-C), 167.4 (Cquart, COOH), 171.6 (Cquart, 
COCH2-) 
MS (PI-EIMS, 70 eV): m/z (%) = 293 ([M•+], 21), 161 ([M - C6H5CH2CHCO] +, 
100), 144 ([M - C6H5CH2CHCO - OH] +, 13), 116 ([M - C6H5CH2CHCO - CO2H] +, 
7), 91 ([C7H7] +, 49) 
Analysis: C18H15NO3 (293.32) 
 calculated C: 73.71 H: 5.15 N: 4.78 
 found C: 73.46 H: 5.09 N: 4.80 
 
2-Methyl-1H-indole-5-sulfonic acid (7.65) 
A suspension of 4-hydrazinobenzenesulfonic acid hemihydrate (7.63) (4.00 g, 
20.28 mmol), acetone (2 ml, 27.20 mmol) and glacial acid (40 ml) was heated at 
110 °C for 3 h. After evaporation of the solvent the resulting hydrazone 7.64 
was treated with concentrated sulfuric acid (21.9 ml) and heated at 130 °C for 
3 h. The annealed solution was made alkaline by addition of sodium carbonate. 
The solvent was removed under reduced pressure. Then again water was 
added and the solution was adjusted to slight acidity with hydrochloric acid (2N). 
The solvent was removed in vacuo. The resulting solid was elutriated with 
methanol, filtered off and washed thoroughly with methanol. Evaporation of the 
solvent yielded a pale brown solid. 
Yield: 3.89 g (18.42 mmol, 91 %, pale brown solid) 
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Mp: >270 °C 
1H-NMR (DMSO-d6): δ [ppm] = 2.37 (d, 3H, 4J = 0.9 Hz, CH3), 6.12 (dq, 1H, 4J 
= 0.9 Hz, 5J = 0.9 Hz, H-3), 7.16 (ddd, 1H, 3J = 8.4 Hz, 5J = 0.5 Hz, 5J = 0.9 Hz, 
H-7), 7.29 (dd, 1H, 3J = 8.4 Hz, 4J = 1.6 Hz, H-6), 7.67 (dd, 1H, 4J = 1.6 Hz, 5J = 
0.7 Hz, H-4) 
MS (ESI, H2O/MeOH + 10 mM NH4Ac): m/z (%) = 234 ([M + Na] +, 34), 229 ([M 
+ NH4] +, 100), 212 ([M + H] +, 19) 
C9H9NO3S (211.24) 
 
7.5.3 Pharmacological methods 
All synthesized indole derivatives were investigated for their inhibitory activity on 
the enzymatic activities of both bovine testicular hyaluronidase and hyaluronate 
lyase of S.agalactiae in a turbidimetric assay, which was developed in our labo-
ratory based on the method of Di Ferrante145 as described in section 5.5.3. 
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Chapter 8 
Summary 
Hyaluronan and hyaluronidases have been used in several medical fields for 
many years. For instance, sodium hyaluronate is frequently applied in the 
treatment of arthritic joints, whereas preparations of bovine testicular hyaluroni-
dase are beneficial in the therapy of different diseases in internal medicine, 
ophthalmology or orthopedics. It has been reported that some hyaluronidases 
are implicated in biological processes like meningitis, septicemia, arthroses, 
fertilization and cancer. Therefore, potent and selective inhibitors are required 
as pharmacological tool to prove and substantiate the physiological and patho-
physiological role of hyaluronidases and their preferred substrate, hyaluronic 
acid. Moreover, such inhibitors might be of therapeutic value, e.g. in the treat-
ment of arthritis, as new anti-fertility agents or as antimicrobial agent against 
penicillin-resistant bacteria. Inspired by the lack of such compounds, the main 
goal of this thesis was the synthesis and identification of lead-like compounds 
and their structural optimization as inhibitors of bovine testicular hyaluronidase 
and hyaluronate lyase from S. agalactiae (hylB4755). The inhibitory activities on 
both hyaluronidases were determined by means of a turbidimetric assay and 
the structure-activity relationships were elaborated. Based on the crystal struc-
ture of a hyaluronate lyase in complex with inhibitors the binding mode of 
structurally related compounds was suggested and used as a model for the de-
sign of new inhibitors. 
L-Ascorbic acid, a purported inhibitor of bovine testicular hyaluronidase, was 
found to weakly inhibit hyaluronate lyase of S. pneumoniae (hylSpn). X-ray 
analysis of the vitamin C-hylSpn complex confirmed that vitamin C binds to the 
active site of the bacterial enzyme suggesting that additional hydrophobic inter-
actions might increase the inhibitory effect. Therefore, as a part of this doctoral 
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project a series of L-ascorbic acid derivatives with additional lipophilic partial 
structures was synthesized and investigated for inhibitory activity against bovine 
testicular hyaluronidase and hyaluronate lyase of S. agalactiae strain 4755 
(hylB4755). Four 6-O-acyl derivatives of L-ascorbic acid were identified as mod-
erate to strong inhibitors of hyaluronidases with preference for the bacterial en-
zyme. At optimum pH (pH 5) the IC50 values for inhibition of hylB4755 range from 
0.9 µM to 475 µM with highest activity for the esters of the long chain alkanoic 
acids supporting the hypothesis that additional hydrophobic interactions in the 
active site contribute to the high affinity. Among the studied vitamin C deriva-
tives, L-ascorbic acid-6-octadecanoate proved to be the most potent inhibitor of 
hylB4755 and BTH with IC50 values of 0.9 µM and 39 µM at pH 5, respectively. 
The octadecanoate is up to 6500 times more potent than the parent compound 
vitamin C and is the most potent inhibitor of bacterial and bovine testicular hya-
luronidase described to date. 
The binding mode of L-ascorbic acid-6-hexadecanoate at hyaluronate lyase 
from S. pneumoniae was determined by X-ray analysis‡‡. The inhibitor binds 
within the catalytic site of the enzyme whereby hydrophobic interactions with 
Trp291, Phe343, His399 and Thr400 and a hydrogen bond between the carb-
oxylic group of the inhibitor and the hydroxyl side chain of Tyr408 are involved. 
This insight into enzyme-inhibitor interactions at molecular level delivered new 
information for further development of more potent and selective inhibitors of 
hyaluronidases. 
Starting from a de novo substrate-based inhibitor design 1,3-diacetylbenzimida-
zole-2-thione was identified as lead compound for hyaluronate lyase of S. aga-
lactiae (IC50 values of 5 µM and 160 µM at physiological pH and optimum pH, 
respectively). The investigation of structural diverse benzimidazoles derived 
from the lead revealed that N-monoacylated and N,N’-diacylated benzimida-
zole-2-thiones inhibit the bacterial enzyme hylB4755 but not the bovine testicular 
hyaluronidase (BTH). For N-monoacylated derivatives IC50 values in the low µM 
range were determined at physiological pH whereas the N,N’-diacylated com-
pounds showed strong inhibition of hylB4755 at both pH optimum and physiologi-
                                            
‡‡ These studies were accomplished in cooperation with M. J. Jedrzejas (Children’s Hospital 
Oakland Research Institute, Oakland, California 94609, USA). The X-ray structure of the 
complex was solved by D. Rigden (National Centre of Genetic Resources and Biotechnology, 
Cenargen/Embrapa, Brasília, D.F. 70770-900, Brazil). 
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cal pH. Nevertheless, only the N,N’-diacylated compound displayed IC50 values 
in the same range as the lead. Regardless of the high inhibitory potency of 
N,N’-diacylated benzimidazoles the development of this class of compounds 
was discontinued due to insufficient stability against moisture. 
Owing to their structural similarity with the aforementioned benzimidazoles cor-
responding benzoxazoles and indoles were also considered promising scaffolds 
for the preparation of hyaluronidase inhibitors. The structure-activity relation-
ships of recently described 2-phenylindole derivatives were in accordance with 
a model based on the X-ray structure of hylSpn co-crystallized with 1-decyl-2-
(4-sulfamoyloxyphenyl)-1H-indol-6-yl-sulfamate. This 3D structure was also 
used to suggest the putative binding mode of benzoxazole-2-thiones. To prove 
this model a series of benzoxazole derivatives was synthesized and investi-
gated for hyaluronidase inhibition. All tested compounds were highly selective 
for the hyaluronate lyase of S.agalactiae strain 4755 vs. the bovine testicular 
hyaluronidase. 3-Acylated benzoxazole-2-thiones inhibited hylB4755 with IC50 
values in the µM range. Interestingly, the thiones were much more potent than 
the corresponding oxo analogues. Within this series, 3-phenyl-1-(2-thioxo-
benzo[d]oxazol-3(2H)-yl)propan-1-one was the strongest inhibitor of hylB4755 
with an IC50 value of 15 µM at optimum pH. The 3-phenylpropanoyl proved to 
be the optimal substituent at the benzoxazole-N. This result is in good agree-
ment with the suggestions from molecular modeling studies. Because of the 
sensitivity of 3-phenylpropanoyl-benzoxazole-2-thione against moisture (hy-
drolysis of the labile amide bond) various structural modifications were made. 
But replacing the alkanoyl with a sulfonyl or an alkyl group or using a benzofu-
rane instead of the benzoxazole moiety resulted in a marked decrease in in-
hibitory activity on hylB4755. In summary, the 3-acylated benzoxazole-2-thione 
derivatives were successfully introduced as a new class of bacterial hyaluroni-
dase inhibitors. The applicability of the de-novo design strategy starting from the 
3D structure of hylSpn was confirmed by the structure-activity relationships of 
benzoxazole-2-thiones, especially, by the identification of the 3-phenylpropanoyl 
derivative as a potent hyaluronate lyase inhibitor. 
Based on the analysis of the binding mode of the aforementioned 2-phenylin-
doles and stimulated by the successful design of benzimidazole- and benzoxa-
zole-type hyaluronidase inhibitors a set of additional indole derivatives was pre-
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pared and screened for activity on hylB4755 and BTH. Generally, the investigated 
indoles showed a preference for the bacterial hyaluronidase with highest activity 
residing in three N-alkylated 5-amino-2-methyl-indoles (inhibitory activities on 
hylB4755 in the micromolar range at optimum pH). Different functional groups 
such as nitro, amino, urea, sulfonamide, carboxylic acid and sulfonic acid were 
introduced in position 5 of the indole scaffold. As a result only the amino group 
and the acidic groups seem to fulfill the structural requirements for potent in-
hibitors derived from indole moiety. Ionic interactions as well as hydrogen bonds 
may play an important role in this enzyme-inhibitor interaction. Surprisingly, the 
N-acylated 5-amino-2-methylindoles had only minor inhibitory activities. The 
synthesized 1,3-disubstituted 5-amino-2-methyl-indoles weakly inhibited 
hylB4755. Compared to the benzoxazole-2-thione the indole structure proved to 
be a less promising scaffold for the synthesis of hyaluronidase inhibitors. 
In summary, ligand-based and structure-based approaches led to the identifica-
tion of hyaluronidase inhibitors with micromolar and submicromolar activities. 
Particularly, the molecular modeling based approach for the design of novel 
hyaluronate lyase inhibitors was very successful. Such hyaluronidase inhibitors 
may be valuable pharmacological tools for the investigation of the role of the 
enzyme and its substrate, hyaluronan, in many biological processes. 
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Chapter 9          Appendix 
List of abbreviations 
 
2D two-dimensional 
3D  three-dimensional 
Ac acetyl 
AIDS acquired immunodeficiency syndrome 
Bn benzyl 
BSA bovine serum albumin 
BSE bovine spongiform encephalopathy 
BTH bovine testicular hyaluronidase 
BVH bee venom hyaluronidase 
CADD Computer-Aided Drug Design 
CDCl3 chloroform 
CDI N,N’-carbonyldiimidazole 
CTAB cetyltrimethylammonium bromide 
Cy cyclohexyl 
DCC dicyclohexylcarbodiimide 
DCM dichloromethane 
DEPT distortionless enhancement by polarization transfer 
DMAP p-dimethylaminopyridine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DSCG disodium cromoglycate 
DTT dithiothreitol 
EC enzyme commission 
GAG glycosaminoglycan 
GBS group B streptococci 
GPI glycosylphosphatidylinositol 
h hour(s) 
Chapter 9 
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ 
 198 
HA hyaluronan 
HAc acetic acid 
HPLC high-pressure liquid chromatography 
HR-MS high resolution mass spectroscopy 
HSAB Hard Soft Acid Base 
hylB3502 hyaluronate lyase of S. agalactiae strain 3502 
hylB4755 hyaluronate lyase of S. agalactiae strain 4755 
hylSpn S. pneumoniae hyaluronidase 
IC50 
concentration of an inhibitor required to give 50% inhibition 
of enzyme activity 
IR infrared spectroscopy 
IU international unit 
kDa kilo Dalton 
Mp melting point 
MS mass spectrometry 
MsCl methanesulfonyl chloride 
n.d. not determined 
NMR nuclear magnetic resonance 
PAD proton acceptance and donation 
PG protecting group 
pH negative logarithm of the hydrogen ion concentration 
Ph phenyl 
ppm parts per million 
rms root mean square 
RT room temperature 
SAR structure-activity relationships 
SEM standard error of the mean 
TCDI N,N’-thiocarbonyldiimidazole 
TEBAC tetrabutylammonium chloride 
THF tetrahydrofuran 
TLC thin layer chromatography 
TMSCl trimethylsilyl chloride 
UV ultra violet 
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UV/VIS-spectra of 6.11 (50 µM in MeCN) 
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UV/VIS-spectra of 6.19 (50 µM in MeCN) 
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UV/VIS-spectra of 7.16 (50 µM in MeCN) 
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UV/VIS-spectra of 6.1 (50 µM in MeCN) 
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